HPTN 066, 
Version 2.0
Page 
1
of 
116
29 Nov
em
ber
2010
HPTN 066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
DAIDS ID: 1085
1
A Study of the HIV Prevention Trials Network
Sponsored by:
Division of AIDS, U.
S. National Institute of Allergy
and Infectious Diseases
U.S. National Institutes of Health
Pharmaceutical Support Provided by:
Gilead Sciences
Protocol Chair(s):
Craig W. Hendrix
Johns Hopkins University
Baltimore, MD, U.S.A
Protocol Co
-
Chair:
Ken 
May
er
Brown University
Boston, MA, U.S.A
Kristine Patterson
University
of North Carolina, Chapel Hill 
Chapel Hill, NC, U.S.A
Version 
2
.0
29 Nov
ember
2010
Non
-
IND study
HPTN 066, Version 
2
.0 
Page 
2
of 
116
29 Nov
em
ber
2010
HPTN 066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
TABLE OF CONTENTS
LIST OF ABBREVIATIONS AND ACRONYMS
................................
................................
....
5
LIST OF TABLES AND FIGURES
................................
................................
............................
7
TERMINOLOGY FOR TENOFOVIR, EMTRICITABINE, AND THEIR DERIVATIVES
................................
................................
................................
................................
.........................
8
P
ROTOCOL TEAM ROSTER
................................
................................
................................
...
9
PROTOCOL SIGNATURE PAGE
................................
................................
...........................
11
SCHEMA
................................
................................
................................
................................
.....
12
OVERV
IEW OF PARTICIPANT DISTRIBUTION AND STUDY DESIGN
.....................
14
1.0
INTRODUCTION
................................
................................
................................
...........
16
1.1
Background and Prior Research
................................
................................
....................
16
1.2
Rationale
................................
................................
................................
.......................
22
2.0
STUDY OBJECTIVES AND DESIGN
................................
................................
.........
25
2.1
Primary
Objectives
................................
................................
................................
........
25
2.2
Secondary
Objectives
................................
................................
................................
....
25
2.3
Study
Design
................................
................................
................................
.................
25
3.0
STUDY POPULATI
ON
................................
................................
................................
.
27
3.1
In
clusion Criteria
................................
................................
................................
..........
2
8
3.2
Exclusion Criteria
................................
................................
................................
.........
29
3.3
Re
cruitment Process
................................
................................
................................
......
30
3.4
Participant Retention
................................
................................
................................
.....
30
3.5
Participant Withdrawal
................................
................................
................................
.
31
4.0
STUDY TREATMENT/PRODUCT/INTERVENTION
................................
.............
31
4.1
Study
Product Formulation/Content/Storage
................................
................................
31
4.2
Study
Product 
Regimen(s)
................................
................................
............................
32
4.3
Study
Product Administration
................................
................................
.......................
32
4.4
Product Supply
and Accountability
................................
................................
..............
34
4.5
Toxicity
Management
................................
................................
................................
...
34
4.6
Management of Specific Toxicities
................................
................................
..............
36
4.7
Clinical Management of Pregna
ncy
................................
................................
..............
41
4.8
Criteria for Earl
y Termination of Study Participation
................................
..................
41
4.9
Concomitant Medications
................................
................................
.............................
42
5.0
STUDY PROCEDURES
................................
................................
................................
43
5.1
Screening Visit
................................
................................
................................
..............
44
5.2
Enrollment Visit
................................
................................
................................
............
46
HPTN 066, Version 
2
.0 
Page 
3
of 
116
29 Nov
em
ber
2010
5.3
Non
-
Intensive Sampling Visits
................................
................................
.....................
47
5.4
Intensive Sampling Visits
................................
................................
.............................
48
5.5
Follow up P
rocedures for Participants who Discontinue Study
Product and for 
Participants who Receive a Biops
y on the Last Study Visit.
................................
....................
48
5.6
Interim Contacts and Visits
................................
................................
...........................
49
5.7
Clinical Evaluations and Procedures
................................
................................
............
49
5.8
HI
V and STI Counseling
................................
................................
..............................
49
5.9
Participant Prepa
ration for Sampling
................................
................................
............
49
6.0
SAFETY MONITORING AND ADVERSE EVENT REPORTING
........................
50
6.1
Safety
Monitoring
................................
................................
................................
.........
50
6.2
Clinical Data Safet
y R
eview
................................
................................
.........................
51
6.3
Adverse Event Definition and Reporting Requirements
................................
..............
52
6.4
Social Harms
................................
................................
................................
.................
54
7.0
STATISTICAL CONSIDERATIONS
................................
................................
..........
55
7.1
Review of Study
Design
................................
................................
...............................
55
7.2
Endpoints
................................
................................
................................
......................
55
7.3
Accrual, Follow
-
up, Retention, and Sample Size
................................
.........................
56
7.4
Study
Arm Assignment
................................
................................
................................
.
60
7.5
Blinding
................................
................................
................................
.........................
60
7.6
Data Anal
ys
is
................................
................................
................................
................
60
8.0
HUMAN SUBJECTS CONSIDERATI
ONS
................................
................................
62
8.1
Ethical Review
................................
................................
................................
..............
62
8.2
In
formed Consent
................................
................................
................................
..........
63
8.3
Risks
................................
................................
................................
..............................
63
8.4
Benefits
................................
................................
................................
.........................
66
8.5
In
centives
................................
................................
................................
......................
66
8.6
Confidentiality
................................
................................
................................
..............
66
8.7
Communicable Disease Reporting Requirements
................................
........................
67
8.8
Study
Discontinuation
................................
................................
................................
...
67
9.0
LABORATORY SPECIMENS AND BIOHAZARD CONTAINMENT
..................
67
9.1
Local Laboratory
Specimens
................................
................................
........................
67
9.2
Network Laboratory Speci
mens
................................
................................
...................
69
9.3
Quality
Control and Quality
Assurance Procedures
................................
.....................
71
9.4
Specimen Storage and Possible Future Research Testing
................................
............
72
9.5
Biohazard Containment
................................
................................
................................
72
10.0
ADMINISTRATIVE PROCEDURES
................................
................................
..........
72
10.
1
Study
Activation
................................
................................
................................
...........
72
10.2
Study
Coordination
................................
................................
................................
.......
73
10.3
Study
Monitoring
................................
................................
................................
..........
74
10.4
Protocol Compliance
................................
................................
................................
.....
74
10.5
Investigator's Records
................................
................................
................................
...
75
10.6
Use of Information and Publications
................................
................................
............
75
HPTN 066, Version 
2
.0 
Page 
4
of 
116
29 Nov
em
ber
2010
11.0
REFERENCES
................................
................................
................................
................
76
APPENDICES
................................
................................
................................
.............................
78
APPENDIX I: SCHEDULE OF EVALUATIONS AND PRO
CEDURES
............................
79
APPENDIX IA: Schedule of Evaluations and Procedures 
-
General Procedures
................
80
APPENDIX IB: Schedule of Evaluations and 
Procedures 
-
Clinical Procedures and 
Laboratory Tests
................................
................................
................................
.........................
81
APPENDIX IC: Schedule of Evaluations and Procedures 
-
Sample Collection for PK 
Evaluation (Drug Testing)
................................
................................
................................
..........
84
APPENDIX 1D: Additional Procedures from Study Participants with Confirmed HIV 
Infection
................................
................................
................................
................................
.......
86
APPENDIX II: SCREENING/ENROLLMENT SAMPLE INFORMED CONSENT FORM 
(Intensive Sampling Cohort)
................................
................................
................................
......
87
APPENDIX III: SCREENING/ENROLLMENT SAMPLE INFORMED CONSENT 
FORM (Non
-
Intensive Sampling Cohort)
................................
................................
..............
103
HPTN 066, Version 
2
.0 
Page 
5
of 
116
29 Nov
em
ber
2010
HPTN 066 
D
OSE
-
P
ROPORTION
ALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
LIST OF ABBREVIATION
S AND ACRONYMS
AE
adverse event
AI
DS
Acquired Immunodeficiency S
yndrome
aPTT  
activated partia
l thromboplastin time
AL
T
alanine aminotransferase
AST
aspartate aminotransferase
BV
bacterial vaginosis
Ca
calcium
CBC
complete blood count
CDC
Centers for Disease Control and Prevention
CORE
(HPTN) Coordinating and Operations Center
Cl
chlo
ride
CRPMC
(NIAID) Clinical Research Products Management Center
CT
Chlamy
dia (Chlam
ydia trachomatis)
DAIDS
Division of AIDS
DOT
Directl
y observed therapy
EAE
expedited adverse event (reporting) 
EC
ethics committee
FDA
(United States) Food and Dru
g Administration
FTC
emtricitabine
FTC
-
TP
emtricitabine triphosphate
GC
gonorrhea (Neisseria Gonorrhoeae)
GCL
P
good clinical laboratory
practice
GCP
good clinical practice
HBsAg
hepatitis B surface antigen
HC03
bicarbonate
HI
V
Human Immunodefic
iency
Virus
HPTN
HI
V Prevention Trials Network
IDS
investigational drug service
IR
B
institutional review board
K
potassium
LDMS
Laboratory
Data Management Sy
stem
LL
local laboratory
LLN
lower limit of normal 
Na
sodium
NAAT
nuc
leic acid amplification test
NI
AI
D
(United States) National Institute of Allergy
and Infectious Diseases
NI
H
(United States) National Institutes of Health
HPTN 066, Version 
2
.0 
Page 
6
of 
116
29 Nov
em
ber
2010
NL
(HPTN) Network Laboratory
NSAID
Non
-
steroidal anti
-
inflammatory
drug
OHRP
Office for Huma
n Research Protection
s
PD
pharmacod
yn
amics
PK
pharmacokinetics
PoR
pharmacist of record 
PrEP
pre
-
exposure proph
yl
axis
PSRT
Protocol Safety
Review Team
PT
prothrombin test
QA
quality
assurance
QC
quality
control
RPR
rapid plasma reagin te
st for sy
philis 
RTI
reproductive tract infection 
RSC
Regulatory
Support Center (formerl
y R
CC)
RUQ
right upper quadrant
SAE
serious adverse event
SDMC
(HPTN) Statistical and Data Management Center
SMC
Study
Monitoring Committee
SOP
standard 
operating procedures
SSP
study
specific procedures (manual)
STI
sexually
transmitted infection
TDF
tenofovir disoproxil fumarate
TDF/FTC
Truvada® (tenofovir disoproxil fumarate and emtricitabine in fixed dose 
combination) 
TFV
tenofovir
TFV
-
DP
ten
ofovir diphosphate
Trich
trichomoniasis (Trichomonas vaginalis)
ULN
upper limit of normal
UTI
urinary
tract infection
HPTN 066, Version 
2
.0 
Page 
7
of 
116
29 Nov
em
ber
2010
HPTN 066 
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRIC
ITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
LIST OF TABLES AND F
IGURES
Figure 1
-
1.  Simulation of tenofovir diphosphate (TFV
-
DP) concentration
................................
18
Figure 1
-
2. Simulation of tenofovir concentration in blood serum
................................
..............
19
Table 1
-
1. Accumulation index for parent and phosphory
lated moieties of TDF and FTC dosed 
either weekly
(168 hours) or dail
y (24 hours).
................................
...........................
21
Table 4
-
1. Study
Product Dosing Arms
................................
................................
........................
32
Table 5
-
1. Screening Visit (up to 30 d
ay
s prior to Enrollment Visit)
................................
...........
45
Table 5
-
2. Enrollment Visit (Day
0)
................................
................................
.............................
46
Table 5
-
3. Non
-
Intensive Sampling Visits (Day
s 1
‡
, 3 
‡
,
7, 14, 21, 28, 35, and 49)
....................
47
Table 5
-
4. Intensive Sampling Visit (Day
s 35 and 49)
................................
................................
.
48
Table 7
-
1. Power for dose proportionality
assessment, 
05
.
0
=
................................
................
58
Table 7
-
2. Power to detect the minimal detectable difference (in fold) for various sample sizes 
and coefficients of variance (CV)
................................
................................
...............
59
Table 7
-
3. Biological matrices for anal
ys
es
................................
................................
..................
61
HPTN 066, Version 
2
.0 
Page 
8
of 
116
29 Nov
em
ber
2010
HPTN 066 
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHAT
E 
I
N 
H
EALTHY 
V
OLUNTEERS
TERMINOLOGY FOR TENO
FOVIR, EMTRICITABINE
, AND THEIR 
DERIVATIVES
Abbreviation
Compound 
name
Comments
TDF
Tenofovir 
disoproxil 
fumarate
This is the inactive, oral formulation of tenofovir (trade 
name: Viread
®
). The ester form enha
nces oral absorption 
and bioavailability
. TDF is rapidly
metabolized after dosing 
to the de
-
esterified pro
-
drug, tenofovir (TFV), which is also 
inactive. 
TFV
Tenofovir
This is the inactive, de
-
esterified form of TDF. This form of 
the drug that is measure
d in serum, blood, other body
fluids, 
and tissue samples. 
TFV
-
DP
Tenofovir 
diphosphate
This is the active, phosphory
lated form of tenofovir that is 
generated in cells. This is the form of the drug that is 
measured in cells (e.g., PBMCs). It is rapidl
y 
de
phosphory
lated to the inactive form outside of cells, and 
has a very
short half
-
life outside of cells in tissue.
FTC
Emtricitabine
This antiretroviral drug
(trade name: Emtriva®)
is co
-
formulated with TDF in Truvada® (TDF/FTC). FTC is an 
inactive pro
-
drug
that is activated in cells by
 
phosphory
lation. This is the form of emtricitabine that is 
measured in serum, blood, other bod
y fluids, and tissue 
samples.
FTC
-
TP
Emtricitabine 
triphosphate
This is the active form of FTC that is generated in cells. 
This is
the form measured in cells (e.g., PBMCs). 
Truvada
®
Tenofovir plus 
emtricitabine
This is the co
-
formulated drug produced b
y Gilead Sciences, 
In
c. Each pill contains 300 mg of TDF and 200 mg of FTC.
HPTN 066, Version 
2
.0 
Page 
9
of 
116
29 Nov
em
ber
2010
HPTN 066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
A
RIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
PROTOCOL TEAM ROSTER
David Borasky
Office of Research Protection 
RTI International 
3040 Cornwallis Rd
RTP, NC
27709
, U.S.A.
Phone:
 
919
-
316
-
3903
Fax:
 
919
-
316
-
3897
E
-
mail:
 
dborasky@rti.org
Ying Chen
SCHARP/FHCRC
1100 Fairview Avenue N
M2
-
C200
PO Box 19024
Seattle, WA 98109, U.S.A
Email:
yqchen@scharp.org  
Phone:
206
-
667
-
7051 
Fax:
206
-
667
-
4812
Myron Cohen
University of North Carolina 
School of Medicine, 
Department of Medicine, 
Division of Infectious 
Diseases
130 Mason Farm Road
Bioinformatics Bldg.
Chapel Hill, NC 27599, 
U.S.A
Email:
myron_cohen@med.unc.edu
Pho
ne:
919
-
966
-
2536 
Fax: 
919
-
966
-
6714
Vanessa Elharrar
Medical Officer 
Prevention Science 
Program/DAIDS/NIAID/NIH 
6700
-
B Rockledge Drive, 5th 
Fl. Rm. 5125 
Bethesda, MD 20892, U.S.A. 
Email
: 
elharrarv
a@niaid.nih.gov
Phone
: 301
-
827
-
0845
Lynda Emel
Senior Project Manager 
-
Perinatal and Prevention
SCHARP/FHCRC
1100 Fairview Avenue North
LE
-
400
PO Box 19024
Seattle, WA 09109 U.S.A
Email
: 
lemel@scharp.org
Phone
: 20
6
-
667
-
5803
Fax
: 206
-
667
-
4812
Susan Eshleman
Jo
hns Hopkins University
720 Rutland Avenue
Ross Bldg., Room 646
Baltimore, MD 21205, U.S.A
Email:
seshlem@jhmi.edu 
Phone:
410
-
614
-
4734 
Fax:
410
-
502
-
9244
Alexia Exarchos
Pharmaceutical 
Representativ
e
Gilead Sciences 
333 Lakeside Drive
Foster City, California 94404
U.S.A
Email
: 
Alexia.Exarchos@gilead.com 
Phone
: 
650
-
522
-
1201
Fax: 
650
-
522
-
5418
Fang Gai
Statistical Research Associate
SCHARP/FHCRC
1100 Fairview Ave. N. 
LE
-
400
P.O. Box 19024
Seattle
, WA 98109
-
1024 
U.S.A
Email
: 
fang@scharp.org
Phone
: 206
-
667
-
7524
Fax
: 206
-
667
-
4812
Craig Hendrix
Protocol Chair
Jo
hns Hopkins University
600 North Wolfe Street
Harvey 502
Baltimore, MD 21287, U.S.A
Email:
cwhendrix@jhmi.edu 
Phone:
410
-
955
-
9707 
Fax:
410
-
955
-
9708

HPTN 066, Version 
2
.0 
Page 
10
of 
116
29 Nov
em
ber
2010
Angela Kashuba
3318 Kerr Hall, 
School of Pharmacy
UNC
-
Chapel Hill
Chapel Hill NC, 27599, 
U.S.A
Email:
akashuba@unc.edu 
Phone:
919
-
966
-
9998 
Fax: 
919
-
962
-
0644
Cheryl Cokley
FHI
2224 E. NC Hwy 54
Durham, NC 27713, U.S.A
Email:
ccokley
@
fhi.org 
Phone:
919
-
544
-
7040 ext. 
11
359
Fax:
919
-
544
-
0207
Ken Mayer
Protocol Co
-
Chair
Fenway Health
1340 Boylston Street
Boston, Ma, U.S.A
Email:
kenneth_mayer@brown.edu 
Phone:
401
-
793
-
4711 
Fax:
401
-
793 4709 
Fax:
617
-
536
-
8602
Laura McKinstry
Projec
t Manager
SCHARP/FHCRC
1100 Fairview Ave. N. 
LE
-
400
P.O. Box 19024
Seattle, WA 98109
-
1024 
U.S.A
Email
: 
lmckinst@scharp.org
Phone
: 206
-
667
-
7322
Fax
: 206
-
667
-
4812
Ayana Moore
FHI
2224 E. NC Hwy 54
Durham, NC 27713, U.S.A
Email:
amoore@fhi.org 
Phone:
919
-
544
-
7040 ext. 
11244 
Fax:
919
-
544
-
0207
Kristine Patterson
Protocol Co
-
Chair
Division of Infectious 
Diseases 
CB# 7030, Bioinformatics 
Building 
130 Mason Farm Road, 2nd 
Floor 
Chapel Hill, NC 27599, 
U.S.A
Email:
kristine_patterson@med.unc.
edu 
Phone:
919
-
966
-
2536 
Fax: 
919
-
966
-
6714
Paul Richardson
HPTN NL QC 
Representative
Jo
hns Hopkins Univ. Dept. of 
Pathology
Pathology Building 306
600 N. Wolfe St.
Baltimore, MD 21287, 
U.S.A.
Email
: pricha18@jhmi.edu
Phone
: 410
-
502
-
0435
Fax
: 410
-
614
-
0430
James F. Ro
oney
Pharmaceutical 
Representative
Gilead Sciences 
Vice President Medical 
Affairs
333 Lakeside Drive
Foster City, California 94404
U.S.A
Email
: 
jim.rooney@gilead.com
Phone
: (650) 522
-
5708
Fax: 
(650) 522
-
5854
Katherine Shin
Pharmacist
Pharmaceutical Affairs 
Branch
Division of AIDS
6700
-
B Rockledge Drive, 
Room 4227
Bethesda, MD 20892
Phone:
301
-
594
-
1517
Fax:
301
-
402
-
1506
Email:
KaShin@niaid.nih.gov
Nirupama Sista
FHI
2224 E. NC Hwy 54
Durham, NC 27713, U.S.A
Email:
nsista@fhi.org 
Phone:
919
-
544
-
7040 ext. 
11590 
Fax:
919
-
544
-
0207
Lei Wang
SCHARP/FHCRC
1100 Fairview Avenue N
M2
-
C200
PO Box 19024 
Seattle, WA 98109, U.S.A
Email:
lwang@scharp.org 
Phone:
206
-
667
-
704
9 
Fax:
206
-
667
-
4812

HPTN 066, Version 
2
.0 
Page 
11
of 
116
29 Nov
em
ber
2010
HPTN 066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
PROTOCOL SIGNATURE PAGE
Version 2.0
29 Nov
ember
2010
A 
Study of the HIV Prevention Trials Network (HPTN)
Sponsored by:
Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases
U.S. National Institutes of Health
I, the Investigator of Record, agree to conduct this study in full accordanc
e with the provisions of 
this protocol. I
agree to maintain all study
documentation for a minimum of three years after 
submission of the site’s final Financial Status Report to the Division of AIDS (DAIDS), unless 
otherwise specified b
y D
AI
DS or the HIV Pr
evention Trials Network (HPTN) Coordinating and 
Operations Center.  Publication of the results of this study
will be governed by
HPTN policies. 
Any
presentation, abstract, or manuscript will be made available b
y t
he investigators to the 
HPTN Manuscript Rev
iew Committee and DAIDS for review prior to submission.
I h
ave read and understand the information in this protocol and will ensure that all associates, 
colleagues, and employees assisting in the conduct of the study
are informed about the 
obligations inc
urred by
their contribution to the study
.
__________________________________       
Name of Investigator of Record
__________________________________
_________________________________
Signature of Investigator of Record
Date
HPTN 066, Version 
2
.0 
Page 
12
of 
116
29 Nov
em
ber
2010
HPTN 066 
D
OSE
-
P
ROP
ORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
Version 2.0
29 Nov
ember
2010
SCHEMA
Purpose:
Describe the dose
-
proportionality
and intra
-
individual variability
of 
tenofovir diphosphate (TFV
-
DP) and emtricitabine triphosphate (FTC
-
TP) 
at stead
y
-
state in healthy
human participants taking Truvada® (
FTC 
200mg/TDF 300 mg
) under direct observation. 
Design
: 
Phase 1, multi
-
site, open label, randomized, 4
-
arm, dose
-
rangin
g, 
pharmacokinetic (PK) study
.
Study Population:
HI
V
-
uninfected, healthy
, sexually
-
active volunteers, including both men 
and women recruited from two sites in the United States (U.S.).
Study Size:
32
participants distributed into four 8
-
person cohorts w
ith 4 men and 4 
women per cohort. 
16
of the original 32 participants (2 men, 2 women per 
dosing cohort), will undergo intensive tissue sampling.
Treatment Regimen:
Research participants will receive doses under the direct observation of 
study
personnel fo
r 5 weeks. Research participants will be enrolled 
randomly
into one of four study
arms: 
1.
FTC 200 mg/TDF 300 mg, one tablet orall
y once weekl
y for 5 weeks
2.
FTC 200 mg/TDF 300 mg, one tablet orall
y t
wice weekl
y for 5 weeks
3.
FTC 200 mg/TDF 300 mg, two tablets 
orally
twice weekl
y fo
r 5 weeks
4.
FTC 200 mg/TDF 300 mg, one tablet once daily
for 
5 weeks
Study Duration:
Approximately
12 months total. Accrual will require approximately
6 months. 
Each participant will be followed for approximately 2 months (screening, 
treatment, and follow
-
up).  
HPTN 066, Version 
2
.0 
Page 
13
of 
116
29 Nov
em
ber
2010
Primary Objectives:
1.
Assess dose
-
proportionality
of intracellular TFV
-
DP and FTC
-
TP 
from weekl
y t
o dail
y dosing.
2.
Describe intra
-
individual variability
in intracellular TFV
-
DP and FTC
-
TP concentrations at steady
-
state (comparis
on of Day
28 and Day
35)
Secondary Objectives: 
1.
Describe the relationship between pre
-
dose (C
t
) and decay
ing 
concentrations of TFV, FTC, and their phosphory
lated derivatives 
(TFV
-
DP and FTC
-
TP) in blood serum, peripheral blood mononuclear 
cells (PBMCs), CD4+ blood cells, total tissue cells, CD4+ tissue cells, 
tissue homogenate, semen, and luminal 
fluid at steady
-
state (Day
35 
[pre
-
dose] and Day
49 [decay
ing, greater than one half
-
life for TFV
-
DP]).
2.
Describe differences in intracellular TFV
-
DP and FTC
-
TP stead
y
-
state 
C
t
between men and women.
3.
Characterize the safet
y p
rofiles of four different TDF/FT
C regimens 
for pre
-
exposure chemoprophy
laxis (PrEP).
Study Sites:
·
Johns Hopkins University, Baltimore MD; USA
·
University
of North Carolina at Chapel Hill, Chapel Hill NC; USA
HPTN 066, 
Version 2.0
Page 
14
of 
116
29 Nov
em
ber
2010
HPTN 066 
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLUL
AR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
Version 2.0
29 Nov
ember
2010
OVERVIEW OF PARTICIP
ANT DISTRIBUTION AND
STUDY DESIGN 
A) Distribution Scheme 
2
me
n
Arm
1: One(1) Tablet 
Weekly
(1x)
; N=8
Arm
2: O
ne(1) Tablet 
Twice Weekly
(2x
); N=8
2
wom
en
2
me
n
2
wom
en
Arm
4: One(1) Tablet 
Daily (7x)
; N=8
2
me
n
2
wom
en
Arm
3: Two(2) Tablets
Twice Weekly
(4x)
; N=8
2
me
n
2
wom
en
FTC 200m
g/TDF 
300 m
g 
Tablet (Truvada
®
)
N=32
2
me
n
2
wom
en
2
me
n
2
wo
me
n
2
me
n
2
wom
en
2
me
n
2
wom
en
Non
-
Intensive Cohort
(Blood Only)
Intensive Cohort
(
Blood + 
Tissue, Lumen, 
Semen)
HPTN 066, Version 
2
.0 
Page 
15
of 
116
29 Nov
em
ber
2010
OVERVIEW OF PARTICIPANT DISTRIBUTION A
ND STUDY DESIGN (cont.)
B) Study Design
Screening
Accumulation
Steady
-
State
Decay
Stud
y da
y
Dosing (Arm 1
-
4
)
PK Blood
Sampling
(Both Cohorts)
PK Tissue/Lumen
/Sem
en 
Sa
mp
ling
(Intensive Cohort only
)
0
7
14
21
28
35
49
42
HPTN 066, 
Version 2.0
Page 
16
of 
116
29 Nov
em
ber
2010
1.0
INTRODUCTION
1.1
Background and Prior Research
1.1.1
Using PrEP for HIV Prevention 
With 2.5 million new HIV infections expected in the coming year, there is an urgent need to find 
effective
way
s to reduce HIV transmission 
(UNA
IDS, 200
8)
. Pre
-
exposure antiretroviral 
chemoproph
yl
axis (PrEP) has been shown to decrease viral transmission in animal models 
(Garcia
-
Lerma et al., 2008; Subbarao et al., 2007; Veazey et al., 2005)
, and post
-
exposure 
pro
phy
laxis has decreased HIV transmission in health care workers 
(Cardo et al., 1997)
and men 
who have sex with men (MSM) 
(Schechter et al., 2004)
. The first human efficacy
t
rials of dail
y 
PrEP are likely
to be completed by
late 2010. These trials are onl
y evaluating dail
y dosing. For 
the majority
of the “at
-
risk” populations, HIV risk
-
taking is unlikely
to occur on a dail
y basis. 
Therefore, less frequent drug dosing (i.e., in
termittent PrEP) will result in decreased drug costs 
and lower risk of toxicity. However, an
y benefit from intermittent PrEP as compared to dail
y 
PrEP could be mitigated by
an increased risk of HIV infection if intermittent PrEP were to 
provide insufficien
t drug concentrations in relevant tissues. The most encouraging data 
suggesting that intermittent PrEP may
be a plausible prevention strategy
comes from a study
by
 
Garcia
-
Lerma and colleagues 
(Garcia
-
Lerma et al., 2009)
, in which monkey
s were well
-
protected from SIV infection after receiving one dose of tenofovir disoproxil fumarate (TDF) 
plus emtricitabine (FTC) at either 7 days, 3 day
s, or 2 hours pre
-
SI
V exposure
followed b
y a 
second dose 2 hours post
-
exposure. While encouraging, these data cannot be directl
y 
extrapolated to humans due to the differences in simian anatomy
and pharmacokinetics as well as 
differences between HIV and the SIV challenge strain. Moreove
r, an efficacy
trial of intermittent 
PrEP can be initiated only after the following pharmacological issues are understood. First, the 
overall drug concentrations achieved in humans receiving various intermittent PrEP regimens 
must be understood. Secondly
, 
the intra
-
individual variability
exhibited between proposed 
intermittent PrEP regimens must be carefully
considered. Lastl
y, drug concentrations must then 
be evaluated in light of 
in vitro
and animal model data to estimate the range of concentrations 
that 
may
be necessary
to provide preventive concentrations of the relevant antiretroviral drugs.   
1.1.2
Significance of Determining Pharmacology of Intermittent PrEP 
The data generated b
y t
he proposed study
will be used to develop a comprehensive multi
-
compartme
nt pharmacokinetic (PK) model.  Assuming dose proportionality
is found, this model 
will be used to estimate extracellular and intracellular drug exposure in multiple compartments 
for an
y dose and dosing interval combination.  This model will be critical to
the following three 
areas: 1) developing an optimal pharmacology
-
based adherence intervention for future PrEP 
studies, 2) assessing adherence in ongoing studies with currentl
y s
tored samples, 3) developing a 
HPTN 066, Version 
2
.0 
Page 
17
of 
116
29 Nov
em
ber
2010
pharmacokinetic
-
pharmacody
namic (PK/PD) model t
o determine target intracellular drug 
exposures that prevent HIV infection. 
1.1.3
Need for Accurate Adherence Data 
All large
-
scale PrEP trials will need to determine medication adherence accuratel
y i
n order to 
interpret the success or failure of an
y pharmaco
logic intervention. Acquisition of HIV infection 
during such trials may
result from failure to achieve protective drug concentrations at the site of 
action. This failure may
be from either (1) full adherence that did not achieve adequate drug 
concentration
s from the prescribed regimen, or (2) poor adherence to the prescribed regimen, 
resulting in concentrations too low to provide protection from HIV infection. Differentiating 
between these two etiologies of PrEP failure are impossible using traditional adhe
rence measures 
[pill counts, medication history
and computer chips in the cap of pill containers (e.g., MEMS 
caps)] as none of these actually
document pill
-
taking behavior.  Using a pharmacologic measure 
in combination with a robust PK model will allow int
erpretation of adherence using stored 
samples from completed studies, and will provide real
-
time information that could be used to 
guide behavioral interventions.
1.1.4
Drug Concentration as an Adherence Measure 
In clinical trials,
measurement of drug concent
rations has been proposed as a potential adherence 
measure to assess medication adherence more accuratel
y. In this method, blood and other clinical 
samples of interest are sampled at specified times and the resultant “observed” drug 
concentrations are comp
ared to the “expected” drug concentrations. The proportional difference 
between the expected and observed drug concentrations is taken as a rough estimate of the 
proportion of prescribed doses that were actuall
y t
aken. An
y differences between the observed 
and expected values are attributed primarily to adherence, since the expected value estimates 
(described below) control for adherence, and since other significant sources of variation (e.g., 
assay
variabilit
y and environmental variables) are reasonabl
y ass
umed to be stable over time.
1.1.5
Drug Concentration Simulation Models
In computer simulation models, the “expected” drug concentration is based on the PK 
characteristics of the drug and the prescribed dosing regimen of the study
.  To facilitate these 
simulat
ions, PK data are available from several reports in which TDF (Viread®) has been 
administered to human research participants. From these studies, one can make some estimates 
of the effective intracellular half
-
life for tenofovir diphosphate (TFV
-
DP), the a
ctive moiet
y of 
the drug, which appears to be approximately ~150 hours 
(Hawkins et al., 2005; Pruvost et al., 
2005; Pruvost et al., 2009)
. From these studies, however, the inter
-
individual variability
for half
-
life
and peak concentration (C
max
) for TFV
-
DP is relativel
y l
arge (coefficient of variation around 
50% to 65%). Accordingly
, the best parameter estimates for such a simulation come from 
HPTN 066, Version 
2
.0 
Page 
18
of 
116
29 Nov
em
ber
2010
individual study
participants. To avoid intensive, frequent PK sampling, w
hich would be 
cumbersome in a large clinical trial, one can employ a combination of (1) population
-
based 
estimates from the studies like those cited above, and (2) data from a few samples from each 
individual in a prospective study
. To remove variability
i
n adherence in estimation of individual 
PK parameter estimates, samples collected from the individuals tested should follow an observed 
dose, thus insuring 100% adherence without variability
. With an observed dose, the possibility
of 
variable adherence aff
ecting subsequent drug concentrations is removed.   This leaves the 
following variables to consider: inter
-
individual PK variability
, assay
variability
, and unknown 
sources of noise that may vary
with time in the environment. Examples of simulations of 
pro
posed dosing strategies of TFV
-
DP in PBMCs (Figure 1
-
1) and TFV in blood serum (Figure 
1
-
2) are shown below. 
Figure 1
-
1.  Simulation of tenofovir diphosphate (TFV
-
DP) concentration
in
PBMCs
(y
-
axis) 
versus time
(x
-
axis) 
anticipated with the four differ
ent regimens planned for this study
: TDF 300 mg 
daily (blue, QD 300), TDF 600 mg twice weekly (Monday & Thursday, red, BIW 600), TDF 300 mg 
twice weekly (Monday & Thursday, green, BIW 300), TDF 300 mg weekly (Monday, purple, QW 300); 
note all regimens are 
administered as Truvada® (TDF/FTC). Note the minor increase in C
tau
and C
ma
x
between Day 28 and Day 35 where intra
-
individual variability will be estimated. 
Simulation parameters 
are based on data from previous studies 
(Hawkins et al., 2005; Pruvost et al., 2005; Pruvost et al., 2009)
. 
Simulations assume dose
-
proportionality and do not include intra
-
individual variation.
HPTN 066, Version 
2
.0 
Page 
19
of 
116
29 Nov
em
ber
2010
Figure 1
-
2. Simulation of tenofovir concentration in blood serum
(y
-
axis) 
versus time
(x
-
axis)
anticipated with the four different regimens planned for this proposal
. The regimens are described in 
Figure 1
-
1. Note the near complete overlap in concentration profiles between all regimens on days when 
the dose is taken. This is due to a very low accum
ulation index (see text below).
To use the computer modeling methods described above, 
two key facts must be determined with 
regard to the interaction of drug, participant, and regimen: intra
-
individual variability and dose
-
proportionality.
Knowledge of the
se variables is essential for planning future studies that use 
estimated PK parameters based on individual drug concentrations to evaluate adherence.
1.1.6
Importance of Intra
-
individual Variability 
Knowledge of intra
-
individual variability
in drug concentrat
ions is necessary
to determine 
accurate sample size estimates for studies that plan to use drug concentration monitoring as an 
adherence measure. Without this parameter, estimates can be made from inter
-
individual 
variability
from existing unpaired studies
. However, the inter
-
individual approach t
ypicall
y 
results in overestimates of variability
and hence a larger than necessary
sample size. 
Alternativel
y, some conservative assumptions can be made for intra
-
participant correlation, 
though this introduces an 
additional variable that may cause estimates to be either too high or too 
low. 
1.1.7
Importance of Dose
-
proportionality
In order for drug concentration to be used as an adherence measure, the dose
-
proportionalit
y 
(i.e., drug concentration at specified times 
changes proportionally
with change in the frequency
 
and amount of drug taken) must be stable at concentrations throughout the adherence range of 
interest: from concentrations associated with 100% adherence down to concentrations associated 
with lower level
s of adherence.  While dose
-
proportionality
is closel
y related to first order PK, 
HPTN 066, Version 
2
.0 
Page 
20
of 
116
29 Nov
em
ber
2010
there are other conditions that will cause disproportionate kinetics, even for a first order drug.  
Very
few drugs exhibit mixed or zero order PK in the clinically
relevant c
oncentration range 
(e.g., aspirin, phen
yt
oin, and fluoxetine). For these drugs, a proportional increase in dose results 
in a disproportionately
large increase in concentration. For other drugs, a proportional increase in 
dose may
result in a disproportiona
tel
y s
mall increase in concentration. This can be seen in drugs 
with saturable absorption, and with drugs that are anabolized to phosphorylated forms within 
cells, such as TFV, FTC, and zidovudine (AZT). For example, because phosphory
lation of AZT
-
monophos
phate within cells is the rate
-
limiting step in AZT
-
triphosphate anabolism, increasing 
the AZT dose can result in disproportionately
small or no increase in AZT
-
triphosphate. For 
either cause of disproportionate PK, the assumption of proportionate change i
n adherence (as 
with expected and observed drug concentrations) becomes more complex. 
While the dose
-
proportionality
for both TDF and FTC are well
-
established 
(Barditch
-
Crovo et 
al., 2001; Gish et al., 2002)
, thi
s proportionality
has not been determined for the phosphory
lated 
moieties of these drugs and must be established for one to use TFV
-
DP or FTC
-
TP as measures 
of adherence to a Truvada
®
(TDF/FTC) regimen. 
Other proportionalit
y factors are dose frequency an
d the accumulation of drug concentration with 
time 
–
characteristics that are unique to each drug and dosing regimen. Drugs that are dosed at 
intervals more frequent than their half
-
life accumulate over time and achieve concentrations that 
are higher at st
ead
y
-
state than following a single dose. This accumulation 
–
the so
-
called 
“accumulation index” or R
ac
–
varies with the ratio of the drug half
-
life to dose frequency
as 
follows: 
R
ac
= 1/(1 
–
e
-
k
)   where 
k
is the elimination rate constant [L
n(2)/half
-
l
ife] and 
t
is the dosing 
interval. 
The greater the drug half
-
life, the greater the accumulation index. The higher the accumulation 
index, the greater the magnitude b
y which drug accumulation will exceed sources of noise in 
drug concentration assessment (
e.g., dosing time variation, assay
variability, assay
sensitivity
, 
and inter
-
and intra
-
individual variability
). When measuring adherence with drug concentration, 
one is assessing the magnitude of difference between the expected concentrations of drug at (
1) 
prescribed dosing intervals assuming 100% adherence, and (2) actual drug concentrations from 
an unobserved dosing period. The difference is attributed to less than 100% adherence. A 
reduction in adherence has the equivalent effect on concentration as a 
reduction in the frequency
 
of dosing (i.e., the concentration falls). Drugs with a large accumulation index provide a greater 
degree of detectable difference between 100% adherence and lesser adherence. For drugs with 
little accumulation (dose frequency
le
ss than their half
-
life), it may
be very
difficult to 
discriminate the concentration associated with a single dose (without any
prior doses) from 
perfect adherence. Therefore, a participant with poor adherence can appear to a have high level 
HPTN 066, Version 
2
.0 
Page 
21
of 
116
29 Nov
em
ber
2010
of adherence w
ith a low accumulation index drug and drug regimen combination. I
n contrast, 
large accumulation index drug and drug regimen combination is very
resistant to “white
-
coat 
adherence”, in which a participant takes one or several doses within the day prior to a
scheduled 
research clinic visit. 
Table 1
-
1
. 
Accumulation index for parent and phosphorylated moieties of TDF and FTC dosed 
either weekly (168 hours) or daily (24 hours).
Drug moieties and regimens are ranked by accumulation 
index. An index of 2 indicate
s a doubling of concentration at steady
-
state compared to a single dose. An 
index of 1 indicates no accumulation at steady
-
state. For example, the concentration observed with 100% 
adherence can look the same as no adherence if the non
-
adherent participant 
takes a single dose prior to 
the observed blood collection when TFV, FTC or TDF/FTC are used with prescribed weekly dosing 
regimens. By contrast, the concentration expected with 100% adherence to Truvada® will be 9.6 (TFV
-
DP) or 2.7 (FTC
-
TP) times the conc
entration observed if a participant has taken only a single dose prior 
to the scheduled observation. 
(Hawkins et al., 2005; Pruvost et al., 2005; Pruvost et al., 2009; Wang et al., 
2004)
Table 1
-
1. Accumulation ind
ex for parent and phosphorylated 
moieties of TDF and FTC dosed either weekly (168 hours) or daily 
(24 hours).
Drug moiety
Half
-
life 
(hours)
Dosing 
interval 
(hours, tau)
Dosing 
interval / 
half
-
life
(tau/HL)
Accumulation 
index
(R
ac
)
TFV
-
DP
150
24
0.2
9.5
FTC
-
TP
36
24
0.7
2.7
TFV
-
DP
150
168
1.1
1.9
TFV
17
24
1.4
1.6
FTC
10
24
2.4
1.2
FTC
-
TP
36
168
4.7
1.0
TFV
17
168
9.9
1.0
FTC
10
168
16.8
1.0
For this reason, TFV
-
DP (the intracellular form of TFV) is an excellent candidate for drug 
adherence monito
ring, especiall
y with daily dosing (Table 1
-
1). With an intracellular half
-
life of 
150 hours, daily
to weekly
dosing of TDF has a TFV
-
DP accumulation index ranging from of 9.5 
to 1.9, offering a great range of sensitivity
for determining reduced adherence 
over a large range 
of dose frequencies.  In contrast, TFV concentration (measured in blood serum), when TDF is 
dosed daily
, would be expected to perform much less well, with a small difference in drug 
accumulation at stead
y
-
state during dail
y dosing when c
ompared to a single dose (e.g., taken on 
the day
of observation). When using TDF on a weekl
y dosing regimen, there is no anticipated 
difference between drug concentrations of serum TFV compared to taking a single dose of TDF 
without any
prior doses. Contra
sting Figure 1
-
1 with Figure 1
-
2 illustrates this point graphically
. 
The different dose regimens are easil
y distinguishable in Figure 1 where intracellular TFV
-
DP is 
measured. In contrast, the TFV serum levels are largel
y overlapping with daily and weekl
y 
dosing at least one day
per week.
HPTN 066, Version 
2
.0 
Page 
22
of 
116
29 Nov
em
ber
2010
1.2
Rationale
1.2.1
Overall Study Rationale
This PK study
is designed to establish the dose
-
proportionality
of TFV and FTC (serum and 
intracellular forms) with daily
to weekl
y dosing. This information is essential to (1) emplo
y dr
ug 
concentration as an adherence measure in future PrEP studies, and (2) to estimate the anticipated 
concentration of parent and active moieties of TFV and FTC in intermittent PrEP regimens 
associated with full adherence to a prescribed regimen. I
n additio
n, intra
-
individual variability
 
will be assessed to improve sample size estimates in future PrEP studies that use drug 
concentration as an adherence measure or where PK
-
PD correlations are planned. The dose
-
proportionality
of intra
-
cellular
phosphates of t
he two components of the study
product has 
not 
previously
been established. Given the complexity of movement of these drugs between body
 
compartments (central compartment, vaginal mucosal tissue, vaginal lumen, gastrointestinal 
mucosal tissue, gastrointest
inal lumen), into cells within these compartments, and intra
-
cellular 
phosphory
lation, it is possible that non
-
dose proportional kinetics, such as mixed or zero
-
order 
saturable processes may
be operating.
1.2.2
Dosing Regimen Rationale 
We propose to study
fou
r different dosing regimens of Truvada® (tablets include 300 mg TDF 
and 200 mg FTC): one tablet daily, two tablets twice weekl
y, one tablet twice weekl
y, and one 
tablet weekl
y. To provide adequate data on dose
-
proportionality
, these regimens are selected t
o 
cover the range of concentrations achieved between daily and weekl
y dosing, representing a 7
-
fold range of anticipated drug concentrations. These regimens will achieve drug concentrations 
anticipated in current PrEP studies that employ
daily
dosing, as w
ell as drug concentrations 
likely
to be achieved with proposed intermittent PrEP regimens with dosing as infrequent as 
weekl
y or twice weekly dosing. In addition to studying three different dosing frequencies (daily, 
twice weekly
, and weekly
), we will stud
y t
wo different doses given twice weekl
y:
a twice
-
weekl
y regular dose (one Truvada® tablet), and a twice
-
weekl
y double
-
dose (two Truvada® 
tablets). This will provide data on dose
-
proportionality
for regimens between the weekl
y and 
daily
dosing. Using the w
eekl
y one Truvada® tablet as reference, these four dosing regimens 
represent anticipated drug exposures of 1x (weekly
), 2x (twice weekl
y), 4x (double
-
dose twice 
weekl
y), and 7x (daily). These proportions will provide sufficientl
y rich data to assess dose
-
p
roportionality
. If dose
-
proportionality
is determined not to hold between weekl
y and dail
y 
dosing, the middle dose regimens provide intermediate points to increase the accuracy
with 
which we can determine the point of deviation from dose
-
proportionality
. F
urther, they
will 
provide rich drug concentration data to understand these intermediate dosing regimens, which 
may
prove useful in future PrEP efficacy
studies should the concentrations of drug prove 
insufficiently
low with weekl
y dosing. 
HPTN 066, Version 
2
.0 
Page 
23
of 
116
29 Nov
em
ber
2010
1.2.3
Dosing Duration
Rationale
Dose
-
proportionalit
y c
an be assessed at an
y point of observation following initiation of dosing. 
Intra
-
individual variability
, however, can best be assessed at two sampling times not anticipated 
to vary
based on PK principles. Essentially
, by
d
efinition, this condition is achieved when 
steady
-
state has been reached. This study
requires direct observation of dosing to rule out 
adherence as a cause for variation in drug concentrations. Therefore, we plan to begin sampling 
for intra
-
individual vari
ability
assessments as early
as possible after dosing, balancing logistical 
difficulties (up to daily
dosing for study
staff and research participants) and PK limitations. 
Intracellular TFV
-
DP concentrations are estimated to achieve between 93% and 97% of 
steady
-
state Cmin (trough) concentrations after 4 half
-
lives and 5 half
-
lives, respectively
, have elapsed 
after initiation of Truvada® dosing. Based on an estimated 150
-
hour TFV
-
DP intracellular half
-
life (FTC
-
TP will achieve steady
-
state earlier, given it
s far shorter 36
-
hour half
-
life), the 4 and 5 
half
-
life points coincide with 28 and 35 day
s of dosing. Laboratory
assay
variation for all of the 
assay
s planned for this study
are more than twice as large as the very small 4% difference in 
concentrations th
at we expect to measure between Day
28 and Day
35. Accordingly
, we plan to 
dose for 35 day
s, and to use samples from Day
28 and Day
35 for our intra
-
individual variability
 
estimates. One could argue for longer periods of dosing to further reduce difference
s between 
doses in the as
ym
ptomatic approach to a true steady
-
state, but we believe that our proposed plan 
provides a reasonable balance between logistical complexity
(dail
y dosing under direct 
observation) and reasonable experimental variation. 
The doub
le
-
dose (two Truvada® tablets) twice
-
weekl
y regimen is onl
y 4/7
th
(57%) of total 
weekl
y dosing for the single dose (one tablet) daily regimen. However, the double
-
dose twice
-
weekl
y regimen includes doses within each dosing day that are twice the dose recom
mended in 
the package insert for both 
FTC and TDF, namel
y 400 mg and 600 
mg
, respectivel
y. We believe 
that there is ample evidence that this dose will be safe in these health
y volunteers based on 
previous clinical testing and based upon pharmacological pri
nciples. First, regarding prior 
clinical studies, as part of their drug development, both TDF and FTC were studied at these 
doses with daily
dosing from 2 to 8 weeks without any
observation of dose
-
dependent adverse 
effects 
(Barditch
-
Crovo et al., 2001; Rousseau et al., 2003; Rousseau et al., 2001)
. 
Kearney
, et al., demonstrated bioequivalence for TDF and FTC compared to the Truvada® 
combination 
(
Kearney
et al., 2004)
. Accordingly
, the data based on dosing single products is 
provided as evidence of each individual component within the combination. 
In the Barditch
-
Crovo 2001 paper, one cohort of HIV
-
infected patients recei
ved 600 mg TDF for 
35 day
s 
–
the highest dose administered 
(Barditch
-
Crovo et al., 2001)
.  The drug demonstrated 
dose
-
proportionalit
y for peak concentration and area under the concentration time curve in blood 
plas
ma over the range from 75 mg to 600 mg TDF daily
. With regard to safety
, 1 placebo and 3 
HPTN 066, Version 
2
.0 
Page 
24
of 
116
29 Nov
em
ber
2010
TFV subjects discontinued the study
earl
y due to lab abnormalities. Six subjects had grade 3 or 4 
adverse events (1 placebo, 5 on TDF). None of the 10 subjects receivi
ng TDF 600 mg dail
y were 
discontinued for either lab abnormalities or experienced a grade 3 or 4 clinical event. 
Accordingl
y, there was no dose
-
response noted in adverse effects in this study
over the dose 
range from 75 mg to 600 mg dail
y for 35 days. We w
ill dose for the same 35 day
duration, but 
the 600 mg dose will only be administered twice weekl
y rather than daily as in this study
. 
In the Rousseau 2001 paper, one cohort of 9 HIV
-
infected subjects received 400 mg dail
y FTC 
for 14 day
s.  Dose
-
proportio
nal increases in FTC and FTC
-
TP concentrations were seen over this 
period. Among all 38 subjects in the study
, FTC was well tolerated at all dosing levels. No 
serious or severe adverse events were noted. Moderate events possibly related to FTC were seen 
an
d were not dose
-
related. While this study
only
dosed for 14 day
s, it is still highly
relevant 
since the only
dose that is anticipated to exceed the intracellular concentrations of the single 
daily
dose cohort is the first dose of the double dose twice week
ly
regimen. Thereafter, all 
intracellular concentrations will fall below those of the single daily dose cohort.
In contrast, we plan to administer the double
-
dose only
twice
-
weekly
. Accordingl
y, we believe 
the double
-
dose twice
-
weekl
y regimen will be at l
east as safe as the daily
dosing regimen. 
Based on pharmacological principles, published estimates of PK parameters for both drugs as 
summarized in Table 1
-
1 above, onl
y t
he very
first dose of the double
-
dose regimen will give an 
intracellular concentrat
ion higher than the concentration following the first dose of the single 
dose daily
regimen. At all other times, the intracellular concentration for the double dose twice 
weekl
y falls below the single dose daily regimen The accumulation index of the fully 
phosphory
lated moieties of tenofovir and emtricitabine dosed dail
y i
s 9.5 and 2.7, respectivel
y. 
Thus, at stead
y
-
state, the intracellular concentration of the fully phosphory
lated moieties exceeds 
that of the peak concentration following a single dose by m
ultiples of those values. Accordingly
, 
even with a doubling of a single dose, the peak intracellular concentrations falls well below the 
steady
-
state concentrations with daily
dosing. With twice weekly
dosing of Truvada® at double 
the recommended dose, the
peak intracellular concentrations are still below those of dail
y 
Truvada® dosing (since the total weekl
y dose is only
4/7
th
the daily
dose total. After the first 
dose, the double
-
dose regimen results in concentrations below the daily
single dose regimen (
see 
Figure 1
-
1 above). 
The serum TFV concentrations will be higher with double
-
dosing twice weekly
when compared 
to daily
dosing of a single tablet (Figure1
-
2). This is because the accumulation index for TFV 
and FTC are onl
y 1.6 and 1.2, respectivel
y, i
ndicating very
little accumulation. Accordingl
y, the 
double dose will exceed the concentration of the daily
single dose TFV and FTC, but only
on the 
2 day
s of the week when the double dose is taken.  I
n addition, the use of double doses with a 
twice
-
weekl
y
frequency
provides the dail
y dose equivalent most closely associated with coitally
-
dependent dosing, in which a dose is taken both before and following intercourse. We believe 
these blood plasma concentrations are less relevant for safet
y i
ssues as the ph
osphory
lated 
HPTN 066, Version 
2
.0 
Page 
25
of 
116
29 Nov
em
ber
2010
moieties are the ones associated with the desired antiretroviral and undesired (non
-
viral) effects 
of the drugs.
2.0
STUDY OBJECTIVES AND
DESIGN
2.1
Primary Objectives
The primary
objectives of this study
are to:
·
Assess dose
-
proportionality
of int
racellular TFV
-
DP and FTC
-
TP from weekly
to dail
y 
dosing (Arms 1
-
4).
·
Describe intra
-
individual variability
in intracellular TFV
-
DP and FTC
-
TP concentrations 
at stead
y
-
state (comparison of Day
28 and Day
35).
2.2
Secondary Objectives
The secondary
objective
s of this study
are to:
·
Describe the relationship between pre
-
dose (C
t
) and decay
ing concentrations of TFV, 
FTC, and their phosphorylated derivatives (TFV
-
DP and FTC
-
TP) in blood serum, 
peripheral blood mononuclear cells (PBMCs), CD4+ blood cells, total tissue cells, CD4+ 
tissue cells, tissue homogenate, semen, and luminal 
fluid at steady
-
state (Day
35 [pre
-
dose] and Day
49 [decay
ing, greater than one half
-
life for TFV
-
DP]).
·
Describe differences in intracellular TFV
-
DP and FTC
-
TP stead
y
-
state C
t
between men 
and women.
·
Characterize the safet
y p
rofiles of four different TDF/FT
C PrEP regimens.
2.3
Study Design
2.3.1
Identification of Study Design
HPTN 066 will be a Phase 1, multi
-
site, randomized, four
-
arm, open label study
of the 
concentrations of TFV, FTC, and their metabolites in various body compartments following oral 
Truvada® dos
ing under direct observation by
the site staff (directly
observed therapy
[DOT]) to 
assure 100% adherence to prescribed dosing regimen. The prescribed dosing regimens range 
from weekl
y t
o dail
y FT
C
/TDF
at one of two possible doses. The overall study
schedu
le and 
sample collection summary
is provided in Appendix I
.  After participant education, informed 
consent, and screening for study
eligibility
, participants will have baseline procedures performed 
(e.g. phlebotomy
) before the first dose. 
HPTN 066, Version 
2
.0 
Page 
26
of 
116
29 Nov
em
ber
2010
2.3.2
Study Sampling
Sampling will occur over 7 weeks: 
at enrollment (pre
-
dose), pre
-
dose #2 (Day
 
1
for treatment 
arm 4, Day
 
3
for treatment arms 2 and 3, and Day 
7
for treatment arm 1) and Days 
7, 14, 21, 28, 
35 and 49 to support each of the several objectives as follows:
1.
Sample blood serum and blood cells (total cells and CD4+ cells) weekl
y for 5 weeks 
(Enrollment and Day
s 7, 14, 21, 28, and 35) to assess rate of accumulation and dose
-
proportionality
in concentrations of extracellular TFV and FTC and intracellular TFV
-
DP 
a
nd FTC
-
TP. 
2.
Sample blood serum and blood cells at stead
y
-
state (Day
28 and Day
35) to assess intra
-
individual variability
.
3.
When participants consent to participate in HPTN 066, they
will be offered the 
opportunity
to participate in the 
intensive sampling c
ohort (to provide mucosal samples)
. 
The slots in the intensive sampling cohort will be balanced b
y gender, so that there will 
be two men and two women who will undergo mucosal sampling in each of the four arms 
of the study
. Potential research participants 
who do not choose to participate in
or are 
i
nevaluable for
the 
intensive sampling cohort
will be offered participation in the non
-
intensive cohort. The study
team will sample rectosigmoid, seminal and vaginal fluid, 
cells, and tissue (in addition to blood)
at Day
s 35 and 49 to compare extracellular 
concentrations of TFV and FTC and intracellular concentrations of TFV
-
DP and FTC
-
TP, and to estimate the elimination rate of drug from these compartments. 
The sampling described must occur on the days prescribe
d given the need to sy
nchronize post
-
dose time (7 day
s) across the four regimens. The blood sampling time should precede the 
established dosing time 
by
no more than one hour
. I
f the participant cannot have tissue sampled 
as prescribed, 
sampling should take
place within the visit window, described in the SSP
. I
n all 
cases, there must be accurate recording of sample collection times. 
Biopsies will not be performed during menstruation. As such, the timing of the first dose will 
need to take into consideratio
n menstrual patterns and will be adjusted accordingl
y.
2.3.3
Summary of Major Endpoints
2.3.3.1
Primary Endpoints
: 
·
Concentrations of TFV and FTC in blood serum
·
Concentrations of TFV
-
DP and FTC
-
TP in PBMCs and CD4+ blood cells
HPTN 066, Version 
2
.0 
Page 
27
of 
116
29 Nov
em
ber
2010
2.3.3.2
Secondary Endpoints
:
·
C
oncentrations of TFV, FTC, TFV
-
DP and FTC
-
TP in blood
·
Concentrations of TFV and FTC in vaginal and rectal secretions
·
Concentrations of TFV and FTC in vaginal
/cervical
and rectal tissue homogenates
·
Concentrations of TFV
-
DP and FTC
-
TP in unselected and CD4+ 
vaginal
/cervical
and 
rectal tissue cells and tissue homogenates
·
Concentrations of TFV, FTC, TFV
-
DP and FTC
-
TP in fluid (vaginal, rectal, semen
), 
cells, and tissue homogenate
·
Adverse experiences, including  safety laboratory studies (hematological, renal, h
epatic 
function) 
2.3.4
Description of Study Population
The study
population will include approximately
32 evaluable (defined Section 7.3), generally
 
healthy
18
-
44 year
-
old men and women, who are HIV
-
uninfected and not pregnant or 
breastfeeding. The upper age 
limit was selected to provide comparability
in age for male 
participants with our pre
-
menopausal female participants and reduce the variability
that might be 
introduced b
y a wider age range that could have a significant impact in this small study
.  
2.3.5
Trial
Duration
The total duration of participation from the Enrollment Visit to the Termination Visit is 7 weeks.  
Visits may
be completed within specified windows around target dates.  The approximate time to 
complete study
enrollment is expected to be six mo
nths.  The time of total study
duration is 
expected to be approximately
twelve months, including the study
follow
-
up period.
Detailed 
information regarding visit windows will be thoroughl
y described in the HPTN 066 Study
 
Specific Procedures (SSP) Manual.
2.3.6
Expected Duration of Participation
The expected duration of participation for enrolled participants 
approximately
two months
.  No 
study
data will be collected after the Day
49 final study
visit. 
3.0
STUDY POPULATION
Thirty
-
two HIV
-
uninfected participants w
ill be included in this study
.  Participants will be 
selected for the stud
y according to the criteria in Section 3.1 and 3.2.  They will be recruited as 
described in Section 3.3 and assigned to a stud
y a
rm as described in Section 7.4. I
ssues related to 
HPTN 066, Version 
2
.0 
Page 
28
of 
116
29 Nov
em
ber
2010
par
ticipant retention and withdrawal from the study, are described in Sections 3.4 and 3.5, 
respectivel
y.
3.1
Inclusion Criteria
Participants who meet 
all
of the following criteria are eligible for inclusion in this study
:
·
18 to 44 y
ears of age, inclusive on th
e date of screening.
·
Provides informed consent for the study
.
·
Non
-
reactive HIV rapid test results at the screening and enrollment visits.
·
An estimated calculated creatinine clearance (eCcr) at least 70 mL/min by the 
Cockcroft
-
Gault formula where:
o
eCcr (fem
ale) in mL/min = [(140 
-
age in years) x (weight in kg) x 0.85] / (72 
x serum creatinine in mg/dL
).
o
eCcr (male) in mL
/min = [(140 
-
age in years) x (weight in kg)] / (72 x serum 
creatinine in mg/dL).
·
Participants are sexually
active
, defined as at least on
e sex
(vaginal or anal 
intercourse)
act in the 30 day
s prior to screening
.  
·
Participants must agree to use condoms for all coital events during study
 
participation.
·
Intensive sampling cohort only
:
o
Not using spermicide as a means of birth control (in conju
nction with a 
condom or diaphragm)  
·
Women must:
o
Be pre
-
menopausal
o
Have regular menstrual cy
cles with at least 21 days between menses (unless 
on contraception that causes amenorrhea or irregular menses) 
o
Have a negative urine pregnancy
test at screening an
d enrollment
o
Be utilizing an alternative method of birth control in addition to condoms 
(hormonal contraceptive, diaphragm or have undergone surgical sterilization) 
or have a vasectomized exclusive male partner.
o
Intensive sampling cohort only
:
§
Have a cervi
x
§
Have documentation of a normal Pap smear within 12 months
HPTN 066, Version 
2
.0 
Page 
29
of 
116
29 Nov
em
ber
2010
3.2
Exclusion Criteria
·
At screening:
o
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater 
than 1.5 X the site laboratory
ULN (upper limit of normal)
o
Hemoglobin less than 10.0 g
/dL
o
Platelet count less than 100,000/mm
3
o
Serum phosphate level below site laboratory
LLN
(lower limit of normal)
o
INR or aPTT greater than site laboratory ULN
o
Other safety
tests (
bicarbonate (
HCO3
)
, 
potassium (
K
)
, 
chloride (
Cl
)
, 
sodium 
(
Na
)
,
calcium (Ca),
f
asting glucose) with results outside of the laboratories 
reference range
o
1+ or greater protein on urine dipstick testing
o
1+ or greater glucose on urine dipstick testing
·
Culture
-
confirmed urinary
tract infection
·
Co
-
enrollment in any
other HIV interventional
research stud
y (
excluding behavioral 
only
interventions) or prior enrollment in the active arm of a HIV vaccine trial.
·
Clinically
apparent or patient report of active skin disorders including: rash, pruritus, 
maculopapular rash, urticaria, vesiculobullous
rash, and pustular rash.
·
Women who are pregnant or breastfeeding.
·
One or more reactive HIV rapid test result
s
at screening or enrollment, even if HIV 
infection is not confirmed.
·
Positive hepatitis B surface antigen (
HBsAg
) test.
·
Excessive use of alcohol (
more than 4 drinks a day
on a regular basis).
·
Interleukin therap
y;
medications with significant nephrotoxic potential, including but 
not limited to amphotericin B, aminogl
yc
osides, cidofovir, foscarnet and s
ystemic 
chemotherap
y;
and medications that may
in
hibit or compete for elimination via active 
renal tubular secretion (including but not limited to probenecid).
·
Participants with a history of having a gastrectomy, colostom
y, ileostomy, or an
y 
other procedure altering the gastrointestinal tract or drug abs
orption. 
·
Intensive sampling cohort only
:
○
A positive test for sy
philis, gonorrhea, or Chlamy
dia 
○
A positive test for HSV
-
2 (individuals with active lesions only
)
○
Findings consistent with bacterial vaginosis, vaginal candidiasis, or 
trichomonas (women only
)
○
History
of STI within 3 months prior to enrollment
○
Medications that prolong clotting time (e.g., warfarin, heparin, clopidogrel 
classes.)
○
Abnormalities of the colorectal mucosa, or significant colorectal s
ym
ptom(s), 
which in the opinion of the clinician r
epresents a contraindication to biopsy 
HPTN 066, Version 
2
.0 
Page 
30
of 
116
29 Nov
em
ber
2010
(including but not limited to presence of an
y unresolved injury
, infectious or 
inflammatory
condition of the local mucosa, and presence of s
ym
ptomatic 
external hemorrhoids).
○
Clinically
apparent pelvic exam finding (ob
served by
study
staff) of genital 
lesions, ery
thema, edema or any
other abnormal phy
sical or pelvic exam 
finding that, in the opinion of the investigator or designee, would 
contraindicate stud
y p
articipation. 
○
Women who have had cervical procedures (coniza
tion, L
EEP procedure, 
cr
yosurgery
) within the previous 6 months.
○
Spermicide as a method for contraception within last 30 day
s
·
Any
other reason or condition that in the judgment of the investigator, would make 
participation in the study
unsafe, complicate i
nterpretation of study
outcome data, or 
otherwise interfere with achieving the stud
y objectives.
3.3
Recruitment Process
Participants will be recruited from a variety
of venues. Examples of such venues include local 
health clinics, local health departments, 
and family
planning clinics. In order to reach a broader 
audience, college and local newspaper advertisements will be utilized. Fliers will be posted on 
frequentl
y visited local venues. Electronic advertisement will include secure list
-
serves 
(university
) 
and craigslist.com. All advertising materials must undergo approval by
local IRB’s. 
3.4
Participant Retention
Once a participant enrolls in this study
, the study
site will make every
effort to retain him/her for 
7 weeks of the stud
y. Retention goal for the
study
is 95%. For each participant who is not fully
 
evaluable (as defined in Section 7.3), an additional participant will be enrolled. Study
site staff 
are responsible for developing and implementing local standard operating procedures (SOPs) to 
target th
is goal.  Components of such procedures include:
·
Thorough explanation of the study visit schedule and procedural requirements during 
the informed consent process and re
-
emphasis at each study
visit.
·
Thorough explanation of the importance of all study tre
atment groups to the overall 
success of the stud
y.
·
Collection of detailed locator information at the study
Screening Visit, and active 
review and updating of this information at each subsequent visit.
·
Use of appropriate and timely visit reminder mechanis
ms.
HPTN 066, Version 
2
.0 
Page 
31
of 
116
29 Nov
em
ber
2010
·
Immediate and multifaceted follow
-
up on missed visits.
·
Mobilization of trained outreach workers or “tracers” to complete in
-
person contact 
with participants at their homes and/or other community
locations.
3.5
Participant Withdrawal
Regardless of the 
participant retention methods just described, participants may
voluntarily
 
withdraw from the stud
y for an
y r
eason at an
y t
ime. The Investigator also may withdraw 
participants from the study
in order to protect their safet
y and/or if they
are unwilling or u
nable 
to comply
with required study
procedures after consultation with the Protocol Chair, DAIDS 
Medical Officer, SDMC Protocol Statistician, and CORE Protocol Specialist. Study
visit and 
dosing requirements for research participant eligibility
for safet
y 
and PK analy
ses is described in 
Section 7.2.   
Participants also may
be withdrawn if the study
sponsor, government or regulatory
authorities
(Including the Office for Human Research Protection
s
(OHRP) and FDA)
, or site I
RBs/ECs 
terminate the stud
y prior 
to its planned end date.  
Every
reasonable effort will be made to complete a final evaluation (as described in Section 5.5) 
of participants who terminate from the stud
y prior to the final study visit, and study staff will 
record the reason(s) for all wit
hdrawals from the study
in participants’ study
records.
4.0
STUDY TREATMENT/PROD
UCT/INTERVENTION
4.1
Study Product Formulation/Content/Storage
The study
product to be dosed in all treatment arms is Truvada®
(FTC
/TDF
) tablet. Truvada® 
tablets are fixed dose com
bination tablets containing emtricitabine (FTC) 200 mg and tenofovir 
disoproxil fumarate (TDF) 300 mg in each tablet.  Each bottle contains a silica gel desiccant 
canister that should remain in the original container to protect the stud
y product from humid
ity
.
Study
Product Storage
FTC/TDF (Truvada®) study
products should be stored at 25°C with excursions permitted to 
15°C 
-
30°C (59°F
-
86°F).
HPTN 066, Version 
2
.0 
Page 
32
of 
116
29 Nov
em
ber
2010
4.2
Study Product Regimen(s)
Study
participants who meet 
the inclusion/exclusion
criteria (see Section
s
3.1 and 3.2
) 
will be 
randomized to one of four open
-
label treatment arms with emtricitabine (FTC) 200 mg/tenofovir 
disoproxil fumarate (TDF) 300 mg (Truvada®).
Table 
4
-
1. 
Study Product Dosing Arms
Treatment 
Arm
Study Product
Number 
of Tablets
Route
Frequency
Duration
1
FTC 200 mg/TDF 300mg
One(1)
Orally
Once Weekl
y
5 Weeks
2
FTC 200 mg/TDF 300mg
One(1)
Orally
Twice Weekl
y
5 Weeks
3
FTC 200 mg/TDF 300mg
Two(2)
Orally
Twice Weekl
y
5 Weeks
4
FTC 200 mg/TDF 300mg
One(1)
Orally
Once Daily
5 Weeks
4.3
Study Product Admini
stration 
FTC/TDF (Truvada®) tablets are administered orally
with or without food.
4.3.1
Directly Observed Therapy (DOT) Guidelines
DOT is defined as directly observed therap
y. A person identified by the Clinical Research Site 
(CRS) must observe and document 
the doses of study
products taken by
the study
 
participant.
Participants randomized to all arms will have all doses (as per randomized study
 
arm) observed and documented. 
The method by
which DOT is to occur should be discussed at length with the particip
ant at study
 
screening. Participants and coordinators should formulate a well
-
described plan for DOT prior to 
entry
. 
It is possible that participants may
start coming to the clinic for DOT for the first few 
weeks and then switch to an alternate location as
CRS study
staff and alternative facilities 
permit.
Each CRS will be responsible for determining who can perform DOT for that site. The 
individual(s) could administer the study
product or observe the study
products being taken, 
depending upon his/her cert
ification and legal requirements of the local jurisdiction. Someone 
who is not medically
trained cannot offer advice about the study
product.
The DOT observer must be an objective third party arranged b
y t
he CRS. Friends or famil
y 
members are not permitte
d as observers. Individuals who might perform DOT include 
phy
sicians, registered nurses, licensed practical nurses, ph
ys
ician’s assistants, nursing assistants, 
certified h
ome health aides, pharmacists,
social workers, outreach workers, or other responsible
individuals designated b
y the CRS.  
HPTN 066, Version 
2
.0 
Page 
33
of 
116
29 Nov
em
ber
2010
DOT may
be delivered in any
location deemed appropriate by
the CRS (i.e., in the home, clinic, 
pharmacy
, or outreach center). The study
staff are responsible for ensuring that confidentiality is 
maintained at the sele
cted locations. 
Examples of clinic
-
based DOT used at sites include:
·
Participant presenting daily
to the site pharmacy
for observed dosing b
y t
he site 
pharmacist who then documents on DOT participant log.
·
Participant presenting daily
to the entrance of th
e hospital/clinic and study
coordinator 
bring participant’s prepared study
product to participant and study
coordinator then 
documents on DOT participant log.
·
Participant and study
coordinator meet at a designated off
-
campus location (coffee shop) 
each mo
rning for DOT and study
coordinator documents on DOT participant log.
CRSs that plan to use off
-
site locations for DOT are advised to give careful consideration to the 
following issues:
●
Confidentiality
: Sites should consider where study paper work will be stored, how 
participants will be identified, how participant’s prepared stud
y p
roduct will be 
transported, and where participants will be observed. Confidentiality
should be discussed 
with participants as plans for their DOT are developed. 
The participant should be 
comfortable with the person who will be observing DOT. 
Sites must also discuss 
confidentiality
with the DOT observer, noting situations where breaches are most likely
 
to oc
cur. DOT observers may
be required to sign a confidentiality
agreement.
The place of DOT administration should be captured on the study treatment record. The primary 
location of DOT administration and an
y alternate or secondary locations of DOT administra
tion 
should be documented in the participants’ study
files as well.
 
A DOT log will be used as a 
primary
source document to record date, time, place, 
study
product 
administered or taken, 
observer signature, participant signature, and an
y i
ntervention for m
issed DOT visit (i.e., 
telephone call). 
Flexibility
and creativity
are needed as sites explore options for DOT delivery. I
t is recognized 
that sites will have some variability
in the way
they
choose to administer DOT, but do need to 
report the delivery
m
echanisms they
choose in the participants’ study
files. 
Sites will be asked to 
inform the study
team of the methods they
are considering before they
are used.
Sites that have 
questions should contact the HPTN 066 protocol team for guidance.
HPTN 066, Version 
2
.0 
Page 
34
of 
116
29 Nov
em
ber
2010
4.3.2
Follow
-
up for 
Missed Appointments
Participants who miss a DOT visit must be contacted b
y t
he clinic. Sites can be flexible (e.g., 
some sites may
choose to do a home visit if this is an available option while others may
choose 
telephone contact).
 
A tracking form has 
been developed for missed DOT visits as part of the 
study
treatment record. Missed visits and reasons for missed visits must be recorded on the 
appropriate CRF.
4.3.3
Take
-
home Supply (for emergencies only) 
Take
-
home dosing may
be provided to participants for 
emergency
purposes.  Additional details 
on the use of the emergency
dose will be provided in the SSP manual.
4.4
Product Supply and Accountability
Study
Product Supply
, Distribution and Accountability
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarat
e (TDF) 300 mg study
product tablets 
are manufactured and provided by
Gilead Sciences, Inc. under the trade name Truvada®.
Study
Product Acquisition
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg st
udy
product
will be 
supplied by
t
he NIAID Clinical Research Products Management Center (CRPMC).  The study
 
site pharmacist can obtain FTC/TDF stud
y products through the CRPMC by following the 
instructions in the 
Pharmacy Guidelines and Instructions for DAIDS Clinical Trial Networks
, 
and i
nstructions in the SSP Manual.
Study
Product Accountability
The site pharmacist is required to maintain records of all FTC/TDF study
products received from 
the CRPMC and subsequently
dispensed to study
participants.  All unused study
products are to 
be h
eld until the study
is completed, terminated, or otherwise instructed b
y t
he sponsor.  Specific 
instructions will be provided by
the sponsor for return or destruction of the study
products.
4.5
Toxicity Management
Guidelines for clinical management and produ
ct hold/discontinuation are outlined in this section.
In general, the site investigator has the discretion to hold study
product at any
time if s/he feels 
that continued product use would be harmful to the participant, or interfere with treatment 
HPTN 066, Version 
2
.0 
Page 
35
of 
116
29 Nov
em
ber
2010
deemed c
linicall
y necessary
according to the judgment of the investigator.  Unless otherwise 
specified below, the investigator should immediately
consult the PSRT for further guid
ance in 
restarting study
drug
or progressing to permanent discontinuation. 
4.5.1
Grading
System
The grading s
ys
tem is located in the Division of AIDS Table for Grading Severity of Adult and 
Pediatric Adverse Events (DAIDS AE Grading Table), 
Version 
1
.0
, December 2004; 
Clarification August 2009, which can be found on the Regulatory
 
Support Ce
nter (RS
C) Web 
site: 
http://rsc.tech
-
res.com/safety
andpharmacovigilance/
. 
4.5.2
Dose Modification 
No dose modifications are permitted.
If absolutel
y necessary, dosing may be delayed for 2 
day
s in Arms 1
-
3 during the first 3 weeks 
on study
. Thereafter, all doses in week 4 and 5 must be taken as scheduled. All doses for 
research participants in Arm 4 must be taken as scheduled. Failure to comply with these schedule 
requirements will result in
termination of the participant from the protocol after a final safet
y 
evaluation. 
4.5.3
Dis
continuation of Study Product
in the Presence of Toxicity
Grade 1 or 2
In general, participants who develop a Grade 1 or 2 AE regardless of relatedness to study produc
t, 
and that is not specifically
addressed below may
continue use of the study
product per protocol.  
Grade 3
Participants who develop a Grade 3 AE or toxicity that is not specifically
addressed below and is 
judged to be related to study
product should ha
ve that study
product permanently
discontinued.  
In general, and unless otherwise decided in consultation with the PSRT, the investigator should 
re
-
evaluate the participant at least weekl
y up to 2 weeks to document resolution of toxicity
to less 
than Grade
2.  
Grade 4
Participants who develop a Grade 4 AE or toxicity that is not specifically
addressed below 
regardless of relationship to study
product should have the stud
y product permanentl
y 
discontinued. The participant should be re
-
evaluated at least we
ekl
y up to 2 weeks to show that 
the adverse event resolves to less than Grade 2.
HPTN 066, Version 
2
.0 
Page 
36
of 
116
29 Nov
em
ber
2010
4.5.4
General Criteria for Discontinuation of Study Product
Participants may
voluntarily
discontinue the study products for an
y reason at an
y t
ime.  Site I
oRs 
will permanently
dis
continue participants from study
product per protocol for any
of the specific 
criteria below, which may be further clarified in the SSP.  Site I
oRs also may
permanently
 
discontinue participants from study
product for use of prohibited medication (per Secti
on 
4.9
), 
for reasons not shown here or in the SSP (e.g., to protect participant
s’
safety
and/or if 
participants are unable or unwilling to comply
with study
product use procedures).  In such 
cases, the Site IoRs should first query the PSRT for review.  The
PSRT will provide a written 
response to the site indicating whether the PSRT has recommended permanent discontinuation of 
study
product based on careful review of all relevant data.
The criteria for permanent discontinuation of study product use for an i
ndividual participant are:
·
Study
product
-
related toxicity
requiring permanent discontinuation of study
product per 
the guidelines above and below
·
Completion of regimen as defined in the protocol
·
Request by
participant to terminate study
product
·
Clinical r
easons determined by
the phy
sician 
·
Acquires HIV infection, hepatitis B infection 
·
Becomes pregnant
Any
research participant who discontinues participation prematurel
y fo
r any
reason should, prior 
to discontinuation and dismissal from the study
, undergo t
he safet
y evaluations regularl
y 
scheduled for the final study
visit on Day
49, at the time of discontinuation.  
4.6
Management of Specific Toxicities
Specific guidance related to permanent discontinuation is also noted here as it pertains to the 
clinical ma
nagement of toxicities.
4.6.1
Nausea and Vomiting
Participants with Grade 1 or 2 nausea or vomiting may be treated s
ym
ptomatically
with 
hy
dration, oral antiemetic therapies or antiemetic suppositories at the discretion of the site 
investigator.  Participants s
hould be instructed to take oral stud
y product with food.  
Participants with Grade 
³
3 nausea and vomiting for which an alternative etiology is not 
established must permanently
discontinue the study
product 
and be treated sy
mptomaticall
y
. 
HPTN 066, Version 
2
.0 
Page 
37
of 
116
29 Nov
em
ber
2010
4.6.2
Diarrhea
Par
ticipants with diarrhea of an
y t
oxicity
grade may
be treated s
ym
ptomatically
with permitted 
antimotility
agents and rehy
dration at the discretion of the site investigator.
Participants with new onset Grade 
³
3 diarrhea that is unresponsive to antimotility
agents and for 
which an alternative etiology
(e.g., infectious diarrhea) is not established must permanentl
y 
discontinue study
product 
and be treated s
ym
ptomatically
.
4.6.3
AST/ALT Elevations
Careful assessments should be done to rule out the use of alcohol, n
on
-
study
medication
-
related 
drug toxicity
, or viral hepatitis as the cause of elevation in AST or AL
T of any
grade.  The 
participant must be carefully
assessed for an
y s
ym
ptoms or signs of hepatotoxicity
, including 
fatigue, malaise, anorexia and nausea, ja
undice, acholic stools, right upper quadrant pain or 
hepatomegal
y.  If the AST/AL
T elevation is considered most likely
to be due to concomitant 
illness or medication, standard management, including discontinuation of the likely
causative 
agent, should be u
ndertaken.
If s
ym
ptoms or signs of clinical hepatitis are present, stud
y 
treatment must be discontinued (see below).
Grade 1
For stud
y participants with less than Grade 1 ALT and AST at study entry, an increase to Grade 
1 AL
T or AST even in an asy
mptomati
c participant may
be of concern.  
AL
T or AST must be repeated as soon as possible (at most within 1 week of the receipt of the 
results) of a new Grade 1 AL
T or AST. Study
treatment may
be continued while repeating ALT 
and AST at the discretion of the inv
estigator provided the participant is as
ymptomatic.  
Grade 2
Participants should have AL
T or AST re
-
checked as soon as possible (at most within 1 week) 
and then be followed weekly until levels are Grade 
£
1. The frequency
of follow up may
be 
altered at t
he discretion of the site investigator following consultation with the PSRT. Study
 
treatment may
continue at the discretion of the investigator provided the participant is 
asy
mptomatic.
Grade 3/4
Study
product should be permanentl
y discontinued for an
y A
L
T or AST of Grade 3 or 4. 
Participants should have AL
T or AST re
-
checked as soon as possible (at most within 1 week).  
Participants should then be followed weekl
y until levels are Grade 
£
1. 
HPTN 066, Version 
2
.0 
Page 
38
of 
116
29 Nov
em
ber
2010
4.6.4
Creatinine Clearance
If the creatinine clearance is <50mL
/min,
it should be confirmed within 1 week of the receipt of 
the results in consultation with the PSRT.  If the creatinine clearance is confirmed to be 
<50mL
/min, the study
product must be permanently
discontinued.  Participants who fail to have a 
confirmed tes
t will permanently
discontinue the study
product. 
4.6.5
Hypophosphatemia
Grades 1 and 2
.
The phosphate should be repeated within 1 week of the receipt of the results.  Supplemental 
phosphate should be given with phosphate
-
rich food or fluid with or without n
eutral phosphate 
solution.  Other causes of phosphate loss should be thoroughl
y ev
aluated.
Grade 3/4
The phosphate should be repeated within 48 hours of the receipt of the results.  Supplemental 
phosphate should be given with phosphate
-
rich food or fluid
with or without neutral phosphate 
solution, and other causes of low phosphate should be thoroughly investigated. During the time 
that supplemental phosphate is provided to the participant and the time that testing is repeated, 
sites should follow product 
hold guidelines described in Section 4.
5
.  If alternative etiologies for 
Hy
pophosphatemia cannot be identified, the study team will give consideration to 
discontinuation of study
drug. Stud
y m
edication should be discontinued for resistance to 
supplemental 
phosphate intervention after 2 day
s.
4.6.6
Genital Sexually Transmitted Infection/Reproductive Tract Infection
Testing for STIs will be performed at screening for all participants. Persons identified as having 
an STI
will be excluded from the intensive cohort 
and will be referred for management according 
to the local standard of care. Testing will be performed at other stud
y visits only if the participant 
develops signs/s
ym
ptoms of an STI or expresses a concern about having acquired a STI infection 
after enroll
ment. If an
y p
articipant acquires an STI during the study
, clinical management will be 
provided in accordance with current CDC guidelines. Probenecid may not be given with study 
medications. If probenecid is necessary for STI treatment, the study dosing wi
ll be discontinued.  
Study
product need not be held in the event of genital STI
/ reproductive tract infection (RTI) 
requiring treatment, unless other product hold guidelines apply. An STI will result in removal 
from the study
onl
y i
f treatment is not compl
ete within one week prior to the tissue sampling 
day
s in the protocol (intensive sampling cohort only
).
HPTN 066, Version 
2
.0 
Page 
39
of 
116
29 Nov
em
ber
2010
4.6.7
HIV and Hepatitis B
HI
V Infection
HI
V testing will be performed at screening and enrollment. I
ndividuals with one or more reactive 
HI
V rapid test resu
lts (regardless of subsequent test results) will be excluded from the study
and 
will be referred for management according to the local standard of care. HIV diagnostic testing 
will also be performed at the end of the stud
y, and at an
y other stud
y visit at 
which a participant 
has signs/s
ym
ptoms of acute HIV infection or expresses a concern about having acquired HIV 
infection after enrollment. 
Hepatitis B
Hepatitis B testing (
HBsAg
) will be performed at screening. Persons with a positive 
HBsAg
test 
will be 
excluded from the study
and will be referred for management according to the local 
standard of care. Hepatitis B testing will be performed at the end of the study
and at other stud
y 
visits if the participant expresses a concern about having acquired hepati
tis B infection after 
enrollment or as clinically
indicated for AST/ALT elevations.  
4.6.8
Manag
ement of sampling complications
Tissue and fluids will be obtained in the intensive sampling cohort on Day
s 35 and 49. All 
subjects will be required to abstain fr
om sexually
activity
for 72 hours following sample 
collection. Subjects will be contacted by
phone 24 hours after sample collection to assess for an
y 
adverse events. 
Cervicovaginal Fluid
Collection of CVF requires women to be recumbent for 5 minutes to a
llow fluid to pool in the 
posterior fornix. The vaginal sample aspirator is then gently
inserted into the vagina without the 
placement of a speculum. This procedure may
cause very
slight discomfort, pressure, or irritation 
that should occur onl
y during the
procedure (<5 minutes). Any
uncomfortable sensations should 
resolve shortl
y after the procedure.
Subjects will not undergo CVF sampling if evidence of vaginitis is present on initial 
examination.
Cervical Cells
Cervical cells
will be collected followin
g the insertion of a speculum into the vagina b
y i
nserting 
a cy
tobrush (two full 360 degree rotations) into the endocervical canal. Minimal discomfort may 
occur with placement of the speculum. Slight bleeding or spotting may
occur after the cy
tobrush 
is re
moved but no more than that which occurs during a normal pap smear. 
HPTN 066, Version 
2
.0 
Page 
40
of 
116
29 Nov
em
ber
2010
Seminal Fluid
Semen will be self
-
collected in a private room in the research unit. Subjects
may
experience 
psy
chological distress and local irritation or discomfort. 
Vaginal Biopsies
During this procedure subjects may
experience some mild pain when the sample is taken. 
Subjects will receive topical anesthetic prior to the procedure.  Bleeding may
also occur at the 
specimen collection site.  Bleeding may be stopped at the biopsy
site wi
th application of a local 
anti
-
coagulant. In very
rare cases, a stitch might need to be placed in order to stop bleeding.  
Under such circumstance, female participants may feel slight soreness or discomfort in the 
vagina for one to two day
s after the vagin
al biopsy
.  Participants may
experience some vaginal 
spotting or bleeding and slight discharge for up to one week after the biopsy.  In rare instances, a 
vaginal biopsy
may
cause infection or prolonged bleeding. 
Subjects will not undergo tissue sampling 
if evidence of vaginitis is present on initial 
examination.
Colon Biopsies
Subjects will be requested to follow a low fiber diet for 3 day
s prior to the procedure and a clear 
liquid diet for 12 hours prior to the procedure. With the procedure, subjects ma
y ex
perience 
abdominal pain, rectal irritation, bloody
bowel movements, dehy
dration, and changes in heart 
rate. There is rare risk of bleeding, perforation and infection with this procedure. In the event that 
other pathology
is observed during flexible sig
moidoscopy
(anorectal lesions, poly
ps, 
ulcerations, etc.), the subject will be informed of the findings and a referral for treatment will be 
provided. 
Study
procedures may
be terminated in the event that any
subject experiences any
of the 
following:  ble
eding from the site that requires aggressive intervention to stop bleeding following 
the sample collection, experiences severe abdominal pain, an
y i
ncreased tenderness or distention 
in the abdominal region, or a change in vital signs from baseline deemed c
linically
significant by
 
the endoscopist/study
phy
sician. 
Any
subject who experiences excessive bleeding (in the opinion of the local study
phy
sician) 
following an
y biops
y procedure will not have further tissue sampling.
Rectal Luminal Fluid
To collect 
the rectal luminal fluid, the clinician will gentl
y i
nsert a clear, plastic, lubricated tube 
into the rectum (no more than 4 inches) through which the luminal fluid will be collected with a 
swab or sponge.
HPTN 066, Version 
2
.0 
Page 
41
of 
116
29 Nov
em
ber
2010
While this is a common medical procedure, it is p
ossible that the participant could experience 
mild discomfort, embarrassment or, rarely
, pain (should they
have another condition that is 
alread
y causing pain in the area).  If there is an
y p
ain experienced during the procedures, the 
study
clinician will a
dapt or stop the procedure.
4.7
Clinical Management of Pregnancy
All study
participants are required to use
condoms for all coital events during
study
participation.  
Women should also be utilizing a second form of contraception as indicated in Section 3.1. 
Study
staff will provide contraceptive counseling to enrolled participants as needed throughout 
the duration of study
participation and will facilitate access to contraceptive services through 
direct service delivery
and/or active referrals to local servic
e providers.  Study
staff also will 
provide participants with male condoms and counseling on use of condoms during every
sex act 
during stud
y participation.  
Pregnancy
testing will be performed at screening, enrollment, Day
28
, Day
35
(intensive 
sampling
cohort onl
y)
,
and Day
49
(pregnancy
testing will be done prior to any
vaginal 
procedures)
. Participants will be encouraged to report all signs or s
ym
ptoms of pregnancy
to 
study
staff.  The site IoR or designee will counsel any participants who become preg
nant 
regarding possible risks to the fetus according to site
-
specific SOPs.  The IoR or designee also 
will refer the participant to all applicable services; however, sites will not be responsible for 
pay
ing for pregnancy
-
related care.  
Participants who a
re pregnant at the termination visit will continue to be followed until the 
pregnancy
outcome is ascertained (or, in consultation with the PSRT, it is determined that the 
pregnancy
outcome cannot be ascertained).  Pregnancy
outcomes will be reported on rel
evant 
CRFs. Outcomes meeting criteria for expedited adverse event (EAE) reporting also will be 
reported on EAE forms
(see Section 6.3.4 below)
. Follow
-
up of pregnant participants bey
ond 
study
duration is onl
y i
ntended to capture pregnancy
outcomes. On
-
goin
g or regular stud
y visits 
will not take place. 
NOTE:
Participants who become pregnant during the course of the study
will permanently
 
discontinue study
product.  
4.8
Criteria for Early Termination of Study Participation
Participants may
voluntarily
withd
raw from the study
for any
reason at an
y time.  Site I
oRs may
, 
with the approval of the PSRT, withdraw participants before their scheduled termination visit to 
protect their safet
y, and/or if participants are unable or unwilling to compl
y with study 
proced
ures.  Participants also may
be withdrawn if the study
sponsors, government or regulatory
 
HPTN 066, Version 
2
.0 
Page 
42
of 
116
29 Nov
em
ber
2010
authorities (including the 
OHRP and FDA
), or site I
RBs/ECs terminate the study
prior to its 
planned end date.  Site investigators are required to consult the Protocol
Chair and Protocol 
Biostatistician prior to the termination of an
y s
tudy
participant.  Study
staff will record the 
reason(s) for all withdrawals in participants’ study records. Stud
y visit and dosing requirements 
for research participant eligibility
for s
afet
y and PK anal
ys
es is described in Section 7.2.
4.9
Concomitant Medications
With the exception of medications listed as prohibited (see below, this section), enrolled stud
y 
participants may
use concomitant medications during stud
y participation.  All conc
omitant 
medications, over
-
the
-
counter preparations, vitamins and nutritional supplements, recreational 
drugs, and herbal preparations reported throughout the course of the study will be recorded on 
CRF designated for that purpose.  
All concomitant medic
ations taken or received b
y participants within the 4 weeks prior to stud
y 
enrollment will be reported on applicable stud
y C
RFs.   Medications used for the treatment of 
AEs that occur during study
participation also will be recorded on applicable study
cas
e report 
forms.
Should participants report use of an
y of the following medications, they will be required to 
discontinue use of study
products and have termination visit evaluations: interleukin therap
y;
 
medications with significant nephrotoxic potential,
including but not limited to amphotericin B, 
aminogl
ycosides, cidofovir, foscarnet and s
ys
temic chemotherapy
; and medications that may
 
inhibit or compete for elimination via active renal tubular secretion (including but not limited to 
probenecid).
Medica
tions that prolong clotting time (e.g., warfarin, heparin, clopidogrel classes) are 
exclusionary
as are the conditions they
treat. Occasional use of aspirin or non
-
steroidal anti
-
inflammatory
drugs (NSAIDs) for analgesia is allowed with restriction. Aspiri
n cannot be taken 
within 1 week of scheduled biopsies. NSAID cannot be taken within 24 hours of scheduled 
biopsy
. Detailed instructions for preparation for biopsies will be included in the SSP. 
Spermicide should not be used by
participants who undergo mu
cosal sampling during the study
.  
Non
-
study
vaginal and rectal products (other than tampons during menstruation, diaphragms and 
female condoms) are also prohibited for individuals undergoing mucosal sampling.  Participants 
who report current use of these p
roducts will be counseled regarding the use of alternative 
methods.  Participants are not expected to require gy
necologic surgical procedures during 
enrollment period; however, should such a procedure be required, the site IoR or designee will 
consult the 
PSRT regarding ongoing product use by
the participant.
HPTN 066, Version 
2
.0 
Page 
43
of 
116
29 Nov
em
ber
2010
5.0
STUDY P
RO
C
EDURES
An overview of the stud
y visit and procedures schedule is presented in Appendix I. Presented 
below is additional information on visit
-
specific study
procedures. Detailed instructions
to guide 
and standardize all study
procedures across sites will be provided in the SSP manual. 
In addition to any Interim Visits that may
occur in accordance with guidance outlined in Section 
5.6, the following visits should take place for study partici
pants:
·
Screening
·
Enrollment
(first dosing day
; Day
0
)
·
Pre
-
dose #2, Sample visit for single blood draw (accumulation index)
·
Day
7, Non
-
Intensive Sampling visit
·
Day
14, Non
-
Intensive Sampling visit
·
Day
21, Non
-
Intensive Sampling visit
·
Day
28, Non
-
Intensive 
Sampling visit
·
Day
35, Non
-
Intensive plus I
ntensive
*†
Sampling visit
·
Day
49, Non
-
Intensive plus I
ntensive
*†
Sampling visit, Termination Visit
*
Note
: Sixteen of the total 32 participants will participate in the intensive sampling. The 
intensive sampling c
ohort will be divided evenly
between men and women from each dosing 
cohort.
† 
Site staff will follow
-
up with participants via telephone, 24 hours after biopsy
to inquire about 
any
complications possibly
resulting from the biopsy
.  
All sampling will occur
no more than one hour
prior to the scheduled dosing time. 
As dosing will be observed by
a stud
y t
eam member, participants will have up to daily
contact 
with the study
team. These will be termed “dosing visits” to distinguish them from study
visits 
liste
d above. 
Reimbursement for stud
y visits will either take place at the end of each study visit, at the end of 
the study
, or in a pro
-
rated manner, depending on site specific scheduling and I
RB approvals.
HPTN 066, Version 
2
.0 
Page 
44
of 
116
29 Nov
em
ber
2010
5.1
Screening Visit 
After providing written informed
consent, potential participants may
be screened for eligibility
 
over two or more visits if necessary
, and eligibility must be confirmed at the enrollment visit (i.e. 
values from screening need to be checked against the eligibility requirements).  For part
icipants 
who do not meet the eligibility
criteria, screening will be discontinued when ineligibility
is 
determined.
For participants who are found to be presumptively eligible based on the evaluations listed below 
at these visits, final eligibility
will b
e confirmed at the Enrollment Visit (Day
0
), scheduled to 
take place within 30 day
s of the Screening visit.  
HPTN 066, Version 
2
.0 
Page 
45
of 
116
29 Nov
em
ber
2010
Table 5
-
1. Screening Visit (up to 30 days prior to Enrollment Visit)
Component
Procedure/Analysis
Administrative
·
Obtain written informed conse
nt for screening/enrollment
·
Verify age
·
Assign Participant ID (PTID)
·
Collect demographic information
·
Collect locator information
·
Assess behavioral eligibility
·
Schedule next visit
Clinical 
·
Collect medical/menstrual history 
·
Collect concomitant medications
·
Perform physical exam  
·
Perform pelvic exam (intensive sampling cohort)  
·
Provide counseling
o
Contraceptive
o
HI
V pre
-
and post
-
test
o
HI
V/STI risk reduction and condom
·
Refer to care for UTI/RTIs/STIs 
·
Provide male condoms
Blood
·
Collect blood samples
o
HI
V di
agnostic testing (see SSP)
o
Safety testing (see SSP)
o
Coagulation testing (
intensive sampling cohort, 
see SSP)
o
HBsAg (confirmatory testing if positive)
o
Syphilis testing (confirmatory tests if positive)
o
Store plasma
Urine
·
Collect urine sample
o
Pregnancy testi
ng (women only)
o
Dipstick urinalysis (if positive for leukocyte esterase or nitrates, perform 
urine culture)
o
GC/CT testing (intensive cohort only)
Pelvic 
·
Collect pelvic samples (intensive sampling cohort women only)
o
Vaginal fluid for wet mount (BV, candi
da, trichomonas), vaginal fluid pH 
o
Pap smear* 
Genital
·
HSV
-
2 testing (if active lesions) (intensive cohort only)
Rectal
·
GC/CT testing (intensive cohort only)
*Not required if a normal PAP smear result was documented w
ithin 12 months of screening.
HPTN 066, Version 
2
.0 
Page 
46
of 
116
29 Nov
em
ber
2010
5.2
Enro
llment Visit
Table 5
-
2. Enrollment Visit 
(Day 0)
Component
Procedure/Analysis
Administrative 
·
Review/update locator information
·
Confirm behavioral eligibility, required for eligibility assessment
·
Randomization
·
Schedule next study visit
·
Follow procedures
for study arm assignment
Clinical 
·
Update medical/menstrual history, required for eligibility assessment 
·
Update concomitant medications, required for eligibility assessment
·
Review pre
-
existing conditions, required for eligibility assessment
·
Perform phys
ical exam  (See Appendix IB), required for eligibility assessment
·
*Refer for UTI/RTIs/STIs, treat or refer for other findings
·
Provide counseling
o
Contraceptive
o
HI
V pre
-
and post
-
test
o
HI
V/STI risk reduction and condom 
o
Protocol adherence, product use/adheren
ce 
·
Provide male condoms 
Blood
·
HI
V diagnostic testing (see SSP)
·
Store plasma 
·
Collect PK blood specimens 
o
Serum 
o
PBMCs 
o
CD4+ blood cells 
Urine
·
Pregnancy testing (women only)
Study Product 
Supply 
·
Administer first dose of study
product
·
Provide an emerg
ency dose(s) of participant’s prepared study product
*I
f indicated (see SSP)
HPTN 066, Version 
2
.0 
Page 
47
of 
116
29 Nov
em
ber
2010
5.3
Non
-
Intensive Sampling 
Visits 
Table 5
-
3. Non
-
Intensive 
Sampling
Visits (
Days 
1
‡
, 
3
‡
, 
7,
14, 21, 
28
, 35, and 49
)
Component
Procedure/Analysis
Administrative
·
Review/update l
ocator information
·
Schedule next study visit
Clinical 
·
Collect interval medical/menstrual history 
·
Review/update concomitant medications
·
Record/update adverse events
·
Coagulation tests (Day 28 only, see SSP, intensive sampling cohort only)
·
Perform directed
physical exam 
·
Reinforce counseling
o
Contraception
o
HI
V/STI risk reduction and male condom 
o
Protocol adherence, product use/adherence 
·
Provide male condoms
Blood
·
Pre
-
dose #2: single bl
ood draw for accumulation index
(Day 
1
for Treatment 
Arm 4, Day 
3
for Tr
eatment Arms 2 and 3, Day 
7
for Treatment Arm 1)
†
·
Safety testing (Days 14
, 28
, 
35
and 49 only
, see SSP)
·
Hepatitis B testing (Day 49 only, see SSP)
·
Store plasma (Day
s
28
and 49
only)
·
HI
V testing (Day 49 only)
·
Collect blood specimens for PK analysis
o
Serum 
o
P
BMCs 
o
CD4+ blood cells 
Urine
·
Collect urine sample (
w
omen only, Day 28
and 49 only
)
o
Pregnancy testing 
Study Product 
Supply
·
Administer study
product
(
if applicable
)
·
Collect unused emergency dose of participant’s prepared study product on Day 
2
8
Visit for
all arms
. Provide a new e
mergency dose of participants’ 
prepared 
study product on Day 2
8
Visit in 
Treatment A
rms
2, 3, and 4
.  
·
Collect unused e
mergency dose of participant
s
’
prepared study product on 
Day 
31 Visit for treatment Arms
2 and 3, and on Day 3
4
Visit for Treatment Arm 4.
*
If indicated (see SSP)
†
Sample collection for each cohort should be done 
no more than 1 hour
prior to the second dose for each cohort. 
These w
ill occur on day 
7
(Cohort 1), Day 
3
(Cohort 2 and 3), and Day 
1
(Cohort 4), as in
dicated.
‡
Day 1 and Day 3 visits are only for the pre
-
dose #2 blood draw
. Only administrative, blood collection, and study 
product supply procedures w
ill take place one these days.  
HPTN 066, Version 
2
.0 
Page 
48
of 
116
29 Nov
em
ber
2010
5.4
Intensive Sampling Visits
Table 5
-
4. Intensive Sampling Visit (Days 35
and 49)
Component
Procedure/Analysis
Administrative
·
Review/update locator information
·
Schedule next study visit
Clinical 
·
Collect interval medical/menstrual history 
·
Review/update concomitant medications
·
Record/update adverse events
·
Perform directed ph
ysical exam 
·
Perform pelvic exam 
·
Reinforce counseling
o
Contraceptive
o
HI
V/STI risk reduction and male condom 
o
Protocol adherence 
·
Male condoms
Blood
·
HI
V diagnostic testing (Day 49 only, see SSP)
·
Hepatitis B testing (Day 49 only, see SSP)
·
Safety testing (se
e SSP) 
·
Store plasma
(Day 49
only)
·
Collect blood specimens for PK testing
o
Serum 
o
PBMCs 
o
CD4+ blood cells 
Urine
·
Collect urine sample (
w
omen 
only
) 
o
Pregnancy testing 
Vaginal 
sampling
†
·
Biopsy, cervical cytobrush, and luminal fluid (see SSP)
Rectosigmoid 
Specimens
†
·
Flexible sigmoidoscopy with biopsies (up to 30) and collection of luminal fluid 
(see SSP)
Semen
†
·
Collect semen sample (Men only, see SSP)
*I
f indicated (see SSP)
† 
Sixteen of the total 32 participants will participate in the intensive sampling
which includes all procedures listed 
above. The intensive sampling cohort w
ill be divided evenly betw
een men and women from each dosing cohort. For 
the remaining subjects, that is, the non
-
intensive cohort, there w
ill be no rectosigmoid, vaginal, or semen
sampling 
on Day 35 and 49. 
5.5
Follow up Procedures for Participants who Discontinue Study Product and for 
Participants who 
Receive a Biopsy on the Last Study V
isit.
Participants who permanently
discontinue study
product for an
y reason will be encouraged t
o 
return to 
the 
clinic to have exit 
s
afety
labs drawn (see SSP). 
This will be their final scheduled 
visit for the study
. 
HPTN 066, Version 
2
.0 
Page 
49
of 
116
29 Nov
em
ber
2010
Participants who are enrolled in the intensive sampling cohort will 
have 
biopsies
collected
on 
Day
49
. As an additional safet
y ch
eck,
these participants will receive a follow
-
up phone call the 
day
following the biops
y t
o evaluate for biopsy
related adverse events.
5.6
Interim Contacts and Visits
Interim contacts and visits (those between regularly scheduled follow up visits) may
be 
perfor
med at participant request or as deemed necessary
by
the investigator or designee at an
y 
time during the stud
y. All interim contacts and visits will be documented in participants’ stud
y 
records and on applicable CRFs.  
Some I
nterim visits may
occur for a
dministrative reasons.  For example, the participant may
 
have questions for stud
y s
taff.  Interim visits at which no data is collected are not documented on 
case report forms. Other interim contacts and visits may occur in response to AEs experienced b
y 
st
udy
participants.  When interim contacts or visits are completed in response to participant 
reports of AEs, stud
y s
taff will assess the reported event clinicall
y, record the event on the case 
report form, and provide or refer the participant to appropriate
medical care.  
5.7
Clinical Evaluations and Procedures
See Appendix I
for an outline of phy
sical exam and pelvic exam components. For directed 
phy
sical exams (
occurring during visits on Day
0
through 49), the extent of the examination is 
determined b
y t
he 
clinical judgment of the clinician based on interim medical history
.  
5.8
HIV and STI Counseling
At any
time during the study
when HIV or STI testing is done on study
participants, they
will be 
informed of their test results as soon as they
become available
. Sites should follow their local 
standard of care for providing HIV and STI counseling and should document these procedure in 
site specific SOPs before study
initiation.   
5.9
Participant Preparation for Sampling
Preparation and safet
y ev
aluations for 
biopsies
As stated in sections 4.6.8, participants should start a low fiber diet 3 day
s before each 
rectal 
biopsy
 
procedure and have a clear liquid diet 12 hours prior to the procedure. They
should also 
refrain from meals (or coffee) the day
of the procedu
re. Enemas will be administered before the 
biopsy
procedures take place.
 
Additional details on the dietary
preparation and enemas will be 
included in the SSP. 
HPTN 066, Version 
2
.0 
Page 
50
of 
116
29 Nov
em
ber
2010
Following enrollment, coagulation testing is done on participants in the intensive sampling 
co
hort at the Day
28 visit. If test results are a Grade 2 or higher, the intensive tissue sampling 
will be cancelled. If possible, these participants may be transferred into non
-
intensive sampling 
cohort if there is an available slot. If a slot is not availa
ble, they
will be terminated from the 
study
. 
Semen sampling preparation
Men should refrain from sexual activity
24
-
48 hours prior to providing semen samples to allow 
for collection of an adequate number of seminal cells. 
6.0
SAFETY MONITORING AN
D ADVERSE E
VENT REPORTING
6.1
Safety Monitoring 
Close cooperation between the Protocol Chair(s), study
site Investigator(s), NIAID 
Medical/Program Officer, CORE Protocol Coordinator, SDMC Biostatistician, and other study
 
team members will be necessary
in order to moni
tor participant safet
y and respond to 
occurrences of toxicity
in a timely
manner. The team will have regularly
scheduled conference 
calls during the period of study
implementation, and additional ad hoc calls will be convened if 
required.
The study
site I
nvestigators are responsible for continuous close monitoring of all AEs that occur 
among stud
y participants, and for alerting the PSRT if unexpected concerns arise. Accrual (but 
not do
s
ing) will be suspended if two or more study participants experience the
same grade 3 or 
higher AE (as defined b
y the DAIDS Standard Toxicity
Tables) judged 
to be 
related to product 
use. The protocol team then will review all pertinent safet
y data and determine whether to 
continue accrual and product use.  A decision to stop t
he trial may
be made by
the protocol team 
at this time or at any
such time that the team agrees that an unacceptable ty
pe and/or frequency
 
of AEs has been observed.
A sub
-
group of the Protocol Team, including the Protocol Chair, DAIDS Medical Officer, one
or 
more site clinicians, and the SDMC Clinical Affairs safet
y Associate, will serve as the Protocol 
Safety
Review Team (PSRT) to be chaired by
the Protocol Chair.  The HPTN SDMC will 
prepare routine safet
y dat
a reports for review b
y t
he PSRT, which will m
eet via conference call 
approximately
once per month or as needed throughout the period of study implementation to 
review safet
y data, discuss product use management and address an
y potential safet
y concerns.  
The content, format and frequency
of safet
y da
ta reports will be agreed upon by
the PSRT and 
the SDMC in advance of study implementation.
HPTN 066, Version 
2
.0 
Page 
51
of 
116
29 Nov
em
ber
2010
Termination Visit. 
If the participant has an adverse event (AE) at the termination visit, the AE, 
for study
purposes, is closed out as “continuing at the end of st
udy
participation” but will be 
followed clinicall
y until resolution or stabilization with updates on status provided to the PSRT.  
Participants who have AEs at the Termination Visit that have not resolved or stabilized will be 
followed bey
ond the Termina
tion Visit until a clinically
acceptable resolution of the AE(s) is 
confirmed and documented.  Clinical acceptability of resolution will be determined b
y t
he site 
investigator of record (IoR) in consultation with the Protocol Safet
y R
eview Team (PSRT).  Fo
r 
participants who are pregnant at the Termination Visit, study
site staff will make every
effort to 
follow the participant until such time that her pregnancy
outcome can be ascertained and 
documented.
6.2
Clinical Data Safety Review
A multi
-
tiered safet
y r
eview process will be followed for the duration of this study
.  The stud
y 
site investigators are responsible for the initial evaluation and reporting of safety
information at 
the participant level, and for alerting the PSRT if unexpected concerns arise.  P
articipant safet
y i
s 
also monitored at the Network level through a series of routine reviews conducted by
the SDMC 
Clinical Affairs staff, the PSRT and study
sponsors.  Additional reviews may
be conducted at 
each of these levels as dictated b
y t
he occurren
ce of certain events.  
HPTN SDMC Clinical Affairs staff will review incoming safet
y data on an ongoing basis. 
Events identified as questionable, inconsistent, or unexplained will be queried for verification.  
Adverse event reports submitted in an expedit
ed manner to the DAIDS Safety Office will be 
forwarded to the DAIDS Medical Officer and SDMC Clinical Affairs staff for review.
The PSRT will meet regularly
via conference call to review clinical data reports generated by
the 
HPTN SDMC.  The content, form
at and frequency
of the clinical data reports will be agreed 
upon by
the PSRT and the SDMC in advance of study
implementation. In addition to the routine 
safet
y data reviews, the PSRT will convene on an ad hoc basis to make decisions regarding the 
handling
of an
y s
ignificant safet
y concerns.  If necessary experts external to the HPTN 
representing expertise in the fields of antiretroviral therap
y, biostatistics, HIV transmission and 
medical ethics may
be invited to join the PSRT safety
review.  A recommendat
ion to stop the 
trial may
be made by
the PSRT at this time or at any
such time that the team agrees that an 
unacceptable t
ype and/or frequency
of AEs has been observed.
In the unlikel
y event that the protocol team or PSRT has serious safet
y co
ncerns that 
lead to a 
decision to permanentl
y discontinue the study product for all participants and stop accrual into 
the study
, the protocol team or PRST will request a review of the data by
the HPTN Study
 
HPTN 066, Version 
2
.0 
Page 
52
of 
116
29 Nov
em
ber
2010
Monitoring Committee (SMC) before recommending that the stud
y be stopped.  If at an
y t
ime, a 
decision is made to discontinue the study
product in all participants, 
the 
site investigators of 
record will notify
the responsible I
RBs/ECs expeditiously
.
6.3
Adverse Event Definition and Reporting Requirements
6.3.1
Adverse Even
ts
An AE is defined as an
y untoward medical occurrence in a clinical research participant 
administered an investigational product and which does not necessarily have a causal 
relationship with the investigational product.  As such, an AE can be an unfavor
able or 
unintended sign (including an abnormal laboratory finding, for example), symptom or disease 
temporally
associated with the use of an investigational product, whether or not considered 
related to the product.  The term “investigational product” for 
this study
refers to the oral 
medication Truvada® (tenofovir disoproxil fumarate/emtricitabine).
Study
participants will be provided instructions for contacting the study
site to report an
y 
untoward medical occurrences they
may
experience, except for poss
ible life
-
threatening events, 
for which they
will be instructed to seek immediate emergency
care.  Where feasible and 
medically
appropriate, participants will be encouraged to seek evaluation where a study
clinician 
is based, and to request that the clinic
ian be contacted upon their arrival.  With appropriate 
permission of the participant, whenever possible, records from all non
-
study
medical providers 
related to untoward medical occurrences will be obtained and required data elements will be 
recorded on st
udy
CRFs.  All participants reporting an untoward medical occurrence will be 
followed clinicall
y until the occurrence resolves (returns to baseline) or stabilizes.
Study
site staff will document in source documents and the appropriate AE Log CRF all AEs 
r
eported b
y or observed in enrolled study participants regardless of severit
y and presumed 
relationship to study
product.  AE severity
will be graded per the DAIDS Table for Grading 
Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarificati
on dated August 
2009).
6.3.2
Serious Adverse Event
Serious adverse event
(SAE) will be defined per U.S. Code of Federal Regulations (CFR) 312.32
and International Conference on Harmonization (ICH), “Good Clinical Practice: Consolidated 
Guidance” (E6) and “Cli
nical Safet
y Dat
a Management: Definitions and Standards for Expedited 
Reporting” (E2A), as AE
occurring at an
y dose that:
·
Results in death 
·
Is life
-
threatening
HPTN 066, Version 
2
.0 
Page 
53
of 
116
29 Nov
em
ber
2010
·
Results in persistent or significant disability
/incapacity
·
Is a congenital anomal
y/
birth defec
t  
·
Requires inpatient hospitalization or prolongation of existing hospitalization 
This includes important medical events that may
not be immediately
life
-
threatening or result in 
death, or hospitalization but may
jeopardize the patient or may
require in
tervention to prevent 
one of the outcomes listed above.
Per I
CH SAE definition, hospitalization itself is not an adverse event, but is an outcome of the 
event. The following t
yp
es of hospitalization do not require expedited reporting to DAIDS:
·
Any
admiss
ion unrelated to an AE (e.g. for labor/delivery
, cosmetic surgery
, 
administrative, or social admission for temporary
placement for lack of place to sleep)
·
Protocol
-
specified admission (e.g. for procedure required b
y protocol)
·
Admission for diagnosis or the
rap
y of  a condition that existed before receipt of study 
agent(s) 
and has not increased in severity
or
frequency
as judg
ed b
y t
he clinical 
investigator
6.3.3
Adverse Event Relationship to Study Product
Relatedness is an assessment made b
y a stud
y clinician o
f whether or not the event is related to 
the study
agent.  Degrees of relatedness will be categorized according to current DAIDS
-
approved guidelines.
6.3.4
Expedited Adverse Event Reporting
6.3.4.1 Adverse Event Reporting to DAIDS
Requirements, definitions an
d methods for expedited reporting of Adverse Events (AEs) are 
outlined in Version 2.0 of the DAIDS EAE Manu
al, which is available on the RS
C website at
http://rsc.tech
-
res.com/safety
andpha
rmacovigilance/
.
The
DAIDS Adverse Experience Reporting Sy
stem (DAERS), an
i
nternet
-
based reporting 
sy
stem must be used for expedited AE reporting to DAIDS.  In the event of system outages or 
technical difficulties, expedited AEs may
be submitted via the
DAIDS EAE Form. For questions 
about DAERS,
please contact DAIDS
-
ES at
DAIDS
-
ESSupport@niaid.nih.gov
or from within 
the DAERS application itself.
Sites where DAERS has not been implemented will submit ex
pedited AEs by
documenting the 
information on the current DAIDS EAE Form. 
This form is available on the RS
C website: 
http://rsc.tech
-
res.com/safety
andpharmacovigilance/
.  For questions ab
out EAE 
reporting, please 
contact the RS
C (
DAIDSRSCSafety
Office@tech
-
res.com
).
HPTN 066, Version 
2
.0 
Page 
54
of 
116
29 Nov
em
ber
2010
6.3.4.2 Reporting Requirements for this Study
T
he 
SAE
Reporting Category
, as defined in Version 2.0 of the DAIDS EAE 
Manual, will be 
used for this study
.
The study
agent
for which expedited reporting 
is
required 
is
: 
Truvada® (
tenofovir disoproxil 
fumarate / emtricitabine (TDF/FTC)
) 
6.3.4.3 Grading Severity of Events
The
Division of AIDS Table for Grading the Severity
of Adult and Pediatric Adverse Events 
(DAIDS AE Grading Table) is 
should be used to grade adverse events
and is available on the 
RS
C website at 
http://rsc.tech
-
res.com/safet
ya
ndpharmacovi
gilance/
.
6.3.4.4   Expedited AE Reporting Period
·
The expedited AE reporting period for this study
is as per the EAE manual
.
·
After the protocol
-
defined AE reporting period, unless otherwise noted, only
SUSARs as 
defined in Version 2.0 of the EAE Manual 
will be reported to DAIDS if the study
staff 
become aware of the events on a passive basis (from publicly
available information).
6.3.5
Pregnancy Outcomes
Pregnancy
outcomes will be collected for all stud
y participants b
y contacting these women soon 
after anti
cipated parturition. After the participant’s final study
contact, an
y pregnancy outcomes 
that meet criteria for SAE reporting as described above (e.g., congenital anomalies) occurring 
among participants will continue to be expeditiously
reported.
6.3.6
Regulato
ry Requirements
In
formation on all reported AEs will be included in reports to applicable regulatory authorities.  
The site IoR/designee will submit AE information in accordance with local regulatory agencies’ 
or other local authorities’ requirements.  Th
e site IoR/designee also will submit AE information 
and an
y other relevant safety information to the IRB in accordance with IRB requirements.
6.4
Social Harms
In order to prevent adverse social events related to study
participation, social harms will be 
moni
tored throughout the study
.  Social harms are any
untoward social occurrences that happen 
HPTN 066, Version 
2
.0 
Page 
55
of 
116
29 Nov
em
ber
2010
to a participant as a result of their participation in the study.  Examples include loss of 
employ
ment, harassment by
neighbors, shunned by
family
, rejection by
partn
er, etc.  Although 
social harms due to this study
are expected to be negligible, they
will be monitored closel
y 
throughout the stud
y.
Information on social harms will be activel
y s
olicited from participants at 
follow
-
up visits and recorded on case report 
forms and captured in the study
database. 
Participants will also be encouraged to report an
y s
ocial harm on an ad hoc basis when it occurs.
In the event that a participant reports social harm, every effort will be made by stud
y s
taff to 
provide appropriat
e care and counseling to the participant, and/or referral to appropriate 
resources for the safet
y o
f the participant as needed. Social harms that are judged b
y t
he 
Investigator of Record to be serious or unexpected will be reported to responsible site’s I
R
B/EC 
at least annuall
y, or according to their individual requirements.
The nature and frequency
of 
these social impact reports will be monitored by
the protocol team on a regular basis. In addition, 
these data will be reviewed by
the HPTN (SMC).
7.0
STATISTI
CAL CONSIDERATIONS
7.1
Review of Study Design
HPTN 066 is a Phase 1, multi
-
site, randomized, four
-
arm, open label study
of TFV and FTC 
concentrations in various body
compartments following oral Truvada® dosing under direct 
observation b
y t
he study
team (dire
ctly
observed therapy
[DOT]) to assure 100% adherence to 
prescribed dosing regimen. The prescribed dosing regimens range from weekly to dail
y 
TDF/FTC (Truvada®
) at one of two possible doses for a total duration of 5 weeks.
Thirt
y t
wo 
participants are sampl
ed weekl
y for blood (serum and cells). At the end of the 5
th
week and 7
th
week, 16 of the 32 participants also undergo seminal fluid, rectosigmoid (tissue and luminal 
fluid) and vaginal sampling (tissue and luminal fluid). Samples are assay
ed for TFV, FTC 
and 
phosphory
lated moieties of these drugs.
7.2
Endpoints
7.2.1
Primary Endpoints
Consistent with the primary
study
objective, the following endpoint will be assessed on Day
28 
and Day
35 across all 4 dosing arms:
·
Concentrations of TFV and FTC in blood serum
·
Conc
entrations of TFV
-
DP and FTC
-
TP in PBMCs and CD4+ blood cells
HPTN 066, Version 
2
.0 
Page 
56
of 
116
29 Nov
em
ber
2010
7.2.2
Secondary Endpoints
Consistent with the secondary
study
objective, the following endpoints will be assessed on Day
 
35 and Day
49 across all 4 dosing arms:
·
Concentrations of TFV, FTC, TFV
-
DP a
nd FTC
-
TP in blood
·
Concentrations of TFV and FTC in vaginal and rectal secretions
·
Concentrations of TFV and FTC in vaginal and rectal tissue homogenates
·
Concentrations of TFV
-
DP and FTC
-
TP in unselected and CD4+ vaginal and rectal tissue 
cells and tissue h
omogenates 
·
Concentrations of TFV, FTC, TFV
-
DP and FTC
-
TP in fluid (rectal, vaginal, semen), 
cells, and tissue homogenate.
·
Adverse experiences, including safety laboratory studies (hematological, renal, hepatic 
function) 
7.3
Accrual, Follow
-
up, Retention, an
d Sample Size
A total of 32 evaluable men and women will be enrolled over a period of approximately
6 
months at multiple sites. An equal number of participants (8 per arm) will be 
randomized
into 
each of the four dosing arms. Each enrolled participant wil
l be followed for 7 weeks. 
Research participants may miss one of the following pre
-
stead
y
-
state study visits when on drug 
(Day
7, Day
14, Day
21) and remain in the stud
y a
nd remain eligible for evaluation in the PK 
outcome anal
ys
is of the study
. Day
0, D
ay
28, Day
35, and Day
49 are required for a participant 
to be considered evaluable. Op
timally
, all study
product dosing
will occur on the date prescribed. 
However, some forgiveness of strict adherence to the schedule will be tolerated as long as the 
total
dose within each week is consistent with the prescribed total. Th
erefore, for arms 1, 2, and 
3,
study
drug dosing
can be delay
ed b
y 2 day
s, during the first 3 weeks of the study
. Thereafter, 
all doses in week 4 and 5 must be taken as scheduled. In Arm 4, 
all doses for research 
participants must be taken as scheduled. Failure to comply with these schedule
d
requirements 
will result in discontinuation 
from the study
after 
a
final safet
y 
evaluation
. 
Evaluable participants are expected to represent 95% of par
ticipants enrolled into the study
. No 
adjustments are made for retention losses since all discontinued or inevaluable participants will 
be replaced. Each stud
y s
ite will establish participant retention procedures to target lost
-
to
-
follow
-
up rates of <5% in
order to minimize additional enrollments to compensate for 
inevaluable participants.
For the intensive cohort, a subject must have all blood on Days 0, 28, 35 and 49, and vaginal, 
seminal, and rectal samples on Day
s 35, and 49 to be evaluable. If the sub
ject is inevaluable for 
HPTN 066, Version 
2
.0 
Page 
57
of 
116
29 Nov
em
ber
2010
the intensive cohort, but has met evaluability
criteria for the non
-
intensive cohort AND there is 
an opening in the non
-
intensive arm
-
gender cohort matching the subject, then they
may
be 
switched in assignment to the non
-
intensive c
ohort. I
f the intensive subject fails to complete all 
required samples OR there is not an opening consistent with their gender/arm, then the 
participant
is discontinued after the final safety evaluation. I
n either case, the subject needs to be 
replaced in 
the intensive sampling group. 
Ty
pical sample sizes for phase I PK studies generally range between 6 and 12 subjects per arm. 
A number of different approaches have been used to assess dose proportionality
in the literature 
(Gough et al., 1995; Hummel et al., 2009; Smith et al., 2000)
. We consider the sample size using 
the following two approaches: 
1) fitting a simple linear regression model between the PK parameter (y) and dose 
dose
y
+
=
, where the h
yp
o
thesis that 
0
=
is tested and the lack of fit of the model is 
generall
y t
ested b
y adding a quadratic term; and 
2) using the power model approach to fit 
)
log(
)
log(
dose
y
+
=
, where 90% CI
around 
is 
compared to the limi
ts 
)
)
ln(
)
ln(
1
,
)
ln(
)
ln(
1
(
r
r
U
L
+
+
, where 
)
,
(
U
L
are the pre
-
defined limits and 
r
is the ratio of the highest to the lowest dose. The power model and the CI approach has become 
more preferred choice in recent years 
(Gough et al., 1995; Smith et al., 2000)
, however, Hummel 
et al. 
(Hummel et al., 2009)
suggested that the choice of bioequivalence default 
values of 
8
.
0
=
L
and 
25
.
1
=
U
seems to be impractically
strict when applied over a dose range that is 
more than doubling apart and proposed a more lenient criterion 
5
.
0
=
L
and 
2
=
U
.
The empirical powe
r of both approaches are computed using a simulation study
with the 
following steps: 
1.
Generate random samples of size n from a normal distribution 
)
,
14
(
´
=
´
=
CV
sd
dose
N
, where 14 is the weekl
y dosing Day 35 
C
from Figure 
1
-
1, and dose = 1, 2, 4 and 7 for Arm 1 to 4 respectively
.
2.
Fit linear regression model 
2
2
1
0
dose
dose
y
´
+
´
+
=
(Smith et al., 2000)
and test 
for nonsignificant intercept and quadratic terms
(Zhou et al., 2006)
.
3.
Fit linear model 
)
log(
)
log(
dose
y
+
=
and compare 90% CI of 
with the pre
-
specified critical interval 
)
36
.
1
)
7
ln(
)
2
ln(
1
,
64
.
0
)
7
ln(
)
5
.
0
ln(
1
(
=
+
=
+
4.
Repeat steps 1
-
3 for 1000 times. The empirical power is calculated as the proportion of 
the replications in which nonsignificant intercept
and quadratic term holds for approach 1 
or the CI
falls entirel
y wi
thin the critical interval for approach 2.
HPTN 066, Version 
2
.0 
Page 
58
of 
116
29 Nov
em
ber
2010
There are at least 4 available groups of participants for estimating inter
-
individual variability
to 
be used here for the purposes of estimating
sample size. These studies, however, present a broad 
range of CV.
In one H
IV
prevention study
in which research participants took a daily
oral dose 
of TDF, the inter
-
individual coefficient of variation in TFV
-
DP concentrations in PBMCs was 
46%. Hawkins et
al. 
(Hawkins et al., 2005)
report range of median concentrations of 85
-
110 
fmol/M cells (Table 7
-
1) for 7 subjects evaluated. Imputing values from the extremes of this 
range would yield a CV of approximately 14%. 
Pruvost et al.
(Pruvost et al., 2009)
report (Table 
7
-
3) range of TFV
-
DP CV% as 28, 36, 35, 54 in a drug interaction stud
y w
ith L
PV/r and NVP. 
Pruvost et al. 
(Pruvost et al., 2005)
report (Table 7
-
1 groups 1 and 3) inter
-
individual CV% of 
42% (group 1) and 83% (group 3). Note none of the above studies were done in health
y 
volunteers 
with one single drug dosed under direct observation. Given that the DOT used in this 
study
is likely
to reduce the variability
, a CV estimate of 25
-
35% seems to be realistic. In the 
simulation study
, we explored a range of CV values from 25% to 45%.
Table
7
-
1. Power for dose proportionality assessment, 
05
.
0
=
Sample size (per arm)
CV
Simple linear model and 
hypothesis testing approach
Power model and CI 
approach
N=6
25%
93.3%
98.4%
35%
93.6%
74.9%
45%
93.2%
33.3%
N=8
25%
95.0%
99.7%
35%
95.1%
81.1%
45%
93.8%
41.8%
N=10
25%
95.5%
99.8%
35%
95.0%
85.0%
45%
94.4%
43.5%
N=12
25%
96.1%
99.7%
35%
93.9%
85.2%
45%
94.6%
43.6%
Simulation results suggested that either 6 or 12 participants per arm would yield sufficient power 
for a
range of coefficient of variation parameters (25% 
-
45%) when dose proportionality
is 
assessed using h
ypothesis testing approach based on simple linear regression model. However, 
the empirical power associated with the power model and the CI approach is m
ore heavil
y 
depend on the value of CV in the relevant range. With CV 
≤ 
35%, a reasonable degree of 
variation given the argument above, we would have 
≥ 81% power to claim dose proportionality
 
with 8 participants per arm. For this reason, in addition to cost and operational considerations, 8 
subjects per arm was selected as t
he minimum size to provide adequate power for the dose
-
proportionality
assessment, our primary
objective. 
HPTN 066, Version 
2
.0 
Page 
59
of 
116
29 Nov
em
ber
2010
For the secondary
objective assessing difference in intracellular TFV
-
DP and FTC
-
TP stead
y 
state Day
35
C
(pre
-
dose concentration) between men and wo
men, we assume the mean TFV
-
DP 
steady
state concentration 
C
is 100 fmol/10
6
cells, and the coefficient of variation between 
people is 35%. Based on the results from Van Belle and Martin 
(Van Belle and Martin, 1993)
, 
we would have onl
y 35% power to detect a 1.5 fold difference (i.e., 100 to 150) betwe
en men 
and women within each dosing arm if an arm has 4 men and 4 women (i.e., a total of 32 
participants distributed evenly
into four arms, 50% men and 50% women). If dose
-
proportionality
holds, then we would be able to make the comparison between men and
women 
across dosing arms. We then would have 89% power to detect a 1.
5 fold difference with a total 
sample size of 32 (16 men and 16 women) selected for this study
. Table 7
-
2 provides power for a 
range of CV, sample size and minimal detectable difference
. The power would reduce with 
smaller sample size, smaller minimal detectable difference, and larger CV.
Table 7
-
2. Power to detect the minimal detectable difference (in fold) for various sample 
sizes and coefficients of variance (CV)
Minimal detectabl
e X
-
fold difference
CV
N per group 
group
1.25
1.5
1.75
0.25
3
0.18
0.48
0.73
4
0.24
0.60
0.85
6
0.33
0.78
0.95
12
0.58
0.97
0.99
16
0.70
0.99
0.99
24
0.86
0.99
0.99
0.35
3
0.12
0.28
0.45
4
0.14
0.35
0.57
6
0.19
0.49
0.74
12
0.34
0.78
0.9
6
16
0.43
0.89
0.99
24
0.59
0.97
0.99
0.45
3
0.09
0.19
0.30
4
0.10
0.23
0.38
6
0.13
0.33
0.53
12
0.22
0.57
0.82
16
0.28
0.69
0.91
24
0.40
0.86
0.98
HPTN 066, Version 
2
.0 
Page 
60
of 
116
29 Nov
em
ber
2010
7.4
Study Arm Assignment
At the time of consent, subjects will designate whether they
will pa
rticipate in the non
-
intensive 
or intensive sampling cohort. Assignment prioritization will go to the intensive sampling cohort.  
Within each of these 2 cohorts and each gender stratum, enrolled participants will be assigned at 
random to one of the four st
udy
arms in a 1:1:1:1 ratio.  The permuted block randomization 
scheme will not be stratified by
site and will be generated and maintained by the HPTN SDMC. 
For each randomized participant who is not fully
evaluable (see section 7.3) an additional 
particip
ant of the same gender will be enrolled into the same arm and the same cohort (intensive 
or non
-
intensive sampling). Details of the randomization sy
stem will be in the SSP Manual. 
7.5
Blinding
There will be no blinding of the study
. All of the outcome measu
res are objectivel
y determined 
drug concentrations for which there should be minimal risk for bias. 
7.6
Data Analysis 
7.6.1
Primary Analyses
7.6.1.1
Dose Proportionality 
Dose proportionality
will be assessed b
y a confidence interval approach based on the powe
r 
model, using Day
35 pre
-
dose concentration (C
t
) data from all evaluable participants in Arms 1
-
4. Dose
-
proportionalit
y will be declared if the 90% confidence interval of the slope completel
y 
falls in the critical interval 
)
36
.
1
)
7
ln(
)
2
ln(
1
,
64
.
0
)
7
ln(
)
5
.
0
ln(
1
(
=
+
=
+
. Anal
yt
e co
ncentrations assessed 
for dose
-
proportionality
will include TFV and FTC in fluids and their phosphorylated moieties, 
TFV
-
DP and FTC
-
TP, in cells. TFV
-
DP and FTC
-
TP will also be assessed in tissue 
homogenates. Weight
-
based or creatinine clearance
-
adjusted i
ntracellular PK parameters may
 
also be used in evaluating dose
-
proportionalit
y (as well as secondary outcomes). Biological 
matrices included in the anal
ys
is will include: serum, PBMC, CD4+ blood cells, rectosigmoid 
and vaginal luminal fluid, semen, and rec
tosigmoid and vaginal tissue specimens (total tissue 
cells, CD4+ tissue cells, tissue homogenate) (see Table 7
-
3).  
HPTN 066, Version 
2
.0 
Page 
61
of 
116
29 Nov
em
ber
2010
Table 7
-
3. Biological matrices for analyses
Blood Samples
Vaginal
,
Rectosigmoid
, and Semen
Sam
ples
Serum
PB
MC
CD4+ 
blood cells
Total t
issue 
cells
CD4+ 
tissue cells
Lu
minal 
fluid & 
semen
Homogenate
TFV
-
DP
X
X
X
X
X
FTC
-
TP
X
X
X
X
X
TFV
X
X
X
FTC
X
X
X
Descriptive statistics, such as means, medians, variance, and interquartile ranges, will be used to 
summarize Day
35 pre
-
dose concentration (C
t
) b
y gender and b
y dose arm. Simple comparison 
of median concentration level between dose arms will be done with standard non
-
parametric 
methods.   Gender
-
or dosing
-
specific CVs of Day 35 pre
-
dose concentration (C
t
) will be 
estimated
. These CV estimates would be informative to the future studies even if dose 
proportionality
does not hold. 
7.6.1.2 Intra
-
Participant Variability
Intra
-
participant variability
will be described b
y t
he coefficient of variation of concentrations 
assessed 
on Day
28 and Day
35, which are assumed to be at stead
y
-
state, using data from all 
evaluable participants across dosing arms. We will confirm that stead
y
-
state was achieved by
 
evaluating drug concentration data from Day
7, 14, and 21. If the dose
-
proportio
nality
is 
established as described earlier, then dose
-
adjusted concentrations will be used for a more robust 
assessment.  These variability
estimates will be calculated for all anal
yt
es in blood and blood 
cells. As supportive evidence, the accumulation dat
a from Day
7, 14, and 21 will also be used to 
estimate the elimination rate constant. Tissue and luminal assessments cannot be calculated due 
to the absence of multiple stead
y
-
state samples. 
7.6.2
Secondary Analyses
7.6.2.1
Intracellular Concentration Decay
The apparent elimination rate constant (k
e
), for intracellular phosphates (TFV
-
DP and FTC
-
TP) 
will be determined b
y estimating the negative slope of the decline in the natural log of 
concentration between Day 35 and Day 49. Half
-
life will be estimated as t
he natural log of 2 
divided by
the elimination rate constant (k
e
). These estimates will be performed for each research 
participant and summarized using descriptive statistics for each arm and the study
as a whole.  
Biological matrices included in the anal
y
sis are the same as shown in Table 7
-
3.
HPTN 066, Version 
2
.0 
Page 
62
of 
116
29 Nov
em
ber
2010
7.6.2.2 Differences between Men and Women
Because the genital tracts of men and women differ greatl
y i
n terms of anatomy
and ph
ys
iology
 
(e.g. pH differences) as well as drug metabolism, it is feasible that there ma
y b
e gender
-
specific 
differences in the pharmacology
of different doses of tenofovir and emtricitabine in different 
mucosal compartments. Differences in tissue concentrations of these drugs could be relevant in 
understanding if gender
-
related differences a
re detected in intermittent PrEP efficacy
trials. 
Some gender
-
related differences may
be primaril
y explained by
differences in body
mass index 
between men and women, so determining the specific reasons for potential gender
-
related 
differences may
be challe
nging with relativel
y s
mall sample sizes. Men and women will be 
recruited into the stud
y i
n equal proportions for comparison. If dose
-
proportionality
is 
established in the primary
objectives, then dose
-
adjusted Day
35 C
t
concentration differences 
(each anal
yt
e, location, and matrix) between men and women will be tested pooling all research 
participants using ANOVA. If dose
-
proportionality
is not established in the primary
aim, 
intracellular PK parameters will be summariz
ed by standard descriptive statistics (such as means, 
medians, and ranges) for each gender within each dose arm. Non
-
parametric methods may
be 
used to compare C
t
between men and women. The lack of statistical power of these comparisons 
due to small sample 
size is acknowledged.
7.6.2.3 Safety Evaluation
Adverse events will be presented b
y i
ndividual listings and in frequency
tables broken down b
y 
body
sy
stem.
Laboratory
test values will be presented in participant listings and in summaries.  Graded 
laborat
ory
values will be summarized.  Boxplots of local laboratory
values will be generated for 
baseline values and for values measured during the course of the stud
y. Each boxplot will show 
the 1st quartile, the median, and the 3rd quartile. Outliers, or values
outside the boxplot, will also 
be plotted. If appropriate, horizontal lines representing boundaries for abnormal values will be 
plotted.
8.0
HUMAN SUBJECTS CONSI
DERATIONS
8.1
Ethical Review
This protocol and the template informed consent form(s) contained in 
Appendices
II and III
—
and an
y s
ubsequent modifications 
—
will be reviewed and approved b
y t
he HPTN Protocol 
Review Committee and DAIDS Prevention Science Review Committee with respect to scientific 
content and compliance with applicable research and huma
n subjects regulations. 
HPTN 066, Version 
2
.0 
Page 
63
of 
116
29 Nov
em
ber
2010
The protocol, site
-
specific informed consent form, participant education and recruitment 
materials, and other requested documents 
—
and any
subsequent modifications 
—
also will be 
reviewed and approved by the ethical review bodies
responsible for oversight of research 
conducted at the stud
y s
ite. 
Subsequent to initial review and approval, the responsible I
RBs/ECs will review the protocol at 
least annuall
y.  The Investigator will make safet
y and progress reports to the I
RBs/ECs at
least 
annually
, and within three months of study
termination or completion.  These reports will include 
the total number of participants enrolled in the study
, the number of participants who completed 
the study
, all changes in the research activity
, and a
ll unanticipated problems involving risks to 
human subjects or others. Study
sites will submit documentation of continuing review to the 
DAIDS Protocol Registration Office, via the HPTN CORE, in accordance with the current 
DAIDS Protocol Registration Polic
y and Procedure Manual.
8.2
Informed Consent
Written informed consent will be obtained from each study
participant
. Each study
site is 
responsible for developing a stud
y IC
F for local use, based on the template in Appendices II
and 
III
, which describes the p
urpose of the stud
y, the procedures to be followed, and the risks and 
benefits of participation, in accordance with all applicable regulations.  The study site is also 
responsible for translating the template 
form into additional languages (if applicable),
and 
verify
ing the accuracy
of the translation by
performing an independent back
-
translation. 
Li
terate 
participants will document their provision of informed consent by
signing their informed consent 
forms.  Participants will be provided with a cop
y of the
ir informed consent forms. 
8.3
Risks
Phlebotomy, STI Screening. 
Phlebotomy
may
lead to discomfort, feelings of dizziness or 
faintness, and/or bruising, swelling and/or infection.  Pelvic examination may
cause mild 
discomfort and/or vaginal bleeding or spott
ing.  Disclosure of STI status may
cause sadness or 
depression in volunteers.  Participation in clinical research includes the risks of loss of 
confidentiality
and discomfort with personal nature of questions.  
Confidentiality
. Although study
sites make 
every
effort to protect participant privacy
and 
confidentiality
, it is possible that participants' involvement in the study
could become known to 
others, and that social harms may
result. 
STI Reporting
. Participants in sites requiring partner notificatio
n in response to diagnosed STI 
or HIV infection could have problems in their relationships with their sexual partners.  
Participants also could have problems in their partner relationships associated with use or 
HPTN 066, Version 
2
.0 
Page 
64
of 
116
29 Nov
em
ber
2010
attempted use of stud
y products.  I
n additio
n, participants could misunderstand the current 
experimental status of the study
medication and as a result increase their HIV risk behaviors 
while in the study
.
Flexible Sigmoidoscopy with Biopsy. 
Flexible sigmoidoscop
y i
s a commonly
practiced medical 
pr
ocedure and the endoscopic procedures done in this trial will not involve any
unusual risks or 
discomforts. The risks associated with these procedures include mild discomfort and the feeling 
of having a “bloated stomach”.  Endoscopic biopsies are painless 
and heal quickly
within 3 day
s. 
On extremely
rare occasions, the endoscopic procedure or biopsies may
lead to pain, infection 
(sepsis), bleeding or perforation of the gastrointestinal tract. Perforation occurs approximately 
once out of every
100,000 proced
ures. If this extremely
rare complication occurs, antibiotics and 
surgery
to repair the tear may
be necessary
.  Participants will be counseled to refrain from sexual 
intercourse for at least 72 hours following the biopsy. 
Anoscopy and luminal fluid colle
ction
. I
t is possible that the participant may
experience mild 
discomfort, embarrassment or, rarel
y, pain (should they have another condition that is alread
y 
causing pain in the area) during this procedure.  If there is an
y pain experienced during the 
proc
edures, the study
clinician will adapt or stop the procedure.
Enema. 
The primary
risk from having an enema is temporary
discomfort.
The procedure may
 
cause a bloated or crampy feeling.
Some air may
be pumped into the rectum as well, causing 
flatulence.
Very
rarely
, the enema tube could make a hole in the rectum causing a bowel 
perforation requiring surgery
.
Vaginal Biopsy
. Vaginal biopsy
carries the risk of
discomfort or pain during the procedure and 
for a few hours afterwards.  Participants may have m
ild vaginal spotting (bleeding) for one or 
two day
s, and will be instructed to avoid sexual intercourse until bleeding stops.  Some 
temporary
discomfort with sexual intercourse may
occur if the biops
y a
reas are still healing.  
There is a small risk of infe
ction and heavier bleeding.  Participants will be instructed to contact 
the clinic if sy
mptoms are bothersome, if heavy
bleeding is noted (soaking through a pad or 
tampon in an hour or less) or if the participant develops any
abnormal odor or discharge fro
m the 
vagina. 
Participants will be counseled to refrain from sexual intercourse for at least 72 hours 
following the biops
y.
HPTN 066, Version 
2
.0 
Page 
65
of 
116
29 Nov
em
ber
2010
Study 
Product
FTC/TDF Combination Tablet
. 
Truvada® tablets are fixed dose combination tablets 
containing emtricitabine (FTC) 200 
mg
and tenofovir disoproxil fumarate (TDF) 300 mg in each 
tablet. 
There is very
little experience in healthy
volunteers taking Truvada®. 
No new or 
unexpected side effects are observed with the TDF 300 mg / FTC 200 mg combination tablet 
than those observed 
when each drug is given separatel
y.  For study Arm 4, the TDF/FTC dosing 
regimens are consistent with package insert recommendations. Participants in Arms 1 and 2 will 
be taking the ty
pical TDF/FTC dose, but at reduced frequency
. Participants in Arm 3 will
be 
taking twice the recommended dose, but at reduced frequency
(twice weekly
rather than daily
), 
representing 57% of the weekl
y recommended dose. Individual daily doses of this magnitude 
were studied during development of both TDF and FTC and these were w
ell tolerated. 
FTC
. 
The following side effects have been associated with the use of FTC: headache, dizziness, 
tiredness, inability
to sleep, unusual dreams, loose or watery
stools, upset stomach (nausea) or 
vomiting, abdominal pain, rash, itching, skin d
arkening of the palms and/or soles, increased 
cough, runn
y nose, abnormal liver function tests, increases in pancreatic enzy
me, increased 
trigl
ycerides, increased creatine phosphokinase. 
FTC is a pregnancy
category
B medication.  No controlled human stud
ies of FTC among 
pregnant women have been conducted.  
TDF
. The most common side effects associated with oral TDF in patients with HIV infection are 
nausea, headache, diarrhea, vomiting, asthenia, flatulence, abdominal distension/pain and 
anorexia.  Less 
common side effects of TDF include kidney
toxicities and low blood phosphate.  
Other side effects reported in the post
-
marketing period include 
weakness, pancreatitis, 
dizziness, shortness of breath, and rash.  TDF has been associated with decreased bone m
ineral 
density
in HIV
-
infected patients taking TDF tablets for 24
-
48 weeks. 
TDF is a pregnancy
category
B medication.  No extensive controlled human studies of TDF 
among pregnant women have been conducted.  
Nucleotide Analogues
.
Lactic acidosis (elevat
ed lactic acid levels in the blood) and severe 
hepatomegal
y (
enlarged liver) with steatosis (fatt
y l
iver) that may
result in liver failure, other 
complications or death have been reported with the use of antiretroviral nucleoside analogues 
alone or in comb
ination.  The liver complications and death have been seen more often in 
women on these drug regimens.  Some nonspecific symptoms that might indicate lactic acidosis 
include: unexplained weight loss, stomach discomfort, nausea, vomiting, fatigue, cramps, m
uscle 
HPTN 066, Version 
2
.0 
Page 
66
of 
116
29 Nov
em
ber
2010
pain, weakness, dizziness and shortness of breath. 
These effects are not expected in this study
 
involving a brief exposure to antiretroviral drug.
Antiretroviral Drugs
. Redistribution/accumulation of body
fat including central obesit
y, 
dorsocervical
fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast 
enlargement, and "cushingoid appearance" have been observed in persons receiving antiretroviral 
drugs. The mechanism and long
-
term consequences of these events are currently
unknow
n. A 
causal relationship has not been established.  These effects are not expected in this study
 
involving a brief exposure to antiretroviral drug.
8.4
Benefits
There 
will
be no direct benefits to participants in this study
.  However, participants and others
may
benefit in the future from information learned from this study
. Specifically
, information 
learned in this study
may lead to the development of a safe and effective PrEP regimen that 
prevents HIV infection.  
8.5
Incentives
Pending IRB/EC approval, parti
cipants will be compensated for their time and effort in this 
study
, and/or be reimbursed for travel to study
visits and time away
from work. Site
-
specific 
reimbursement amounts will be specified in the study
IC
Fs. 
8.6
Confidentiality
All study
-
related info
rmation will be stored securely
at the study
site.  All participant 
information will be stored in locked file cabinets in areas with access limited to study
staff.  All 
laboratory
specimens, reports, study
data collection, process, and administrative forms
will be 
identified by
a coded number only
to maintain participant confidentiality
.  All records that 
contain names or other personal identifiers, such as locator forms and informed consent forms, 
will be stored separatel
y from study records identified by 
code number.  All local databases will 
be secured with password
-
protected access s
ys
tems.  Forms, lists, logbooks, appointment books, 
and an
y other listings that link participant ID numbers to other identifying information will be 
stored in a separate, loc
ked file in an area with limited access.
Participant’s study
information will not be released without the written permission of the 
participant, except as necessary
for monitoring by
the NIAID and/or its contractors, Gilead 
Sciences; representatives of th
e HPTN CORE, SDMC, and/or NL
, U.S. FDA, 
OHRP, 
and/or site 
IR
Bs/ECs.  
HPTN 066, Version 
2
.0 
Page 
67
of 
116
29 Nov
em
ber
2010
The HPTN has obtained a Certificate of Confidentiality
from the US Department of Health and 
Human Services that will be applicable for this study
.  Sites may
register under the Certific
ate 
through the HPTN CORE once they have obtained local I
RB approvals for the study
.  This 
Certificate protects study staff from being compelled to disclose study
-
related.  information b
y 
any
US Federal, State or local civil, criminal, administrative, legi
slative, or other bod
y.
All protected health information (PHI) will be protected according to the provisions of the 
HI
PAA and will only
be used or disclosed as allowed b
y t
he privacy
rule pursuant to relevant 
waivers or authorizations, or as required b
y f
ederal law.
8.7
Communicable Disease Reporting Requirements
Study
staff will compl
y with all applicable local requirements to report communicable diseases 
identified among stud
y p
articipants to local health authorities.  Participants will be made aware 
of al
l reporting requirements during the stud
y i
nformed consent process.
8.8
Study Discontinuation
The study
may
be discontinued at any
time by
NIAID, 
site IRBs/ECs, 
the HPTN, Gilead 
Sciences, 
OHRP or other governmental agencies as part of their duties to ensure 
that research 
subjects are protected
.  
9.0
LABORATORY SPECIMENS
AND BIOHAZARD CONTA
INMENT
9.1
Local Laboratory Specimens
As described in Section 5, the following t
ypes of specimens will be collected for testing at the 
local laboratory
: 
Blood
·
HI
V diagnostic 
testing (see SSP)
o
HI
V rapid test
o
HI
V Western blot (for HIV confirmatory
testing)
o
APTI
MA HIV
-
1 RNA Qualitiative Assay
(GenProbe, Inc., GenAptima assay)
·
Safety
testing: 
o
CBC
o
AST/AL
T
o
Creatine and calculated creatinine clearance
o
phosphate
o
HCO3, Na
,
Cl, K,
Ca,
glucose
·
Coagulation testing:
HPTN 066, Version 
2
.0 
Page 
68
of 
116
29 Nov
em
ber
2010
o
INR, PT and PTT
·
Hepatitis testing (
HBsAg
)
·
Sy
philis testing
·
Plasma storage
·
Blood samples for PK analy
sis (drug levels)
o
Serum
o
PBMCs
o
CD4+ cells
·
Quantitative HIV RNA assay
(for an
y participant who acquires HIV infection during the 
study
).
·
CD4 cell count (for an
y participant who acquires HIV infection during the study)
·
Genoty
ping and additional plasma storage (for any participant who acquires HIV 
infection during the study
–
see Appendix 1D)
Urine
·
Pregnancy
testing (women only
)
·
CT/GC
testing
·
Dipstick for urinal
ys
is. If positive for leukocy
te esterase or nitrates, perform urine culture
Pelvic Specimens (women only
)
·
Vaginal wet mount (for BV, candida, trichomonas)
·
Vaginal pH 
(if Amstel criteria are used for diagnosis of BV)
·
Pap smear (
if a normal result is not documented within 12 months)
Responsibility of Study Sites
Study
sites must adhere to standards of good clinical laboratory
practice (GCL
P), the HPTN 
Manual of Laboratory Operations, and local Standard Operating Procedures (SOPs
) for proper 
collection, processing, labeling, and transport of specimens to the local laboratory
. 
Procedures Performed at Local Laboratories
General requirements
Local laboratories must adhere to standards of GCLP, the HPTN Manual of L
aboratory
 
Operati
ons, and local SOPs for proper specimen receipt, testing, aliquoting, storage, and 
shipment of specimens (see below). Specimen testing and storage must be documented using the 
Laboratory
Data Monitoring Sy
stems (LDMS).  Clinical sites in must document that
their 
clinical laboratories are CLIA
-
certified and must meet DAIDS requirements for external quality
 
assurance (QA) testing. External Quality Control (QC) of CLIA
-
waived tests (e.g. HIV rapid 
tests) may
be required. HPTN NL
staff will conduct period visit
s to each site to assess the 
HPTN 066, Version 
2
.0 
Page 
69
of 
116
29 Nov
em
ber
2010
implementation of on
-
site QC procedures, including proper maintenance of laboratory
testing 
equipment and use of appropriate reagents. HPTN NL staff will follow
-
up directly
with site staff 
to resolve an
y QA or QC problems ident
ified through proficiency
testing and/or on
-
site 
assessments.
HI
V diagnostic testing
HI
V infection status will be assessed both at screening
,
enrollment, at the end of the study
, and at 
any
study
visit at which a participant expresses a concern about havi
ng acquired HIV infection. 
Diagnostic testing algorithms are provided in the SSP. HIV rapid testing will be used to screen 
participants for HIV infection.  HIV rapid test kits must be FDA
-
cleared. Preference is given to 
FDA
-
cleared OraSure Oraquick HIV
-
1/2
, Clearview HIV
-
1/2 Stat Pak, or Clearview Complete 
HI
V
-
1/2.  Participants with one or more reactive HIV rapid test results will not be eligible for 
enrollment, regardless of subsequent test results. In those cases, HIV infection status will be 
confirmed u
sing local HIV testing guidelines. After enrollment, if HIV infection is suspected or 
documented, the HPTN NL
should be contacted. HIV infection must be confirmed for an
y 
enrolled participant using two independent samples.
Processing of samples for PK ana
ly
sis (measurement of drug levels)
Blood samples will be processed locally
to isolate serum and cells of interest. Detailed 
procedures for processing, freezing, storing, and shipping tissue samples are provided in the SSP 
Manual. 
Shipping
Sites must have
the capability
for shipping samples to the HPTN NL for Pharmacology
, 
Virology
, QA, and other testing. All specimens must be shipped in accordance with International 
Air Transportation Association (IATA) specimen shipping regulations and must be documented
in the L
DMS. 
Sample storage
Specimens will be stored at study
sites and shipped to the HPTN NL
upon request. 
9.2
Network Laboratory Specimens
Testing Performed at the HPTN NL
Virology
The HPTN NL will perform testing to determine HIV infection status in
selected cases and will 
perform HIV diagnostic testing for QC. The HPTN NL may
also perform specialized assay
s to 
characterize HIV viruses and the immune response to HIV infection in an
y participant who 
becomes HIV
-
infected during the study
. HI
V resistanc
e testing will be performed at the time of 
HI
V diagnosis (see Appendix I
D). HIV resistance test results from that study visit (time of HIV 
HPTN 066, Version 
2
.0 
Page 
70
of 
116
29 Nov
em
ber
2010
diagnosis) will be provided to study
sites at study
closure. Results from that testing will be 
provided to study
site
s prior to study
closure with approval of the HPTN NL and the Protocol 
Chair. That testing may
be performed at a commercial laboratory
(e.g., Monogram Biosciences). 
Additional testing may
be performed for research purposes, either at the HPTN NL
, or at an 
outside laboratory
designated by
the HPTN NL. This may
include testing with assay
s used for 
anal
ys
is of HIV incidence testing to evaluate the fading of resistant variants (including minority
 
variants assay
s) HIV subty
ping, and other testing to characterize
HI
V viruses and/or the host 
response to HIV infection. Results from those tests will not be returned to study
sites or study
 
participants. 
STI
Testing
The HPTN NL will perform HSV
-
2 PCR testing and GC/CT nucleic acid amplification testing 
(NAAT). Result
s from these tests will be returned to study
participants.
Pharmacology
The HPTN NL will perform all drug testing for this protocol. Drugs will be measured in serum, 
PBMCs, CD4+ blood cells, total tissue cells, CD4+ tissue cells, tissue homogenate, and lu
minal 
(vaginal and rectosigmoid) fluid using assay
s that have an assay
validation report (AVR) and 
SOP approved b
y t
he CPQA. Results from these tests will not be returned to study
participants.
As described in Section 5, the following t
ypes of specimens w
ill be collected for testing at the 
HPTN NL
: 
Blood
·
Serum for drug levels
·
PBMC for drug levels
·
CD4+ blood cells for drug levels
·
Plasma for storage (for QC of HIV testing, and for viral characterization in any 
participant who acquires HIV infection during 
the study
)
Rectosigmoid Sampling
·
Tissue biopsy
intact (for homogenate)
·
Tissue total cells ly
sate
·
Tissue CD4+ cells ly
sate
·
Luminal fluid
Vaginal Sampling
·
Tissue biopsy
intact (for homogenate)
·
Tissue total cells ly
sate
·
Tissue CD4+ cells ly
sate
·
Luminal flui
d
HPTN 066, Version 
2
.0 
Page 
71
of 
116
29 Nov
em
ber
2010
·
Cervical 
cells (from 
cy
tobrush
)
Note: Vaginal tissues will be processed in the priority listed above and will be dependent upon 
the amount of tissue collected during the biopsy
. Sites will collect up to 5 biopsies; however, the 
upper limits will be depe
ndent upon site specific IRB approvals.
Genital swabs
·
For HSV
-
2 testing (onl
y i
f active lesions are present)
Seminal Fluid
·
Drug levels
Rectal swabs
·
For GC/CT testing
All specimen collection and specimen processing procedures will be outlined in the stu
dy
 
specific procedures manual. 
Each stud
y s
ite will adhere to standards of good laboratory
practice and the HPTN Network 
Laboratory
Manual for proper collection, processing, labeling, and transport of specimens for the 
NL
.  All specimens will be shipped 
in accordance with I
ATA specimen shipping regulations. All 
shipments will be documented using the HPTN LDMS as described in the SSP manual.
9.3
Quality Control and Quality Assurance Procedures
The clinical sites will document that their clinical laboratories
are CLIA
-
certified and/or 
participate in DAIDS sponsored EQA programs. NL staff will conduct periodic visits to each site 
to assess the implementation of on
-
site laboratory
QC procedures, including proper maintenance 
of laboratory
testing equipment and us
e of appropriate reagents. NL staff will follow
-
up directly
 
with site staff to resolve any QC or QA problems identified through proficiency testing and/or 
on
-
site assessments. 
Throughout the course of the study
, the HPTN NL will select a random 
sample of s
tored specimens to test for QA purposes. NL
staff will follow
-
up directly
with site 
staff to resolve an
y QA problems identified through this process.
QC for HIV Diagnostic Testing
Before performing HIV diagnostic testing, all sites must validate their tes
ting algorithm, and the 
validation study
must be approved b
y t
he HPTN NL
. Local laboratories will perform testing for 
HI
V diagnosis at screening, enrollment, and other scheduled visits. Algorithms for HIV 
diagnostic testing are provided in the SSP. 
HPTN 066, Version 
2
.0 
Page 
72
of 
116
29 Nov
em
ber
2010
QC fo
r HIV RNA Monitoring 
Quantitative HIV RNA (viral load) testing will be performed at local laboratories for an
y 
participant with confirmed HIV infection. Note that this is distinct from use of qualitative HIV 
RNA testing that may
be performed to determine 
HI
V infection status in selected cases. Local 
laboratories must participate in the DAIDS Virology
QA program, with EQA results that are 
deemed satisfactory
by
the HPTN NL.
QC for CD4 Cell Count Determination
CD4 cell count testing will be performed at loc
al laboratories for an
y participant with confirmed 
HI
V infection. U.S. laboratories performing CD4 cell count testing must be CLIA
-
certified; 
enrollment in the DAIDS I
mmunology
QA (IQA) program is preferred. 
9.4
Specimen Storage and Possible Future Research 
Testing
Study
site staff will store all plasma specimens collected in this study
until all protocol
-
related 
testing has been completed, including QC testing and other testing performed at or coordinated 
by
the HPTN NL. Study
staff will also store all samp
les collected for drug testing as directed b
y 
the NL
. The stud
y s
ite will be informed by
SCHARP when shipments to the NL are required, 
and will be instructed which samples to ship. I
n addition, study
participants will be asked to 
provide written informed c
onsent for their specimens to be stored after the end of the stud
y for 
possible future testing.  The specimens of participants who do not consent to long
-
term storage 
and additional testing will be destro
yed at the end of the study.
9.5
Biohazard Containment
As the transmission of HIV and other blood
-
borne pathogens can occur through contact with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions 
will be employ
ed b
y all personnel in the drawing of blood and shipping a
nd handling of all 
specimens for this study
, as currently
recommended by
the U.S. Centers for Disease Control and 
Prevention.  All infectious specimens will be transported in accordance with U.S. regulations (42 
CFR 72).
10.0
ADMINISTRATIVE 
PROCEDURES
10.1
Study A
ctivation
Prior to implementation of this protocol, and any
subsequent full version amendments, each site 
must have the protocol and the protocol consent form(s) approved, as appropriate, b
y t
heir local 
institutional review board (I
RB)/ethics committee (E
C) and an
y other applicable regulatory
 
entity
(RE). Upon receiving final approval, sites will submit all required protocol registration 
documents to the DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory
 
Support 
Center (RS
C).  The DAIDS PRO w
ill review the submitted protocol registration packet to ensure 
that all of the required documents have been received.
HPTN 066, Version 
2
.0 
Page 
73
of 
116
29 Nov
em
ber
2010
Site
-
specific informed consent forms (ICFs) 
WILL
be reviewed and approved by the DAIDS 
PRO and sites will receive an Initial Registratio
n Notification from the DAIDS PRO that 
indicates successful completion of the protocol registration process. A copy of the Initial 
Registration Notification should be retained in the site's regulatory files.
Upon receiving final IRB/EC and any other appli
cable RE approval(s) for an amendment, sites 
should implement the amendment immediately
.  Sites are required to submit an amendment 
registration p
acket to the DAIDS PRO at the RS
C.  The DAIDS PRO will review the submitted 
protocol registration packet to en
sure that all the required documents have been received. Site
-
specific ICF(s) WILL NOT be reviewed and approved by the DAIDS PRO and sites will receive 
an Amendment Registration Notification when the DAIDS PRO receives a complete registration 
packet. A cop
y of the Amendment Registration Notification should be retained in the site's 
regulatory
files.
For additional information on the protocol registration process and specific documents required 
for initial and amendment registrations, refer to the current v
ersion of the DAIDS Protocol 
Registration Manual.
Pending successful protocol registration and submission of all required documents, CORE staff 
will “activate” the site to begin stud
y operations.  Study
implementation may
not be initiated 
until a study
ac
tivation notice is provided to the site.
10.2
Study Coordination
The United States Food and Drug Administration (U.S. FDA) has been informed of this study
and has provided an IND
-
exemption.
Assignment of all sponsor responsibilities for this study
will be s
pecified in a Clinical Trials 
Agreement executed b
y DAIDS and Gilead Sciences.
Study
implementation will be directed by
this protocol as well as the SSP manual. The SSP 
manual 
—
which will contain reference copies of the 
Requirements for Source Documentat
ion in 
DAIDS Funded and/or Sponsored Clinical Trials
, as well as the DAIDS 
Manual for Expedited 
Reporting of Adverse Events to DAIDS, Version 2.0, dates January 2010 
and the DAIDS 
Toxicity
Tables 
—
will outline procedures for conducting stud
y visits; data 
and forms 
processing; AE assessment, management and reporting; dispensing stud
y p
roducts and 
documenting product accountability
; and other study
operations.  
Study
CRFs will be developed by
the study
team and HPTN SDMC.  Data will be transferred to 
the H
PTN SDMC, entered, and cleaned using the SDMC DataFax data management s
ys
tem. 
HPTN 066, Version 
2
.0 
Page 
74
of 
116
29 Nov
em
ber
2010
Quality
control reports and queries routinel
y will be generated and distributed to the study sites 
for verification and resolution.   
Close coordination between protocol team m
embers will be necessary
to track study
progress, 
respond to queries about proper stud
y i
mplementation, and address other issues in a timely
 
manner.  Rates of accrual, adherence, follow
-
up, and AE incidence will be monitored closely b
y 
the team as well as 
the HPTN Study
Monitoring Committee.  The Protocol Chair, DAIDS 
Medical Officer, Protocol Biostatistician, and CORE Protocol Specialist will address issues 
related to stud
y eligibility and AE management and reporting as needed to assure consistent case 
man
agement, documentation, and information
-
sharing across sites. 
10.3
Study Monitoring
On
-
site study
monitoring may
be performed in accordance with DAIDS policies.  Study
monitors 
will visit the site to:
·
Verify
compliance with human participants and other rese
arch regulations and guidelines; 
·
Assess adherence to the study
protocol, study
-
specific procedures manual, and local 
counseling practices; and
·
Confirm the quality
and accuracy
of information collected at the stud
y s
ite and entered 
into the study
databas
e.  
Site investigators will allow study
monitors to inspect study
facilities and documentation (e.g., 
informed consent forms, clinic and laboratory
records, other source documents, case report 
forms), as well as observe the performance of study
procedure
s. Investigators also will allow 
inspection of all study
-
related documentation b
y a
uthorized representatives of the HPTN CORE, 
SDMC, NL
, NIAID, Gilead Sciences, 
FDA 
and 
other 
U.S. government and regulatory
 
authorities. A site visit log will be maintained a
t the study
site to document all visits.
10.4
Protocol Compliance
The study
will be conducted in full compliance with the protocol.  The protocol will not be 
amended without prior written approval b
y t
he Protocol Chair and NIAID Medical Officer.  All 
protocol
amendments must be submitted to and approved by
the relevant IRB(s)/EC(s) and the 
DAIDS Regulatory
 
Support Center (RS
C) prior to implementing the amendment.
HPTN 066, Version 
2
.0 
Page 
75
of 
116
29 Nov
em
ber
2010
10.5
Investigator's Records
The study
site investigator will maintain, and store in a secure manner, 
complete, accurate and 
current stud
y r
ecords throughout the stud
y.  The investigator will retain all study records for at 
least three years after the completion of the study, unless directed otherwise by DAIDS.  Study 
records include administrative documen
tation, including site registration documents and all 
reports and correspondence re
lated
to the study
, as well as documentation related to each 
participant screened and/or enrolled in the stud
y, including informed consent forms, locator 
forms, case report 
forms, notations of all contacts with the participant, and all other source 
documents.
10.6
Use of Information and Publications
Publication of the results of this study
will be governed b
y HPTN policies.  Any presentation, 
abstract, or manuscript will be sub
mitted by
the Investigator to the HPTN Manuscript Review 
Committee, DAI
DS, and Gilead Sciences for review prior to submission.
HPTN 066, Version 
2
.0 
Page 
76
of 
116
29 Nov
em
ber
2010
11.0
REFERENCES
Barditch
-
Crovo, P., S.G. Deeks, A. Collier, S. Safrin, D.F. Coakley
, M. Miller, B.P. Kearney
, 
R.
L.
Coleman, P.D. Lamy, J.O. Kahn, I. McGowan, and P.S. L
ietman. 2001. Phase i/ii 
trial of the pharmacokinetics, safet
y, and antiretroviral activity of tenofovir disoproxil 
fumarate in human immunodeficiency
virus
-
infected adults. 
Antimicrob Agents 
Chemothe
r
. 45:2733
-
9.
Cardo, D.M., D.H. Culver, C.A. Ciesielski, P.U. Srivastava, R. Marcus, D. Abiteboul, J. 
Heptonstall, G. Ippolito, F. Lot, P.S. McKibben, and D.M. Bell. 1997. A case
-
control 
study
of HIV seroconversion in health care workers after percutaneous
exposure. Centers 
for Disease Control and Prevention Needlestick Surveillance Group. 
N Engl J Med
. 
337:1485
-
90.
Garcia
-
Lerma, G., M.
-
E. Cong, and J. Mitchell. 2009. Prevention of Rectal Simian HI
V 
Transmission in Macaques by
Intermittent Pre
-
exposure Prop
hy
laxis with Oral Truvada 
(Abstract 47). 
In
16th Conference on Retroviruses and Opportunistic Infections (CROI
 
2009), Montreal, Canada.
Garcia
-
Lerma, J.G., R.A. Otten, S.H. Qari, E. Jackson, M.E. Cong, S. Masciotra, W. L
uo, C. 
Kim, D.R. Adams, M. Monsour, 
J. L
ipscomb, J.A. Johnson, D. Delinsky
, R.F. Schinazi, 
R. Janssen, T.M. Folks, and W. Heneine. 2008. Prevention of rectal SHIV transmission in 
macaques b
y d
aily
or intermittent prophy
laxis with emtricitabine and tenofovir. 
PLoS 
Med
. 5:e28.
Gish, R.G., N.W.
Leung, T.L
. Wright, H. Trinh, W. Lang, H.A. Kessler, L. Fang, L.H. Wang, J. 
Delehant
y, A. Rigney, E. Mondou, A. Snow, and F. Rousseau. 2002. Dose range stud
y of 
pharmacokinetics, safet
y,
and preliminary
antiviral activity
of emtricitabine in adults with 
h
epatitis B virus infection. 
Antimicrob Agents Chemother
. 46:1734
-
40.
Gough, K., M. Hutchinson, and O. Keene. 1995. Assessment of dose proportionality
: report from 
the pharmaceutical industry
. 
Drug Information Journal
. 29:1039
-
1048.
Hawkins, T., W. Veikley,
R.L
. St Claire, 3rd, B. Guyer, N. Clark, and B.P. Kearney. 2005. 
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and 
lamivudine triphosphate in patients receiving triple
-
nucleoside regimens. 
J Acquir 
Immune Defic Syndr
. 39:
406
-
11.
Hummel, J., S. McKendrick, C. Brindley
, and R. French. 2009. Exploratory assessment of dose 
proportionality
: review of current approaches and proposal for a practical criterion. 
Pharm Stat
. 8:38
-
49.
Kearney, B.P.
, 
J. Zong
, 
J. Begley
, and J. Shah. 2
004. 
Bioequivalence of combination tenofovir 
DF/emtricitabine tablets for one
-
pill once daily administration [poster no. 7.3]
. 
In
5th 
International Workshop on Clinical Pharmacology of HIV Therapy
, Rome, I
taly.
Pruvost, A., E. Negredo, H. Benech, F. Theodo
ro, J. Puig, E. Grau, E. Garcia, J. Molto, J. Grassi, 
and B. Clotet. 
2005. Measurement of intracellular didanosine and tenofovir 
phosphory
lated metabolites and possible interaction of the two drugs in human 
immunodeficiency
virus
-
infected patients. 
Antimic
rob Agents Chemother
. 49:1907
-
14.
Pruvost, A., E. Negredo, F. Theodoro, J. Puig, M. Levi, R. Ayen, J. Grassi, and B. Clotet. 2009. 
Pilot pharmacokinetic study
of human immunodeficiency
virus
-
infected patients 
receiving tenofovir disoproxil fumarate (TDF): 
investigation of s
ys
temic and intracellular 
interactions between TDF and abacavir, lamivudine, or lopinavir
-
ritonavir. 
Antimicrob 
Agents Chemother
. 53:1937
-
43.
HPTN 066, Version 
2
.0 
Page 
77
of 
116
29 Nov
em
ber
2010
Rousseau, C.M., R.W. Nduati, B.A. Richardson, M.S. Steele, G.C. John
-
Stewart, D.A. Mbori
-
Ngacha,
J.K. Kreiss, and J. Overbaugh. 2003. Longitudinal anal
ys
is of human 
immunodeficiency
virus ty
pe 1 RNA in breast milk and of its relationship to infant 
infection and maternal disease. 
J Infect Dis
. 187:741
-
7.
Rousseau, F.S., J.O. Kahn, M. Thompson, D. Mild
van, D. Shepp, J.P. Sommadossi, J. 
Delehant
y, J
.N. Simpson, L
.H. Wang, J.B. Quinn, C. Wakeford, and C. van der Horst. 
2001. Prototy
pe trial design for rapid dose selection of antiretroviral drugs: an example 
using emtricitabine (Coviracil). 
J Antimicrob Ch
emother
. 48:507
-
13.
Schechter, M., R.F. do Lago, A.B. Mendelsohn, R.I
. Moreira, L.H. Moulton, and L
.H. Harrison. 
2004. Behavioral impact, acceptability
, and HIV incidence among homosexual men with 
access to postexposure chemoproph
yl
axis for HIV. 
J Acquir I
mmune Defic Syndr
. 
35:519
-
25.
Smith, B.P., F.R. Vandenhende, K.A. DeSante, N.A. Farid, P.A. Welch, J.T. Callaghan, and S.T. 
Forgue. 2000. Confidence interval criteria for assessment of dose proportionality
. 
Pharm 
Res
. 17:1278
-
83.
Subbarao, S., A. Ramos, C.
Kim, D. Adams, M. Monsour, S. Butera, T. Folks, and R.A. Otten. 
2007. Direct stringency
comparison of two macaque models (single
-
high vs. repeat
-
low) 
for mucosal HIV transmission using an identical anti
-
HI
V chemoproph
yl
axis 
intervention. 
J Med Primatol
. 3
6:238
-
43.
UNAIDS. 2008. Report on the Global AIDS Epidemic.
Van Belle, G., and D.C. Martin. 1993. Sample Size as a Function of Coefficient of Variation and 
Ratio of Means. 
American Statistician
. 47:165
-
167.
Veazey
, R.S., M.S. Springer, P.A. Marx, J. Dufour
, P.J. Klasse, and J.P. Moore. 2005. Protection 
of macaques from vaginal SHI
V challenge b
y an orally delivered CCR5 inhibitor. 
Nat 
Med
. 11:1293
-
4.
Wang, L.H., J. Begley, R.L
. St Claire, 3rd, J. Harris, C. Wakeford, and F.S. Rousseau. 2004. 
Pharmacokinetic 
and pharmacody
namic characteristics of emtricitabine support its once 
daily
dosing for the treatment of HIV infection. 
AIDS Res Hum Retroviruses
. 20:1173
-
82.
Zhou, J., J. L
i, and B. Coate. 2006. Empirical Power Estimation for Phase I Dose Proportionality 
S
tudies Based on Power
-
Law Model Using Confidence Interval Criteria. 
In
SUGI
31, San 
Francisco, California.
HPTN 066, 
Version 2.0
Page 
78
of 
116
29 Nov
em
ber
2010
APPENDICES
HPTN 066, 
Version 2.0
Page 
79
of 
116
29 Nov
em
ber
2010
APPENDIX I: SCHEDULE
OF EVALUATIONS AND 
P
RO
C
EDURES
HPTN 066, 
Version 2.0
Page 
80
of 
116
29 Nov
em
ber
2010
APPENDIX IA: SCHEDUL
E OF EVALUATIONS AND
PROCEDURES 
-
GENERAL PROCEDURES
Phase
Sc
reening
Enrollment
Accumulation
Steady
-
State
Decay
Study Week
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Study Day
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Treatment Arm and 
Regimen
1. FTC 200 mg/TDF 
300 m
g one tablet orally 
once w
eekly for 5 
weeks
X
X
X
X
X
2. FTC 200 mg/TDF 
300 m
g  one tablet 
orally
tw
ice weekly for 
5 w
eeks
X
X
X
X
X
X
X
X
X
X
3. FTC 200 mg/TDF 
300 m
g  two tablets 
orally t
wice weekly for 
5 w
eeks
X
X
X
X
X
X
X
X
X
X
4. FTC 200 mg/TDF 
300 m
g C one table
t 
once daily for 
5 w
eeks
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Administrative and 
Behavioral Procedures
Informed Consent
X
Locator Information
X
X
X
X
X
X
X
X
Dem
ographic 
Information
X
Medical History 
Questionnaire
X
HPTN 066, Version 
2
.0 
Page 
81
of 
116
29 Nov
em
ber
2010
APPENDIX IB: SCHEDUL
E OF EVALUATIONS AND
PROCEDURES 
-
CLINICAL PROCEDURES
AND LABORATORY 
TESTS
Phase
SCR
ENR
Accumulation
Steady
-
State
Decay
Study Week
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Study Day
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
5
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Clinical 
Procedures and 
Laboratory 
Tests
Blood 
(Serum/Plasm
a)
HIV Diagnostic 
Testing
a
X
X
X
Safety testing
b
X
X
X
X
X
Coagulation 
testing
c
X
X
HBsAg
*
X
X
Syphilis Testing
k,
*
X
Plasma storage
X
X
X
X
Urine
Pregna
ncy test
j 
(w
om
en)
X
X
X
X
X
Dipstick 
urinalysis
d
, 
*
X
GC/CT testing
k,
*
X
HPTN 066, Version 
2
.0 
Page 
82
of 
116
29 Nov
em
ber
2010
Phase
SCR
ENR
Accumulation
Steady
-
State
Decay
Study Week
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Study Day
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
5
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Pelvic (wom
en) 
(intensive cohort
only)
Wet mount
e
X
Vaginal fluid pH
f
X
Pap Smear
g
X
Genital lesions 
(if present
;
(intensive cohort 
only)
HSV
-
2 testing
h
, 
*
X
Rectal (intensive 
cohort only)
GC/CT testing
i
, 
*
X
HPTN 066, Version 
2
.0 
Page 
83
of 
116
29 Nov
em
ber
2010
FOOTNOTES FOR APPENDIX IB
a
Perform testing as described in the SSP. Participants with one or more HIV rapid test results are not eligible for enrollment, even if HIV infection is
not confirmed. HIV diagnostic testing should be repeated at any study visit if a participant expresses a concern that he/she may have acquired HIV 
infection. 
b
Safety testing includes CBC, ALT/AST, phosphate, creatinine (for estimated creatinine clearan
ce), electrolytes (HCO3, K, Cl, Na),
Ca,
glucose. 
c
Coagulation testing includes 
INR, PT and PTT
. Intensive sampling cohort only.
d
If urine dipstick is positive for leukocyte esterase or nitrates, perform urinalysis along with urine culture.
e
Wet mount 
includes testing for BV, candida, trichomonas.
f
Vaginal pH testing is only required if Amstel criteria are used for diagnosis of BV.
g 
A Pap smear will be performed if a normal test result cannot be documented within the previous 12 months.
h
A PCR
-
based 
test for HSV
-
2 will be performed at the HPTN NL.
i
Rectal GC/CT NAAT testing will be performed at the HPTN NL.
j
Pregnancy testing 
will be 
done before any vaginal 
study 
procedures are performed.
On Day 35, pregnancy testing will only be performed on women 
in the intensive sampling cohort
. 
k
These tests are only for participants in the intensive sampling cohort
*
Individuals
with a positive result for any of these tests are not eligible for enrollment, and will be referred for care. Confirmatory testing sho
uld be 
performed as needed according to local testing guidelines. Testing should be repeated at any study visit if a participant expresses a concern that he/she 
ma
y have acquired hepatitis B or an STI.
HPTN 066, Version 
2
.0 
Page 
84
of 
116
29 Nov
em
ber
2010
APPENDIX IC: SCHEDUL
E OF EVALUATIONS AND
PROCEDURES
-
SAMPLE COLLECTION F
OR PK EVALUATION 
(DRUG TESTING)
Phase
SCR
ENR
Accumulation
Steady
-
State
Decay
Study Week
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Study Day
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
PK Sampling
Blood serum
X
4
2
3
X
1
X
X
X
X
X
Blood PBMC
X
4
2
3
X
1
X
X
X
X
X
Blood CD4+ cells
X
4
2
3
X
1
X
X
X
X
X
Rectosigmoid 
tissue homogenate
X
a
X
a
Rectosigmoid
tissue 
total cells
X
a
X
a
Rectosigmoid
tissue 
CD4+ cells
X
a
X
a
Rectosigmoid 
luminal fluid
X
a
X
a
Vaginal tissue 
homogenate
X
a
X
a
Vaginal tissue 
total cells
X
a
X
a
Vaginal tissue 
CD4+ cells
X
a
X
a
Vaginal fluid
X
a
X
a
Semen
X
a
X
a
HPTN 066, Version 
2
.0 
Page 
85
of 
116
29 Nov
em
ber
2010
In rows for Blood Serum, Blood P
BMC, and Blood CD4 cells, days 1
-
7
, the number indicates a sample collection for each cohort (indicated by cohort 
number
, as listed in the protocol schema
) 
no more tha
n one hour before
the second dose for each cohort. These will occur on day 
7
(Cohort 1), Day 
3
(Cohort 2 and 3), and Day 
1
(Cohort 4).
a 
Sixteen participants who agree to intensive tissue sampling will be enrolled in a balanced fashion across dosing cohort
s such that two men and two 
women per cohort are enrolled.  For other participants, they will only have blood and blood cells collected on Day 35 and 49. 
HPTN 066, 
Version 2.0
Page 
86
of 
116
29 Nov
em
ber
2010
APPENDIX 1D: 
ADDITIONAL PROCEDURE
S FROM STUDY PARTICI
PANTS WITH 
CONFIRMED HIV INFECT
ION
1
All stored samples from HIV seroconverters wil
l be centralized at the HPTN NL. 
2 
The HPTN NL will coordinate HIV resistance testing using samples shipped to the HPTN NL. HIV 
resistance test results from this study visit (time of HIV diagnosis) will be provided to study sites at study 
closure. Results
from this testing may be provided to study sites prior to study closure with approval of 
the HPTN NL and the Protocol Chair. 
3
Additional testing may be performed at the HPTN NL or at another laboratory designated by the HPTN 
NL for research purposes; th
ose results will not be returned to study sites or study participants. This 
testing may include HIV subtyping, minority variants assays, other assays to characterize HIV viruses 
and/or the host response to HIV infection.
Additional safety testing will also
be performed on all 
participants who seroconvert during the study. 
4
Participants 
who seroconvert during study participation
will 
have a final safety visit (visit may be split if 
necessary) after confirmation of their HIV status
.
Time of dia
gnosis
All subsequent visits
4
CD4 cell count testing
X
HI
V viral load testing
X
Shipment of samples to the HPTN NL
1
X
X
HI
V resistance testing 
2
X
Other testing 
3
X
X
Additional plasma storage
X
X
HPTN 066, 
Version 2.0
Page 
87
of 
116
29 Nov
em
ber
2010
APPENDIX II: SCREEN
ING/ENROLLMENT SAMPLE INFORMED CONSENT 
FORM (Intensive Sampling Cohort)
HPTN 066, 
Version 2.0
Page 
88
of 
116
29 Nov
em
ber
2010
SAMPLE
INFORMED
CONSENT
DOCUMENT
(
Intensive Sampling Cohort
)
HPTN
066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
29
N
OV
EMBER
2010
V
ERSION 
2.0
PRINCIPAL INVESTIGATOR: 
[I
nsert Name]
PHONE:  
[I
nsert Number]
GENERAL OVERVIEW 
You are being asked to take part in a research study
.
Joining this study
is voluntary
. 
You may
refuse to j
oin, or you may withdraw your consent to be in the study, for an
y r
eason.
Research studies are designed to obtain new knowledge that may help other people in the future.  
You may
not receive an
y direct benefit from being in the research stud
y. There also 
may
be risks 
to being in research studies.
Details about this study
are discussed below.  It is important that you understand this information 
so that y
ou can make an informed choice about being in this research stud
y.  You will be given a 
copy
of this co
nsent form.  You should ask the researchers named above, or staff members who 
may
assist them, any
questions y
ou have about this study
at an
y t
ime.
YOUR PARTICIPATION IS VOLUNTARY
This consent form gives information about the study that will be discussed
with y
ou. Once you 
understand the stud
y, and if you agree to take part, you will be asked to sign your name on this 
form. You will be given a cop
y of this form to keep. 
Before you learn about the study, it is important that you know the following:
·
Your 
participation is voluntary
.  You do not have to take part in the screening tests or in 
the study
.
·
You may
decide not to take part in the study
or to leave the stud
y at an
y t
ime without 
losing your regular medical care.
·
If you decide not to take part in the
study
, you can still join another study
at a later time if 
there is one available and you qualify.    
·
You cannot join this study
if you are taking part in another stud
y of drugs, medical 
devices or vaginal/rectal products.  You are asked to tell the stud
y s
taff about any
other 
studies y
ou are taking part in or thinking of taking part in.  This is very
important for 
yo
ur safet
y.  
HPTN 066, Version 
2
.0 
Page 
89
of 
116
29 Nov
em
ber
2010
 
PURPOSE OF THE STUDY
This study
is being conducted to look at how the body handles the dru
g Truvada® 
when it is 
given in different amounts and at different time schedules. This study will also look at the 
difference of medication amount in men and women.
The study
will look at levels of Truvada® in the blood, reproductive tract and gastrointes
tinal 
tract of female and male volunteers.  The aim is to establish how much of the drug (taken b
y 
mouth) reaches the reproductive and gastrointestinal tracts when given at different doses and at 
different dose schedules. It is believed that the presence o
f this drug in the reproductive and 
gastrointestinal tracts may
be beneficial in the prevention of the transmission of the AIDS virus.  
About 32 participants will be enrolled in the stud
y at 2 different sites in the United States.  About 
16 people will b
e enrolled in the study
here at [study
site].  The study
should take approximately
 
12 months to complete. Each participant will be followed for approximately 2 months.
The study
will take samples of blood once a week for the first 5 weeks after taking Tru
vada® 
according to the dose you are assigned to. After that time, blood samples and tissue samples from 
the gastrointestinal tract (from men and women) will be collected. Samples will also be collected 
from the vagina in women. Men will be asked to donate 
a semen sample. All of these samples 
are to look at drug concentrations.  You will then have a second set of blood sample and tissue 
biopsies after you have stopped taking the study drug for 2 weeks. The study will also collect 
information on the safet
y of
the medication.
Only
16 of the 32 participants will provide tissue/semen/vaginal samples as part of study
 
participation. The remaining participants will only provide blood samples. Potential participants 
will decide with study
staff which group they
will
enroll in before they
are consented for the 
study
. 
Truvada® is a tablet that is a combination of two medications
—
emtricitabine and tenofovir. This 
medication is used to treat people who have HIV.  The tablets are generall
y s
afe when used as 
treatment fo
r H
IV.  These tablets are not a cure for HIV/AIDS, but they are very effective for 
improving the health of people who have HIV/AIDS.  Although these tablets improve the health 
of people with HIV, 
we do not know if they work to protect against HIV.
The resu
lts of this 
study
may
be used in the future to determine if this medication can be taken by
healthy
people to 
prevent them from getting HIV.
The United States Food and Drug Administration (U.S. FDA) has been informed of this study. 
Truvada has not been ap
proved b
y t
he U.S. FDA for the prevention of HIV. 
Before you decide whether to take part in the study, we would like to explain the purpose of the 
study
, the risks and benefits, what is expected of you, and what to expect from us.  This consent 
form migh
t contain some words that are unfamiliar.  Please ask questions about any
thing y
ou do 
not understand or want to learn more about.
HPTN 066, Version 
2
.0 
Page 
90
of 
116
29 Nov
em
ber
2010
STUDY GROUPS
There are four stud
y groups.  Each group will have 8 people.  There will be 4 women and 4 men 
in each group.  If
you decide to take part in the study, you will be randomly assigned to one of 
the four groups, like flipping a coin.  Once you are assigned to a group, you cannot change to 
another group.  The four groups will each be given the same medication, but it wil
l be provided 
in different doses.
·
One group will take one Truvada® tablet one time each week for five weeks
·
One group will take one Truvada® tablet two times each week for five weeks
·
One group will take two Truvada® tablets two times each week for five we
eks
·
One group will take one Truvada® tablet each day for five weeks
All four groups are very
important to the study
.  It is very important that each person takes 
his/her medication as provided.  Because of this, all participants will be observed b
y a stud
y 
employ
ee when taking the medication so that we can be sure that the participant has taken the 
medication on the right day
and at the right time.  This means that some people will be required 
to come to the clinic every
day
(including Saturday
and Sunday
)
to get their medication.
CRITERIA FOR STUDY PARTICIPATION
In order to participate in the study
, you must meet all of the following criteria:
·
Be 18 to 44 years of age, inclusive on the date of screening.
·
Provide informed consent for the study
.
·
Provide in
formation on how to contact and locate you
·
Be willing to be tested for HIV infection and receive your test results.
·
Be H
IV negative.
·
Have good kidney function.
·
Be sexually
active (at least one sex
act 
-
vaginal or anal intercourse 
-
in the previous 30 
day
s
). 
·
Agree to use condoms.
·
Women must:
o
Be pre
-
menopausal
o
Have regular menstrual cy
cles with at least 21 days between menses (unless on 
contraception that causes lack of or irregular menses) 
o
Have a cervix
o
Have a negative urine pregnancy
test
o
Have documentat
ion of a normal Pap smear within 12 months
o
Be utilizing an alternative method of birth control in addition to condoms 
(hormonal contraceptive, diaphragm or have undergone surgical sterilization) or 
have a vasectomized exclusive male partner.
o
Not using sper
micide as a means of birth control (with a condom or a diaphragm)
HPTN 066, Version 
2
.0 
Page 
91
of 
116
29 Nov
em
ber
2010
REASONS WHY YOU WOULD NOT BE ABLE TO PARTICIPATE 
You will not be able to participate in the stud
y i
f any
of the following things apply
to y
ou:
·
Blood tests that show the following:
○
Poor 
liver function
○
Anemia (low blood counts)
○
Abnormal laboratory
values
·
Co
-
enrollment in any
other HIV research study
that involves an experimental drug or 
prior enrollment in the active arm of a HIV vaccine trial.
·
Active skin disorders.
·
Excessive use of alcoh
ol (more than 4 drinks a day
on a regular basis).
·
Any
procedure that has altered the stomach or intestines or drug absorption.
·
Abnormalities that will not allow the biopsies to be taken. 
·
Pelvic exam abnormalities. 
·
Women who have had cervical procedures w
ithin the previous 6 months.
·
A positive test for sy
philis, gonorrhea, chlam
ydia, hepatitis B, or HSV
-
2 (individuals 
with active lesions only
).
·
Bacterial vaginosis, vaginal candidiasis, or trichomonas (women onl
y).
·
Sexually
transmitted infection within the 
last 3 months
·
Women who are pregnant or breastfeeding.
·
A reactive or positive HIV test result at screening or enrollment, even if you are found to 
be HIV
-
uninfected based on further testing.
·
Medications that prolong blood clotting time.
·
Medications that af
fect the kidney
or liver. 
·
Any
thing else in the judgment of the study
clinician that would make participation in the 
study
unsafe, complicate interpretation of stud
y outcome data, or otherwise interfere with 
achieving the stud
y objectives.
STUDY 
PROCEDURE
S
Screening and Enrollment Procedures:
If you agree to have the screening tests, the screening visits will be performed in one to two 
visits, but may
be done in more than two if necessary
. However, if a person agrees to be enrolled, 
the enrollment visit 
must take place within 30 day
s of the very
first screening visit.  
Screening Visit:
Your screening visit will happen after you read, discuss, understand, and sign this form. Study 
staff will help you understand the form and answer your questions before y
ou sign this form. The 
procedures done at this visit will take about 2
-
3 hours.   
HPTN 066, Version 
2
.0 
Page 
92
of 
116
29 Nov
em
ber
2010
The study
staff will: 
·
Ask you where you live and other questions about you, your medical health, and your 
sexual practices.  
·
Discuss the details of “directl
y observed the
rapy
” and identify
how y
ou will be able to 
come to the clinic (or other identified designation) to receive your medication. You will 
need to understand that you have a 1 in 4 chance of having to come to the clinic every 
day
to receive y
our medication.
·
If t
hese questions show that y
ou may
be eligible for the study
and you are a woman, you 
will give urine for a pregnancy
test.   If you are pregnant, you are not eligible for the 
study
.  The stud
y s
taff will refer you to available sources of medical care and ot
her 
services you may need.  If the study is still open after your pregnancy, you can come 
back here to find out if you are eligible then.
●
If you are a woman who is not pregnant
or breastfeeding
or a man, you will talk with 
study
staff about HIV, HIV testin
g, and ways to avoid HIV and other infections passed 
through sex. You will be asked to give a blood sample (up to 20 mL
or 4 teaspoons) for 
HI
V testing. You will be told your result as soon as it is available. You will talk with the 
study
staff about the m
eaning of your results and how you feel about them. Sometimes 
HI
V tests are not clearly
positive, but also not clearly
negative. In that case, we will do 
more tests until we know your status for sure. You must receive your HIV test results to 
be in the stu
dy
. If the test shows that y
ou have HIV, y
ou will not be eligible for the study
. 
The study
staff will tell you about other studies you may be eligible for, if any. They will 
refer you to available sources of medical care and other services you may need. Yo
ur 
partner(s) may
also have access to free HIV counseling and testing if needed.
●
Measure your weight.
●
Perform a complete ph
ys
ical examination including your genital area. 
●
Examine inside y
our vagina (if y
ou are a woman).
o
The study
staff will collect fluid 
from your vagina to test for infections. These 
infections are called trichomoniasis, candidiasis, and bacterial vaginosis (BV). 
●
Talk with you about contraception and ways to prevent sexually transmitted diseases.
●
Test your urine for:
o
Chlamy
dia and gonorrh
ea.  These are sexually
transmitted infections.  
o
Common urine infections and the health of your kidneys
●
Collect 
40
mL
(about 8 teaspoons)
of blood 
for 
:
o
Sy
philis
testing
.  This is a sexually
transmitted infection.  
o
To check the h
ealth of your blood, live
r and kidney
s.
o
Hepatitis B
testing
.  This is an infection of the liver that can be passed from mother 
to baby
, through sex, or through body
fluids infected with hepatitis B.  If the tests 
show that you have hepatitis B that is active in your liver, you wil
l not be eligible 
for the stud
y.  If the tests show that you have had hepatitis B in the past, but it is no 
longer active in your liver, or that you are immune to hepatitis B because of a prior 
immunization, y
ou may
be eligible for the stud
y.
o
Plasma storag
e for stud
y related testing and long
-
term storage (if you provide 
consent)
●
Give you condoms.
HPTN 066, Version 
2
.0 
Page 
93
of 
116
29 Nov
em
ber
2010
The results of the tests listed above will be available within 1
-
2 weeks after your visit.  You will 
be contacted about the results of y
our tests when they
are av
ailable.  A small amount of plasma 
will be stored from this visit. No other samples collected at the time of screening will be kept or 
used for an
y other tests other than those listed above.
Confirmation of Eligibility:
Once all the results of the screeni
ng tests are known, the study
staff will:
●
Tell you your test results from your screening visit and what they mean.  If the results 
show that you might have some health problems, you may not be eligible for the study.  
Study
staff will refer y
ou to availabl
e sources of medical care and other services you may 
need.  Later, if these problems resolve, you can come back to find out if you are eligible 
at that time.
●
Refer you for treatment of a urinary tract infections and sexually transmitted infections, if 
yo
u 
need it.  If you need this treatment, you will not be eligible for the study.
●
If you have a reactive or positive HI
V test or a test that shows that y
ou have active 
hepatitis B infection, you will not be eligible for the study, but you will be referred to t
he 
appropriate clinic or other medical resource.
●
Give you referrals for other health services if you need them. 
●
Id
entify
a clear plan for directly
observed therapy
. 
Enrollment Visit:
If you are eligible for this study and decide to take part in the stud
y, you will be asked to return 
for the enrollment visit. At that time, the study
staff will: 
●
Perform a urine pregnancy test (women only)
●
Collect 
up to 5
0
mL
(about 
10
teaspoons) of 
blood for
:
o
HI
V diagnostic testing 
o
To check the amount of medication (Tr
uvada®) in y
our blood.
●
Review and update your contact details.
●
Review and update your medical history.
●
Talk with you again about HIV and other infections passed through sex and how to avoid 
these. 
●
Id
entify
your stud
y group.
●
Give you condoms.
●
Administer yo
ur first dose of study
medication to y
ou and review the procedures for all 
future doses to be observed by
study
personnel.
Before your second dose:
Before you take your second dose of study medication, you will have blood drawn (
up to 4
0
mL
 
or about 
8
tea
spoons).
At Visits on Days 7, 14, 
21, 
and 2
8
, 
yo
u will:
●
Tell study
staff if y
ou had any
health problems since y
our last visit.
●
Tell study
staff about an
y medications, herbal treatments and supplements you are taking.
●
Tell study
staff an
y new information o
n where you live and how to keep in contact with 
yo
u. They
will use this information to remind y
ou of visits. I
f you miss a visit, the study
 
HPTN 066, Version 
2
.0 
Page 
94
of 
116
29 Nov
em
ber
2010
staff will try
to contact you by [
site
-
specific methods
]. They
also may
visit y
our home. 
They
will try
to reach you
through the contact people that you list.  If they talk to these 
people, they
will not say
why
they
want to reach you.  
●
Talk with study
staff about way
s to avoid HIV and other infections passed through sex.  
●
Talk to study
staff about adherence to the d
irectl
y observed therap
y r
egimen (if 
necessary
).
●
Talk with study
staff about contraception.
·
Give a urine sample for a pregnancy test (women only, Day 28 onl
y)
.
·
Give blood (up to 65 mL
or about 13 teaspoons): 
o
To check the amount of medication (Truvada®) in
your blood. 
o
To confirm that the medication is not causing problems for certain parts of y
our 
body
such as the liver and kidney
s and to check the health of your blood (Days 14 
and 28 only
). 
o
Plasma storage for stud
y related testing and long
-
term storage (
if you provide 
consent; Day
s 28).
●
Get condoms.
The Enrollment and Days 7, 14, 21, and 28 visits will take 1
-
2 hours each.
At Visits on Days 35 and 49
, you will:
●
Participate in the same activities as the previous visits.  
●
Have an exam of the rectum and c
olon and small samples of your rectal tissue will be 
taken to measure the amount of the medications in your rectal tissue. For this, you will be 
taken to the endoscop
y area where a doctor will perform a flexible sigmoidoscopy (also 
known as an endoscop
y).
 
To do this, the doctor will use an endoscope to look inside 
yo
ur rectum. An endoscope is a long, thin tube with a camera in it.  The doctor will use a 
long wire with a tiny
pincher to take up to 30 small biopsies of y
our intestinal lining. 
Each biops
y i
s 
a small piece of tissue measuring smaller than the surface of a pencil 
eraser and about the thickness of a dime.
●
Have a clear, plastic, lubricated tube gentl
y i
nserted into the rectum (no more than 4 
inches) in order to collect the rectal luminal fluid wit
h a swab.
●
Have a vaginal exam (women only
), and vaginal fluids, vaginal cells and small samples 
of vaginal tissue will be collected to measure the medication levels in your vaginal fluids, 
cells and tissue. (These samples will not be taken during menstruat
ion so the timing of 
yo
ur menstrual cy
cle will have to be considered before y
ou take the first study
 
medication dose. Pregnancy
tests will be performed just prior to any
vaginal sampling 
and confirmed to be negative prior to an
y vaginal procedure.)  
●
Provi
de a semen sample (men only). 
●
Provide 
50
mL
(about 10 teaspoons)
of blood for: 
o
T
ests to confirm that the medication is not causing problems for certain parts of 
yo
ur bod
y s
uch as the liver and kidney
s,
o
HI
V test and Hepatitis B test and 
(Day
49 onl
y)
o
Plas
ma storage for stud
y related testing and long
-
term st
orage (if you provide 
consent; 
Day
49 onl
y).
●
U
rine for a pregnancy
test
(women only
)
.
HPTN 066, Version 
2
.0 
Page 
95
of 
116
29 Nov
em
ber
2010
The Day
s 35 and 49 visits may
take 2
-
4 hours each. I
n some cases, due to scheduling limitations, 
these visits may
re
quire visiting the clinic on 2 different day
s.
Men will be asked to abstain from sex for 24
-
48 hours before semen collection. 
All p
articipants should start a low fiber diet 3 day
s before each 
rectal biopsy
 
procedure and have 
a clear liquid diet 12 hours
prior to the procedure. They should also refrain from meals (or 
coffee) the day
of the procedure. Enemas will be administered before the biopsy
procedures take 
place
. 
An enema is a procedure that introduces liquids into the rectum and colon through the 
an
us to cleanse the lower intestinal tract.
One day
after the biopsies, a study
team member will contact you b
y phone to see how you’re 
doing.
AT ANY TIME IN THE STUDY
If you have health problems that may be caused by sexually transmitted infections, you w
ill:
·
Have an exam of your genital area and inside your vagina.
·
Give blood, urine, and/or vaginal fluid to test for infections passed through sex or other 
vaginal infections
·
Be referred for treatment of an
y s
exually
transmitted infection.
Any
time HIV or S
TI
testing is done during the study
, study
staff will contact you to provide you 
with the test results as soon as they
become available. Study
staff will also provide you with 
information related to your health that is discovered at an
y s
tudy
visit.
If yo
u have to leave the study
for an
y r
eason, you will have one additional follow
-
up visit where 
yo
u will have the same activities as at the Day
7 through Day
21 visits as well as blood tests to 
confirm the drug has not caused an
y p
roblems in certain parts of 
your bod
y s
uch as the liver and 
kidney
s. You will also have an HIV and hepatitis b test and a urine pregnancy
test (women onl
y).
Study
staff will review and assess any
medical conditions that y
ou have during the study
. Study
 
staff may
contact y
ou after th
e stud
y has ended to be sure that you do not have an
y continuing 
medical problems that require medical attention.
POSSIBLE FUTURE TESTS
Some of the blood that you give during this stud
y m
ay
be left over after all of the study
tests are 
completed.  The stu
dy
staff also would like to keep y
our leftover blood. 
Future tests on stored 
blood may
be unrelated to this study
.
You will be asked to sign at the end of this consent form to 
give permission for that. Even if you do not give permission to store your bloo
d after the stud
y, 
yo
u can still be in this study
. You may
also withdraw y
our consent for specimen storage at an
y 
time. 
RISKS AND/OR DISCOMFORTS
Blood Draws and Sexually Transmitted Infection Testing
Whenever your blood is drawn, you may:
HPTN 066, Version 
2
.0 
Page 
96
of 
116
29 Nov
em
ber
2010
·
Feel discomfor
t or pain. 
·
Feel dizzy
or faint. 
·
Have a bruise, swelling, small clot, or infection where the needle goes in your arm or 
finger.
When y
ou have genital exams, y
ou may
:
·
Feel discomfort in your genital area and/or inside your vagina.
·
Women may
have a small 
amount of vaginal bleeding
which will stop shortly
after the 
exam.
Rectal Exam and Tissue Samples
Whenever you have a rectal exam and tissue samples are taken, you may:
·
Have mild discomfort 
·
Have the feeling of a “bloated stomach” 
On extremely
rare occa
sions, y
ou may
have: 
·
Pain 
·
In
fection
·
Bleeding or 
·
Perforation of the gastrointestinal tract (occurs about once out of every 100,000 
procedures and may
require hospitalization and surgical management) 
When rectal fluid is collected via insertion of the p
lastic tube into the anus, on rare occasion you 
may
:
·
Experience mild discomfort 
·
Have pain (should you have another condition that is alread
y c
ausing pain in the area) 
When y
ou have an enema, y
ou may
experience:
·
T
emporary
discomfort
c
ause
d
by
a bloated o
r cramping feeling
 
·
Some air may
be pumped into the rectum 
causing gas
 
·
On extremely
rare occasion
, the enema tube could make a hole in the rectum requiring 
surgery
You should not have anal sexual intercourse or insert any
thing into y
our rectum for at l
east 72 
hours after the tissue sampling.
Vaginal Exam and Tissue Samples
Whenever you have a vaginal exam and tissue samples are taken, you may:
·
Have discomfort or pain during the procedure and for a few hours after  
·
Have mild vaginal spotting (bleeding)
for one or two day
s
·
Have temporary
discomfort with sexual intercourse  
There is a very
small risk that y
ou may
:
·
Get an infection 
HPTN 066, Version 
2
.0 
Page 
97
of 
116
29 Nov
em
ber
2010
·
Have heav
y bleeding  
You should not have vaginal sexual intercourse or insert any
thing into our vagina for at least 72 
ho
urs after the tissue sampling.
Study Medications
About 5 out of 100 people with HIV taking Truvada® tablets have these occasional side effects 
which usually
go awa
y after stopping the drug:
·
Upset stomach, vomiting, gas, loose or watery
stools  
·
Dizziness 
or headache 
·
Abdominal pain 
·
Lack of energy/general body weakness
·
Mild problems of kidney
function that are onl
y d
etected b
y l
aboratory
tests
·
Shortness of breath or cough 
·
Rash, including allergic reaction 
·
Anxiety
·
Joint pain, muscle pain, or other pain 
sy
ndrome
·
Fever
Fewer than 5 out of 100 people with HIV taking 
Truvada® 
tablets have:
·
Skin discoloration/darkening of the palms and/or soles of the feet
Potentially
serious side effects are rare, but include:
·
Liver function problems
·
Serious kidney
damage 
or failure
·
Low phosphate levels (a chemical in the blood) or protein or sugar in the urine
·
In
flammation or swelling and possible damage to the pancreas
·
Bone pain and bone changes such as thinning and softening which may increase the risk 
of  breakage
·
Aller
gi
c reaction
·
Lactic acidosis and severe hepatomegaly
(enlarged liver) with steatosis (fatty
liver) that 
may
result in liver failure, other complications and death have been reported with the use 
of antiretroviral nucleoside analogues alone or in combinatio
n.  The liver complications 
and death have been seen more often in women on these drug regimens. Some 
nonspecific s
ym
ptoms that might indicate lactic acidosis include: unexplained weight 
loss, stomach discomfort, nausea, vomiting, fatigue, weakness, and sh
ortness of breath.
·
If you are infected with both Hepatitis B and HIV, you should be aware that your liver 
function tests may
increase, and sy
mptoms associated with hepatitis (an acute 
inflammation of the liver) may
worsen if
emtricitabine
or tenofovir is s
topped
.
Some people taking 
emtricitabine, one of the ingredients in Truvada®, experienced the following 
side effects:
·
In
ability
to sleep, unusual dreams
·
Runny
nose
HPTN 066, Version 
2
.0 
Page 
98
of 
116
29 Nov
em
ber
2010
·
Rash, itching, which sometimes can be a sign of an allergic reaction
·
In
creases in pancreati
c enzy
me (substances in the blood), which could mean a problem 
with the pancreas 
·
In
creased trigl
yc
erides 
·
In
creased creatine phosphokinase (CPK), which could mean muscle damage
Some people taking tenofovir, one of the ingredients in Truvada®, experienced
the following 
side effects:
·
Depression
·
In
flammation or swelling and possible damage to the pancreas and liver
·
Allergic reaction: sy
mptoms may
include fever, rash, upset stomach, vomiting, loose or 
watery
stools, abdominal pain, achiness, shortness of brea
th, a general feeling of illness 
or a potentially
serious swelling of the face, lips, and/or tongue
You could have these side effects or other side effects that we do not know about.
Other Possible Risks
We do not know if there are other risks if you use
herbal treatments or supplements while y
ou 
are using the tablets.  Please tell study
staff if y
ou are using an
y h
erbal treatments or 
supplements.  
We will perform an HIV test, which is routinely
done before HIV drugs are tested in non
-
HI
V 
subjects.
You
will be counseled before and after this test is done.
In
accordance with some state 
laws, all positive tests must be reported to the state health department.
In the event that you test 
positive for HIV, you will be notified and provided with counseling.
If you do test positive, the 
test results will become part of public health records.  A positive result will be placed in y
our 
hospital chart in order to provide you with the best of care.  You are not required to make these 
results available to your ins
urance compan
y or employer.
We will perform screening for common sexually
transmitted diseases, including 
bacterial 
vaginosis, s
yphilis, gonorrhea, Chlam
ydia, HSV
-
2 and trichomonas
.  This is being done because 
infections could affect the measurements of d
rug concentrations in cervicovaginal fluid or 
vaginal tissue that will be taken in this study
.  Sy
philis, gonorrhea, and Chlamy
dia are reportable 
sexually
transmitted infections in some states, and positive results must be reported with y
our 
name to the lo
cal health department.  With any
positive result for any
of these tests, y
ou will be 
referred to an infectious diseases provider for confirmation (if needed) and treatment.   
In addition, there may be uncommon or previously unknown risks that might occur.
You should 
report an
y problems to the researchers immediately.
There may
also be some social risks to participating in this study. You may feel embarrassed or 
uncomfortable with some of the questions you will be asked, some of the procedures that will b
e 
done, or some of the test results that you will receive. You may also experience stigma as a result 
of being involved in an HIV study because people may assume that you are HIV
-
infected. 
HPTN 066, Version 
2
.0 
Page 
99
of 
116
29 Nov
em
ber
2010
Pregnancy and Breastfeeding
If you become pregnant during the stu
dy
, or within 28 day
s after completing the stud
y, you 
should notify
the study
personnel right away
for safet
y m
onitoring. If you become pregnant 
during the stud
y, you will stop using the tablets right away. The stud
y s
taff will refer you to 
available sourc
es of medical care and other services y
ou or your bab
y m
ay
need. The study
does 
not pay
for this care.  
Please tell your obstetrician about your stud
y participation. Your study doctor will ask that you, 
or your obstetrician, provide updates on the progre
ss of your pregnancy
and its outcome.  The 
study
doctor will make this information available to the study
sponsor for safet
y m
onitoring 
follow
-
up.  
We do not know if Truvada® 
tablets have an
y effect on pregnancy, on the fetuses of women 
who use tablets
when pregnant, or on the babies of women who use tablets when breastfeeding. 
Because of this, pregnant women and women who are breastfeeding will not be allowed to 
participate in this study
. Women who join the study
must use condoms in addition to an effe
ctive 
contraception and method must have pregnancy
tests at the screening visit, before starting the 
study
, and at visits 4, 5, and 6 while in the study
.  Effective contraception includes hormonal 
methods (such as the birth control pill or shot), intrauter
ine contraceptive device (IUCD); and 
sterilization.  You should not use spermicides as a method of contraception while participating in 
this study
.  
BENEFITS
You will not receive an
y direct benefit from being in this study
. You or others may
benefit in 
the 
future from information learned in this study
. 
NEW INFORMATION
You will be told any
new information learned during this study
that might affect y
our 
willingness to stay
in the study
. For example, if information becomes available
that shows
that 
the m
edication may
be causing bad effects, you will be told about this.
You will also be told 
when the results of the study
may
be available, and how to learn about them.  
WHY YOU MAY BE WITHDRAWN FROM THE STUDY WITHOUT YOUR 
CONSENT
You may
be withdrawn from 
the study
without y
our consent if an
y o
f the following occur: 
·
Become pregnant.
·
Are breastfeeding.  
·
Are taking certain medications that affect your kidneys.
·
Are unable or unwilling to follow all of the study
procedures or instructions.  
·
Could be harmed 
by
continuing to take tablets.
·
The study
is stopped or canceled.
·
The study
staff feels that stay
ing in the study
would be harmful to y
ou.
·
You are not able to attend clinic visits or complete all of the study
procedures.
·
You are not able to have directly ob
served therapy according to study
instructions.
HPTN 066, Version 
2
.0 
Page 
100
of 
116
29 Nov
em
ber
2010
·
Other reasons, as decided by
the study
staff.
·
You become HIV positive
If you become HIV positive during the course of the study
or are withdrawn for an
y r
eason
, you 
will have 
a
final study
visit for safet
y 
testing before you are withdrawn from study participation. 
ALTERNATIVES TO PARTICIPATION
[
Sites to include/amend the following if applicable: 
There may
be other studies going on here or
in the community
that y
ou may
be eligible for. If you wish, we will 
tell y
ou about other studies
that we know about. There also may
be other places where you can go for HIV counseling and
testing and contraception. We will tell y
ou about those places if you wish.]
COSTS TO YOU
There is no cost to you for being in this stu
dy
. 
REIMBURSEMENT
[
Sites to insert information about local reimbursement
amount and schedule
:
]
You will receive [$xx] for your time, effort, and travel to and from the clinic. 
CONFIDENTIALITY
We will do every
thing we can to keep y
our personal informati
on confidential.  
To help us keep 
yo
ur personal information confidential, we have obtained a Certificate of Confidentiality
from 
the US Federal Government.  This certificate protects researchers from being forced to tell 
people who are not connected with t
his study
, such as the court s
ys
tem, about y
our participation.  
However, it is not possible to guarantee confidentiality
. Your personal information may
be 
disclosed if required b
y l
aw. 
Even with the Certificate of Confidentiality
, if the study
staff lear
ns of possible child abuse 
and/or neglect or a risk of harm to yourself or others, we will be required to tell the proper 
authorities.
The study
staff will also use y
our personal information, if needed, to verify that y
ou are not 
taking part in an
y other 
research studies. This includes other studies conducted by
[site name] 
and studies conducted b
y other researchers that study
staff know about. An
y publication of this 
study
will not use y
our name or identify
you personally
.
Your records may
be reviewed b
y
:
●
the United States Food and Drug Administration (FDA)
●
the United States National I
nstitutes of Health (NIH)
●
the United States Department of Heath and Human Services (DHHS), Office of Human 
Research Protection (OHRP)
●
[
insert names of applicable IRBs/ECs
]
●
study
staff
●
study
monitors
●
the compan
y t
hat makes Truvada® tablets (Gilead Sciences)
HPTN 066, Version 
2
.0 
Page 
101
of 
116
29 Nov
em
ber
2010
[Sites to include/amend the following if applicable:
] [
Local/state/national
] regulations require 
study
staff to report the names of people who test positive for [
HIV and 
other infections
] passed 
during sex to the [
local health authority
]. Outreach workers from the [
health authority
] may
then 
contact you about informing your partners, since they also should be tested. If you do not want to 
inform your partners yourself, the
outreach workers will contact them, according to the 
confidentiality
guidelines of the [
health authority
].
RESEARCH
-
RELATED INJURY
[Sites to specify institutional policy:
] 
It
is unlikely that y
ou will be injured as a result of stud
y 
participation. If you
are injured, the [
institution
] will give you immediate necessary treatment for 
yo
ur injuries. You [
will/will not
] have to pay
for this treatment. You will be told where y
ou can 
get additional treatment for your injuries. There is no program to pay money o
r give other forms 
of compensation for such injuries either through this institution or the NIH. You do not give up 
any
legal rights by
signing this consent form.
PROBLEMS OR QUESTIONS
If you ever have an
y questions about the study
, or if y
ou have a resea
rch
-
related injury
, you 
should contact [
insert name of the investigator or other study staff
] at [
insert telephone number 
and/or physical address
].
If you have questions about your rights as a research participant, you should contact [
insert name 
or title
of person on the IRB/EC or other organization appropriate for the site
] at [
insert physical 
address and telephone number
].
If you have questions about whom to contact at the research site, you should contact [
insert name 
of the investigator or community 
educator or CAB member
] at [
insert physical address and 
telephone number
].
HPTN 066, Version 
2
.0 
Page 
102
of 
116
29 Nov
em
ber
2010
SIGNATURES
[Insert signature blocks as required by the local IRB/EC:]
 
If you have read this consent form, or 
had it read and explained to you, and you understand the information, 
and you voluntarily agree 
to join the study
, please sign y
our name or make your mark below. Also, please indicate if you 
are willing to allow your leftover samples to be stored for future testing. 
Specimens Stored for Future Testing
_____ My
initials 
indicate that an
y l
eft
-
over samples may
be stored for future testing:
_____ 
I d
o not agree to allow leftover samples to be saved for long term storage and future 
testing after the stud
y
____________________ 
________________________ 
______________
P
articipant Name (print)
Participant Signature
Date
____________________ 
________________________
______________
Study
Staff Conducting 
Study
Staff Signature
Date
Consent Discussion (print)
____________________ 
________________________ 
_________
_____
Witness Name (print)
Witness Signature
Date
HPTN 066, 
Version 2.0
Page 
103
of 
116
29 Nov
em
ber
2010
APPENDIX III: SCREEN
ING/ENROLLMENT SAMPL
E INFORMED CONSENT 
FORM (
Non
-
Intensive Sampling Cohort
)
HPTN 066, 
Version 2.0
Page 
104
of 
116
29 Nov
em
ber
2010
SAMPLE
INFORMED
CONSENT
DOCUMENT
(NON
-
Intensive Sampling Cohort
)
HPTN
066
D
OSE
-
P
ROPORTIONALITY 
A
ND 
I
NTRA
-
I
NDIVIDUAL 
V
ARIABILITY 
O
F 
I
NTRACELLULAR 
T
ENOFOVIR 
D
IPHOSPHATE 
A
ND 
E
MTRICITABINE 
T
RIPHOSPHATE 
I
N 
H
EALTHY 
V
OLUNTEERS
29
N
OV
EMBER
2010
V
ERSION 
2.0
PRINCIPAL INVESTIGATOR: 
[I
nsert Name]
PHONE:  
[I
nsert Number]
GENERAL OVERVIEW 
You are being asked to
take part in a research study
.
Joining this study
is voluntary
. 
You may
refuse to join, or you may withdraw your consent to be in the study, for an
y r
eason.
Research studies are designed to obtain new knowledge that may help other people in the future.
 
You may
not receive an
y direct benefit from being in the research stud
y. There also may be risks 
to being in research studies.
Details about this study
are discussed below.  It is important that you understand this information 
so that y
ou can make an in
formed choice about being in this research stud
y.  You will be given a 
copy
of this consent form.  You should ask the researchers named above, or staff members who 
may
assist them, any
questions y
ou have about this study
at an
y t
ime.
YOUR PARTICIPATION I
S VOLUNTARY
This consent form gives information about the study that will be discussed with you. Once you 
understand the stud
y, and if you agree to take part, you will be asked to sign your name on this 
form. You will be given a cop
y of this form to keep. 
Before you learn about the study, it is important that you know the following:
·
Your participation is voluntary
.  You do not have to take part in the screening tests or in 
the study
.
·
You may
decide not to take part in the study
or to leave the stud
y at an
y t
ime without 
losing your regular medical care.
·
If you decide not to take part in the study, you can still join another study
at a later time if 
there is one available and you qualify.    
·
You cannot join this study
if you are taking part in another stud
y
of drugs, medical 
devices or vaginal/rectal products.  You are asked to tell the study
staff about any
other 
studies y
ou are taking part in or thinking of taking part in.  This is very
important for 
yo
ur safet
y.  
HPTN 066, Version 
2
.0 
Page 
105
of 
116
29 Nov
em
ber
2010
 
PURPOSE OF
THE STUDY
This study
is being conducted to look at how the body handles the drug Truvada® 
when it is 
given in different amounts and at different time schedules. This study will also look at the 
difference of medication amount in men and women.
The study
 
will look at levels of Truvada® in the blood, reproductive tract and gastrointestinal 
tract of female and male volunteers.  The aim is to establish how much of the drug (taken b
y 
mouth) reaches the reproductive and gastrointestinal tracts when given at dif
ferent doses and at 
different dose schedules. It is believed that the presence of this drug in the reproductive and 
gastrointestinal tracts may
be beneficial in the prevention of the transmission of the AIDS virus. 
However, half of the study participants 
will only
participate in the blood portion of the study
. 
That is the group that you are being evaluated for.
Potential participants will decide with study
 
staff which group they
will enroll in before they
are consented for the study
.
The study
will take s
amples of blood once a week for the first 5 weeks after taking Truvada® 
according to the dose you are assigned to. All of these samples are to look at drug 
concentrations.  The study will also collect information on the safet
y of the medication.
Truvada® 
is a tablet that is a combination of two medications
—
emtricitabine and tenofovir. This 
medication is used to treat people who have HIV.  The tablets are generall
y s
afe when used as 
treatment for HIV.  These tablets are not a cure for HIV/AIDS, but they
are
very
effective for 
improving the health of people who have HIV/AIDS.  Although these tablets improve the health 
of people with HIV, 
we do not know if they work to protect against HIV.
The results of this 
study
may
be used in the future to determine if thi
s medication can be taken by healthy people to 
prevent them from getting HIV.
The United States Food and Drug Administration (U.S. FDA) has been informed of this study. 
Truvada has not been approved b
y t
he U.S. FDA for the prevention of HIV. 
About 32 pa
rticipants will be enrolled in the stud
y at 2 different sites in the United States.  About 
16 people will be enrolled in the study
here at [study
site].  The study
should take approximately
 
12 months to complete. Each participant will be followed for appro
ximately
2 months.
Before you decide whether to take part in the study, we would like to explain the purpose of the 
study
, the risks and benefits, what is expected of you, and what to expect from us.  This consent 
form might contain some words that are un
familiar.  Please ask questions about any
thing y
ou do 
not understand or want to learn more about.
STUDY GROUPS
There are four stud
y groups.  Each group will have 8 people.  There will be 4 women and 4 men 
in each group.  If you decide to take part in the 
study
, you will be randomly assigned to one of 
the four groups
, like flipping a coin
.  Once you are assigned to a group, you cannot change to 
another group.  The four groups will each be given the same medication, but it will be provided 
in different doses
.
HPTN 066, Version 
2
.0 
Page 
106
of 
116
29 Nov
em
ber
2010
·
One group will take one Truvada® tablet one time each week for five weeks
·
One group will take one Truvada® tablet two times each week for five weeks
·
One group will take two Truvada® tablets two times each week for five weeks
·
One group will take one Truv
ada® tablet each day
for five weeks
All four groups are very
important to the study
.  It is very important that each person takes 
his/her medication as provided.  Because of this, all participants will be observed b
y a stud
y 
employ
ee when taking the medic
ation so that we can be sure that the participant has taken the 
medication on the right day
and at the right time.  This means that some people will be required 
to come to the clinic every
day
(including Saturday
and Sunday
) to get their medication.
CRITE
RIA FOR STUDY PARTICIPATION
In order to participate in the study
, you must meet all of the following criteria:
·
Be 18 to 44 years of age, inclusive on the date of screening.
·
Provide informed consent for the study
.
·
Provide information on how to contact and 
locate y
ou
·
Be willing to be tested for HIV infection and receive your test results.
·
Be H
IV negative.
·
Have good kidney function.
·
Be sexually
active (
at least one sex act 
-
vaginal or anal intercourse 
-
in the previous 30 
day
s
)
.
·
Agree to use condoms.
·
Women m
ust:
o
Be pre
-
menopausal
o
Have regular menstrual cy
cles with at least 21 days between menses (unless on 
contraception that causes lack of or irregular menses) 
o
Have a negative urine pregnancy
test
o
Be utilizing an alternative method of birth control in additio
n to condoms 
(hormonal contraceptive, diaphragm or have undergone surgical sterilization) or 
have a vasectomized exclusive male partner.
REASONS WHY YOU WOULD NOT BE ABLE TO PARTICIPATE 
You will not be able to participate in the stud
y i
f any
of the follo
wing things apply
to y
ou:
·
Blood tests that show the following:
○
Poor liver function
○
Anemia (low blood counts)
○
Abnormal laboratory
values
·
Co
-
enrollment in any
other HIV research study
that involves an experimental drug or 
prior enrollment in the active arm 
of a H
IV vaccine trial.
HPTN 066, Version 
2
.0 
Page 
107
of 
116
29 Nov
em
ber
2010
·
Active skin disorders.
·
Positive test for Hepatitis B
·
Excessive use of alcohol (more than 4 drinks a day on a regular basis).
·
Women who are pregnant or breastfeeding.
·
A reactive or positive HIV test result at screening or enrollment,
even if you are found to 
be HIV
-
uninfected based on further testing.
·
Medications that affect the kidney
or liver. 
·
Any
thing else in the judgment of the study
clinician that would make participation in the 
study
unsafe, complicate interpretation of stud
y o
utcome data, or otherwise interfere with 
achieving the stud
y objectives.
STUDY 
PROCEDURES
Screening and Enrollment Procedures:
If you agree to have the screening tests, the screening visits will be performed in one to two 
visits, but may
be done in more
than two if necessary
. However, if a person agrees to be enrolled, 
the enrollment visit must take place within 30 day
s of the very
first screening visit.  
Screening Visit:
Your screening visit will happen after you read, discuss, understand, and sign th
is form. Study
 
staff will help you understand the form and answer your questions before you sign this form. The 
procedures done at this visit will take about 2
-
3 hours.   
The study
staff will: 
·
Ask you where you live and other questions about you, your m
edical health, and y
our 
sexual practices.  
·
Discuss the details of “directl
y observed therap
y” and identify how you will be able to 
come to the clinic (or other identified designation) to receive your medication. You will 
need to understand that you have a
1 in 4 chance of having to come to the clinic every
 
day
to receive y
our medication.
·
If these questions show that you may be eligible for the study and you are a woman, you 
will give urine for a pregnancy
test.   If you are pregnant, you are not eligible f
or the 
study
.  The stud
y s
taff will refer you to available sources of medical care and other 
services you may need.  If the study is still open after your pregnancy, you can come 
back here to find out if you are eligible then.
●
If you are a woman who is not
pregnant
or bre
a
stfeeding
or a man, you will talk with 
study
staff about HIV, HIV testing, and ways to avoid HIV and other infections passed 
through sex. You will be asked to give a blood sample (up to 20 mL
or 4 teaspoons) for 
HI
V testing. You will be to
ld y
our result as soon as it is available. You will talk with the 
study
staff about the meaning of your results and how you feel about them. Sometimes 
HI
V tests are not clearly
positive, but also not clearly
negative. In that case, we will do 
more tests un
til we know your status for sure. You must receive your HIV test results to 
be in the study
. If the test shows that y
ou have HIV, y
ou will not be eligible for the study
. 
HPTN 066, Version 
2
.0 
Page 
108
of 
116
29 Nov
em
ber
2010
The study
staff will tell you about other studies you may be eligible for, if any. The
y will 
refer you to available sources of medical care and other services you may need. Your 
partner(s) may
also have access to free HIV counseling and testing if needed.
●
Measure your weight.
●
Perform a complete ph
ys
ical examination. 
●
Talk with you about con
traception and way
s to prevent sexually
transmitted diseases.
●
Test your urine for:
o
T
he health of your kidneys
●
Collect 
35
mL
(about 7 teaspoons)
of 
blood
:
o
To check the h
ealth of your blood, liver and kidneys.
o
Hepatitis B
testing
.  This is an infection of th
e liver that can be passed from mother 
to baby
, through sex, or through body
fluids infected with hepatitis B.  If the tests 
show that you have hepatitis B that is active in your liver, you will not be eligible 
for the stud
y.  If the tests show that you ha
ve had hepatitis B in the past, but it is no 
longer active in your liver, or that you are immune to hepatitis B because of a prior 
immunization, y
ou may
be eligible for the stud
y. 
o
Plasma storage for stud
y related testing and long
-
term storage (if you prov
ide 
consent)
●
Give you condoms.
The results of the tests listed above will be available within 1
-
2 weeks after your visit.  You will 
be contacted about the results of y
our tests when they
are available.  A small amount of plasma 
will be stored from this vi
sit. No other samples collected at the time of screening will be kept or 
used for an
y other tests other than those listed above.
Confirmation of Eligibility:
Once all the results of the screening tests are known, the study staff will:
●
Tell you your test r
esults from your screening visit and what they mean.  If the results 
show that you might have some health problems, you may not be eligible for the study.  
Study
staff will refer y
ou to available sources of medical care and other services you may 
need.  La
ter, if these problems resolve, y
ou can come back to find out if you are eligible 
at that time.
●
Refer you for treatment of a urinary tract infections and sexually transmitted infections, if 
yo
u need it.  If you need this treatment, you will not be eligible
for the study
.
●
If you have a reactive or positive HI
V test or a test that shows that y
ou have active 
hepatitis B infection, you will not be eligible for the study, but you will be referred to the 
appropriate clinic or other medical resource.
●
Give you refe
rrals for other health services if you need them. 
●
Id
entify
a clear plan for directly
observed therapy
. 
Enrollment Visit:
If you are eligible for this study and decide to take part in the stud
y, you will be asked to return 
for the enrollment visit. At th
at time, the study
staff will: 
●
Perform a urine pregnancy test (women only)
●
Collect 
up to 5
0
mL
of blood (about 
10
teaspoons) for:
HPTN 066, Version 
2
.0 
Page 
109
of 
116
29 Nov
em
ber
2010
o
HI
V diagnostic testing and
o
To check the amount of medication (Truvada®) in your blood.
●
Review and update your contact detai
ls.
●
Review and update your medical history.
●
Talk with you again about HIV and other infections passed through sex and how to avoid 
these. 
●
Id
entify
your stud
y group.
●
Give you condoms.
●
Administer your first dose of study medication to you and review the pro
cedures for all 
future doses to be observed by
study
personnel.
Before your second dose:
Before you take your second dose of study medication, you will have blood drawn
(
4
0 mL
or 
about 
8
teaspoons)
.
At Visits on Days 7, 14, 21, 28, 35, and 49 
yo
u will:
●
T
ell study
staff if y
ou had any
health problems since y
our last visit.
●
Tell study
staff about an
y medications, herbal treatments and supplements you are taking.
●
Tell study
staff an
y new information on where you live and how to keep in contact with 
yo
u. They
will use this information to remind y
ou of visits. I
f you miss a visit, the study
 
staff will try
to contact you by [
site
-
specific methods
]. They
also may
visit y
our home. 
They
will try
to reach you through the contact people that you list.  If they talk t
o these 
people, they
will not say
why
they
want to reach you.  
●
Talk with study
staff about way
s to avoid HIV and other infections passed through sex.  
●
Talk to study
staff about adherence to the directl
y observed therap
y r
egimen (if 
necessary
).
●
Talk with
study
staff about contraception.
●
Give blood (
up to 6
5
mL
or about 
13
teaspoons): 
o
T
o check the health of your blood, liver and kidneys
.
 
o
To c
heck the amount of medication (Truvada®) in your blood
.
o
To 
confirm that the medication is not causing problems f
or certain parts of your 
body
such as the liver and kidney
s (Day
 
14, 
28, 35, and 49 only
). 
o
For an HIV test and Hepatitis test (Day 49 onl
y).
o
Plasma storage for stud
y related testing and long
-
term st
orage (if you provide 
consent; 
Day
s 28 and
49 only
).
●
Get 
condoms.
●
Give a urine sample 
for a pregnancy
test (
Women only
; 
Day
28 and 49 only).  
The Enrollment and all subsequent study
visits will take 1
-
2 hours each.
HPTN 066, Version 
2
.0 
Page 
110
of 
116
29 Nov
em
ber
2010
AT ANY TIME IN THE STUDY
If you have health problems that may be caused by sexually transmitted
infections, you will:
·
Have an exam of your genital area and inside your vagina.
·
Give blood, urine, and/or vaginal fluid to test for infections passed through sex or other 
vaginal infections
·
Be 
referred
for treatment of an
y s
exually
transmitted infection.
Any
time HIV or STI testing is done during the study
, study
staff will contact you to provide you 
with the test results as soon as they
become available. Study
staff will also provide you with 
information related to your health that is discovered at an
y s
tudy
visit. 
If you have to leave the study for an
y r
eason, you will have one additional follow
-
up visit where 
yo
u will have the same activities as at the Day
7 through Day
21 visits as well as blood tests to 
confirm the drug has not caused an
y p
roblems i
n certain parts of your bod
y s
uch as the liver and 
kidney
s. You will also have an HIV and hepatitis b test and a urine pregnancy
test (women onl
y).
Study
staff will review and assess any
medical conditions that y
ou have during the study
. Study
 
staff may
c
ontact y
ou after the study
has ended to be sure that you do not have an
y continuing 
medical problems that require medical attention.
POSSIBLE FUTURE TESTS
Some of the blood that you give during this stud
y m
ay
be left over after all of the study
tests are 
completed.  The stud
y s
taff also would like to keep y
our leftover blood. 
Future tests on stored 
blood may
be unrelated to this study
. 
You will be asked to sign at the end of this consent form to 
give permission for that. Even if you do not give permission
to store your blood after the stud
y, 
yo
u can still be in this study
.
You may
also withdraw y
our consent for specimen storage at an
y 
time.
RISKS AND/OR DISCOMFORTS
Blood Draws and Sexually Transmitted Infection Testing
Whenever your blood is drawn, you m
ay
:
·
Feel discomfort or pain. 
·
Feel dizzy
or faint. 
·
Have a bruise, swelling, small clot, or infection where the needle goes in your arm or 
finger.
When y
ou have genital exams, y
ou may
:
·
Feel discomfort in your genital area and
/or
inside y
our vagina.
·
Women
may
h
ave a small amount of vaginal bleeding
which will stop shortly
after the 
exam.
Study Medications
About 5 out of 100 people with HIV taking Truvada® tablets have these occasional side effects 
which usually
go awa
y after stopping the drug:
·
Upset stoma
ch, vomiting, gas, loose or watery
stools  
HPTN 066, Version 
2
.0 
Page 
111
of 
116
29 Nov
em
ber
2010
·
Dizziness or headache 
·
Abdominal pain 
·
Lack of energy/general body weakness
·
Mild problems of kidney
function that are onl
y d
etected b
y l
aboratory
tests
·
Shortness of breath or cough 
·
Rash, including allergic rea
ction 
·
Anxiety
·
Joint pain, muscle pain, or other pain s
yndrome
·
Fever
Fewer than 5 out of 100 people with HIV taking 
Truvada® 
tablets have:
·
Skin discoloration/darkening of the palms and/or soles of the feet
Potentially
serious side effects are rare, but i
nclude:
·
Liver function problems
·
Serious kidney
damage or failure
·
Low phosphate levels (a chemical in the blood) or protein or sugar in the urine
·
In
flammation or swelling and possible damage to the pancreas
·
Bone pain and bone changes such as thinning and so
ftening which may
increase the risk 
of  breakage
·
Allergic reaction
·
Lactic acidosis and severe hepatomegaly
(enlarged liver) with steatosis (fatty
liver) that 
may
result in liver failure, other complications and death have been reported with the use 
of anti
retroviral nucleoside analogues alone or in combination.  The liver complications 
and death have been seen more often in women on these drug regimens. Some 
nonspecific s
ym
ptoms that might indicate lactic acidosis include: unexplained weight 
loss, stomach d
iscomfort, nausea, vomiting, fatigue, weakness, and shortness of breath.
·
If you are infected with both Hepatitis B and HIV, you should be aware that your liver 
function tests may
increase, and sy
mptoms associated with hepatitis (an acute 
inflammation of th
e liver) may
worsen if
emtricitabine
or tenofovir is stopped
.
Some people taking 
emtricitabine, one of the ingredients in Truvada®, experienced the following 
side effects:
·
In
ability
to sleep, unusual dreams
·
Runny
nose
·
Rash, itching, which sometimes can be
a sign of an allergic reaction
·
In
creases in pancreatic enzy
me (substances in the blood), which could mean a problem 
with the pancreas 
·
In
creased trigl
yc
erides 
·
In
creased creatine phosphokinase (CPK), which could mean muscle damage
Some people taking teno
fovir, one of the ingredients in Truvada®, experienced the following 
side effects:
·
Depression
·
In
flammation or swelling and possible damage to the pancreas and liver
HPTN 066, Version 
2
.0 
Page 
112
of 
116
29 Nov
em
ber
2010
·
Allergic reaction: sy
mptoms may
include fever, rash, upset stomach, vomiting, loose or 
wate
ry
stools, abdominal pain, achiness, shortness of breath, a general feeling of illness 
or a potentially
serious swelling of the face, lips, and/or tongue
You could have these side effects or other side effects that we do not know about.
Other Possible Ri
sks
We do not know if there are other risks if you use herbal treatments or supplements while you 
are using the tablets.  Please tell study
staff if y
ou are using an
y h
erbal treatments or 
supplements.  
We will perform an HIV test, which is routinely
done
before HIV drugs are tested in non
-
HI
V 
subjects.
You will be counseled before and after this test is done.
In
accordance with some state 
laws, all positive tests must be reported to the state health department.
In the event that you test 
positive for H
IV, you will be notified and provided with counseling.
If you do test positive, the 
test results will become part of public health records.  A positive result will be placed in y
our 
hospital chart in order to provide you with the best of care.  You are no
t required to make these 
results available to your insurance compan
y or employer.
In addition, there may be uncommon or previously unknown risks that might occur.  You should 
report an
y problems to the researchers immediately.
There may
also be some soci
al risks to participating in this study
. You may
feel embarrassed or 
uncomfortable with some of the questions you will be asked, some of the procedures that will be 
done, or some of the test results that you will receive. You may also experience stigma as 
a result 
of being involved in an HIV study because people may assume that you are HIV
-
infected. 
Pregnancy and Breastfeeding
If you become pregnant during the stud
y, or within 28 days after completing the stud
y, you 
should notify
the study
personnel right
away
for safet
y m
onitoring. If you become pregnant 
during the stud
y, you will stop using the tablets right away. The stud
y s
taff will refer you to 
available sources of medical care and other services you or your bab
y m
ay
need. The study
does 
not pay
for t
his care.  
Please tell your obstetrician about your stud
y participation. Your study doctor will ask that you, 
or your obstetrician, provide updates on the progress of your pregnancy and its outcome.  The 
study
doctor will make this information available 
to the study
sponsor for safet
y m
onitoring 
follow
-
up.  
HPTN 066, Version 
2
.0 
Page 
113
of 
116
29 Nov
em
ber
2010
We do not know if Truvada® tablets have an
y effect on pregnancy, on the fetuses of women who 
use tablets when pregnant, or on the babies of women who use tablets when breastfeeding. 
Because of this, 
pregnant women and women who are breastfeeding will not be allowed to 
participate in this study
. Women who join the study
must use condoms in addition to an effective 
contraception 
method 
and must have pregnancy
tests at the screening visit, before s
tartin
g the 
study
, and at visit
4 while in the study
.  Effective contraception includes hormonal methods 
(such as the birth control pill or shot), intrauterine contraceptive device (IUCD); and 
sterilization.  You should not use spermicides as a method of contrac
eption while participating in 
this study
.  
BENEFITS
You will not receive an
y direct benefit from being in this study
. You or others may
benefit in the 
future from information learned in this study
. 
NEW INFORMATION
You will be told any
new information 
learned during this study
that might affect y
our 
willingness to stay
in the study
. For example, if information becomes available
that shows
that 
the medication may
be causing bad effects, you will be told about this.
You will also be told 
when the results 
of the study
may
be available, and how to learn about them.  
WHY YOU MAY BE WITHDRAWN FROM THE STUDY WITHOUT YOUR 
CONSENT
You may
be withdrawn from the study
without y
our consent if an
y o
f the following occur: 
·
Become pregnant.
·
Are breastfeeding.  
·
Are 
taking certain medications that affect y
our kidney
s.
·
Are unable or unwilling to follow all of the study
procedures or instructions.  
·
Could be harmed b
y continuing to take tablets.
·
The study
is stopped or canceled.
·
The study
staff feels that stay
ing in the
study
would be harmful to y
ou.
·
You are not able to attend clinic visits or complete all of the study
procedures.
·
You are not able to have directly observed therap
y according to stud
y i
nstructions.
·
Other reasons, as decided by
the study
staff. 
·
You become 
HI
V positive
If you become HIV positive during the course of the study or are withdrawn for an
y r
eason, you 
will have a final stud
y vi
sit for safet
y t
esting before you are withdrawn from study participation.
ALTERNATIVES TO PARTICIPATION
[
Sites to inclu
de/amend the following if applicable: 
There may
be other studies going on here or
in the community
that y
ou may
be eligible for. If you wish, we will tell you about other studies
that we know about. There also may
be other places where you can go for HIV c
ounseling and
testing and contraception. We will tell y
ou about those places if you wish.]
HPTN 066, Version 
2
.0 
Page 
114
of 
116
29 Nov
em
ber
2010
COSTS TO YOU
There is no cost to you for being in this study. 
REIMBURSEMENT
[
Sites to insert information about local reimbursement
amount and schedule
:
]
You will 
receive [$xx] for your time, effort, and travel to and from the clinic.
CONFIDENTIALITY
We will do every
thing we can to keep y
our personal information confidential.  
To help us keep 
yo
ur personal information confidential, we have obtained a Certificate of
Confidentiality
from 
the US Federal Government.  This certificate protects researchers from being forced to tell 
people who are not connected with this study
, such as the court s
ys
tem, about y
our participation.  
However, it is not possible to guarantee co
nfidentiality
. Your personal information may
be 
disclosed if required b
y l
aw. 
Even with the Certificate of Confidentiality
, if the study
staff learns of possible child abuse 
and/or neglect or a risk of harm to yourself or others, we will be required to t
ell the proper 
authorities.
The study
staff will also use y
our personal information, if needed, to verify that y
ou are not 
taking part in an
y other research studies. This includes other studies conducted b
y [
site name] 
and studies conducted b
y other resea
rchers that study
staff know about. An
y publication of this 
study
will not use y
our name or identify
you personally
.
Your records may
be reviewed b
y:
●
the United States Food and Drug Administration (FDA)
●
the United States National I
nstitutes of Health (NIH
)
●
the United States Department of Heath and Human Services (DHHS), Office of Human 
Research Protection (OHRP)
●
[
insert names of applicable IRBs/ECs
]
●
study
staff
●
study
monitors
●
the compan
y t
hat makes Truvada® tablets (Gilead Sciences)
[Sites to include/ame
nd the following if applicable: 
] [
Local/state/national
] regulations require 
study
staff to report the names of people who test positive for [
HIV and other infections
] passed 
during sex to the [
local health authority
]. Outreach workers from the [
health aut
hority
] may
then 
contact you about informing your partners, since they also should be tested. If you do not want to 
inform your partners yourself, the outreach workers will contact them, according to the 
confidentiality
guidelines of the [
health authority
].
RESEARCH
-
RELATED INJURY
[Sites to specify institutional policy:
] 
It
is unlikely that y
ou will be injured as a result of stud
y 
participation. If you are injured, the [
institution
] will give you immediate necessary treatment for 
yo
ur injuries. You [
will/
will not
] have to pay
for this treatment. You will be told where y
ou can 
HPTN 066, Version 
2
.0 
Page 
115
of 
116
29 Nov
em
ber
2010
get additional treatment for your injuries. There is no program to pay money or give other forms 
of compensation for such injuries either through this institution or the NIH. You do n
ot give up 
any
legal rights by
signing this consent form.
PROBLEMS OR QUESTIONS
If you ever have an
y questions about the study
, or if y
ou have a research
-
related injury
, you 
should contact [
insert name of the investigator or other study staff
] at [
insert 
telephone number 
and/or physical address
].
If you have questions about your rights as a research participant, you should contact [
insert name 
or title of person on the IRB/EC or other organization appropriate for the site
] at [
insert physical 
address and 
telephone number
].
If you have questions about whom to contact at the research site, you should contact [
insert name 
of the investigator or community educator or CAB member
] at [
insert physical address and 
telephone number
].
HPTN 066, Version 
2
.0 
Page 
116
of 
116
29 Nov
em
ber
2010
SIGNATURES
[Insert signatur
e blocks as required by the local IRB/EC:
] 
If you have read this consent form, or 
had it read and explained to you, and you understand the information, and you voluntarily agree 
to join the study
, please sign y
our name or make your mark below. Also, please
indicate if y
ou 
are willing to allow your leftover samples to be stored for future testing.
Specimens Stored for Future Testing
_____ My
initials indicate that any
left
-
over samples may
be stored for future testing:
_____ 
I d
o not agree to allow le
ftover samples to be saved for long term storage and future 
testing after the stud
y
____________________ 
________________________ 
______________
Participant Name (print)
Participant Signature
Date
____________________ 
________________________
___
___________
Study
Staff Conducting 
Study
Staff Signature
Date
Consent Discussion (print)
____________________ 
________________________ 
______________
Witness Name (print)
Witness Signature
Date